

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1650497> since 2019-04-29T10:06:15Z

Published version:

DOI:10.1530/EJE-18-0608

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults, in collaboration with the European Network for the Study of Adrenal Tumors

Martin Fassnacht^{1,2*}, Olaf M. Dekkers^{3,4,5}, Tobias Else⁶, Eric Baudin^{7,8},
Alfredo Berruti⁹, Ronald R. de Krijger^{10, 11, 12, 13}, Harm R. Haak^{14,15, 16},
Radu Mihai¹⁷, Guillaume Assie^{18, 19}, Massimo Terzolo^{20*}

¹ Dept. of Internal Medicine I, Div. of Endocrinology and Diabetes, University Hospital, University of Würzburg, Würzburg, Germany

² Comprehensive Cancer Center Mainfranken, University of Würzburg, Würzburg, Germany

³ Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, the Netherlands

⁴ Department of Clinical Endocrinology and Metabolism, Leiden University Medical Centre, Leiden, the Netherlands

⁵ Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark

⁶ Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI, USA

⁷ Endocrine Oncology and Nuclear Medicine, Institut Gustave Roussy, Villejuif, France

⁸ INSERM UMR 1185, Faculté de Médecine, Le Kremlin-Bicêtre, Université Paris Sud, Paris, France

⁹ Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, Medical Oncology, University of Brescia at ASST Spedali Civili, Brescia, Italy.

¹⁰ Dept. of Pathology, Erasmus MC University Medical Center, Rotterdam, The Netherlands

¹¹ Dept. of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands

¹² Dept. of Pathology, Reinier de Graaf Hospital, Delft, The Netherlands

¹³ Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands

¹⁴ Department of Internal Medicine, Máxima Medical Centre, Eindhoven/Veldhoven, the Netherlands

¹⁵ Maastricht University, CAPHRI School for Public Health and Primary Care, Ageing and Long-Term Care, Maastricht, the Netherlands

¹⁶ Department of Internal Medicine, Division of General Internal Medicine, Maastricht University Medical Centre+, Maastricht, the Netherlands.

¹⁷ Department of Endocrine Surgery, Churchill Cancer Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

¹⁸ Department of Endocrinology, Reference Center for Rare Adrenal Diseases, Reference Center for Rare Adrenal Cancers, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, France

¹⁹ Institut Cochin, Institut National de la Santé et de la Recherche Médicale U1016, Centre national de la recherche scientifique UMR8104, Université Paris Descartes, Sorbonne Paris Cité, Paris, France

²⁰ Internal Medicine, San Luigi Hospital, Dept. of Clinical and Biological Sciences, University of Turin, Orbassano, Italy

*corresponding authors

Correspondence should be addressed to Martin Fassnacht (Email fassnacht_m@ukw.de) and Massimo Terzolo (Email: terzolo@usa.net)

Abstract

Adrenocortical carcinoma (ACC) is a rare and in most cases steroid hormone producing tumor with variable prognosis. The purpose of these guidelines is to provide clinicians with best possible evidence-based recommendations for clinical management of patients with ACC based on the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. We predefined four main clinical questions, which we judged as particularly important for the management of ACC patients and performed systematic literature searches: (A) What is needed to diagnose an ACC by histopathology? (B) Which are the best prognostic markers in ACC? (C) Is adjuvant therapy able to prevent recurrent disease or reduce mortality after radical resection? (D) What is the best treatment option for macroscopically incompletely resected, recurrent or metastatic disease? Other relevant questions were discussed within the group. **SELECTED RECOMMENDATIONS:** (i) We recommend that all patients with suspected and proven ACC are discussed in a multidisciplinary expert team meeting (ii) We recommend that every patient with (suspected) ACC should undergo careful clinical assessment, detailed endocrine work-up to identify autonomous hormone excess, and adrenal-focused imaging. (iii) We recommend that adrenal surgery for (suspected) ACC should be performed only by surgeons experienced in adrenal and oncological surgery aiming at a complete en-bloc resection (including resection of oligo-metastatic disease). (iv) We suggest that all suspected ACC should be reviewed by an expert adrenal pathologist using the Weiss score and providing Ki67 index. (v) We suggest adjuvant mitotane treatment in patients after radical surgery that have a perceived high risk of recurrence (ENSAT stage III, or R1 resection, or Ki67 >10%). (vi) For advanced ACC not amenable to complete surgical resection, local therapeutic measures (e.g. radiation therapy, radiofrequency ablation, chemo-embolization) are of particular value. However, we suggest against the routine use of adrenal surgery in case of widespread metastatic disease. In these patients we recommend either mitotane monotherapy or mitotane, etoposide, doxorubicin, and cisplatin depending on prognostic parameters. In selected patients with a good response, surgery may be subsequently considered. (vii) In patients with recurrent disease and a disease-free interval of at least 12 months, in whom a complete resection/ablation seems feasible, we recommend surgery or alternatively other local therapies. Furthermore, we offer detailed recommendations about the management of mitotane treatment and other supportive therapies. Finally, we suggest directions for future research.

1. Summary of recommendations

After the review process all Recommendations without Rational will be provided here as summary.

2. Adrenocortical Carcinoma – epidemiology, pathogenesis, clinical presentation, and general prognosis

Epidemiology and pathogenesis

The estimated incidence of adult adrenocortical carcinoma (ACC) is between 0.7 – 2.0 per million per year {Kebebew, 2006 #3;Kerkhofs, 2013 #2}. ACC can occur at any age with a peak incidence between 40 and 60 years, and with women being more often affected (55-60%). In adults, the vast majority of ACCs are sporadic. Occasionally, however, they occur as part of hereditary syndromes such as Li-Fraumeni syndrome, Lynch syndrome, multiple endocrine neoplasia (MEN) 1 and familial adenomatous polyposis {Berruti, 2012 #20;Petr, 2016 #34}. In recent years several multi-center studies have shed light on the pathogenesis of ACC {de Reynies, 2009 #14;Fragoso, 2012 #18;Ronchi, 2013 #324}{Jouinot, 2017 #17}, but ‘multi-omic’ studies {Assie, 2014 #12;Juhlin, 2015 #19;Zheng, 2016 #16} reveal that only a minority of ACC cases have pathogenic driver mutations. For details on this topic we refer to recent reviews {Assie, 2014 #11;Else, 2014 #135;Faillot, 2016 #277}.

Clinical presentation (Table 1)

ACC may present with autonomous adrenal hormone excess or with symptoms caused by an abdominal mass. An increasing number of cases are diagnosed within the group of incidentally discovered adrenal masses (incidentalomas) (\approx 10-15%). However, the likelihood of an adrenal incidentaloma being an ACC is low {Terzolo, 1997 #359;Cawood, 2009 #326;Fassnacht, 2016 #46}. About 50-60% of patients with ACC have clinical hormone excess. Hypercortisolism (Cushing’s syndrome), or mixed Cushing’s and virilizing syndromes are observed in the majority of these patients. Pure androgen excess is less frequent while estrogen or mineralocorticoid excess are very rare {Seccia, 2005 #360;Fassnacht, 2011 #61;Else, 2014 #135;Berruti, 2014 #35;Kerkhofs, 2015 #78;Fassnacht, 2013 #60}. Non-specific symptoms from an abdominal mass include abdominal discomfort (nausea, vomiting, abdominal fullness) or back pain. Classical malignancy-associated symptoms such as weight loss, night sweats, fatigue or fever are rarely present.

Table 1: Clinical presentation of ACC[#]

Autonomous adrenal hormone excess	50-60 %
Hypercortisolism (Cushing’s syndrome)*	50-70 %
Androgen excess (virilization) in female patients*	20-30 %
Estrogen excess (feminization) in male patients*	5 %
Mineralocorticoid excess*	2-3 %
Non-specific symptoms from an abdominal mass	30-40 %
Incidentally detected by imaging for other purpose	10-15 %

[#] number derived from: {Berruti, 2014 #35;Fassnacht, 2009 #56;Johanssen, 2010 #69}, and the ENSAT ACC registry

* frequently combined

General prognosis

The median overall survival of all ACC patients is about 3-4 years. The prognosis is, however, heterogeneous. Complete surgical resection provides the only means of cure. In addition to radical surgery, disease stage, proliferative activity/tumor grade, and cortisol excess are independent prognostic parameters (see also section 4.2. and 5.5.). Five-year survival is 60-80% for tumors confined to the adrenal space, 35-50% for locally advanced disease, and much lower in case of metastatic disease with reported percentages ranging from 0% to 28% {Icard, 2001 #79; Bilimoria, 2008 #80; Sturgeon, 2006 #81; Fassnacht, 2010 #57; Fassnacht, 2009 #58; Fassnacht, 2011 #61; Fassnacht, 2012 #28; Kerkhofs, 2015 #78}.

3. Methods

3.1. Guideline working group

This guideline was developed by The European Society of Endocrinology (ESE) in collaboration with the European Network for the Study of Adrenal Tumours (ENSAT). The chairs of the working group Martin Fassnacht and Massimo Terzolo as well as the methodological expert Olaf Dekkers were appointed by the ESE Clinical Committee. Tobias Else served as representative of The Endocrine Society, USA, and Radu Mihai as representative of the European Society of Endocrine Surgeons. The other members were suggested by the chairs and approved by the Clinical Committee of ESE. The multidisciplinary team consisted of the following experts: endocrinologists (Guillaume Assie (France), Olaf Dekkers (The Netherlands), Tobias Else (USA), Martin Fassnacht (Germany), Harm Haak (The Netherlands), Massimo Terzolo (Italy), oncologists (Eric Baudin (France), Alfredo Berruti (Italy), a pathologist Ronald de Krijger (The Netherlands), and an endocrine surgeon Radu Mihai (UK). The working group had three in-person meetings (November 2016, September 2017, and March 2018) and communicated by phone and email. Consensus was reached upon discussion; minority positions were taken into account in the rationale behind recommendations. Prior to the process, all participants completed conflict of interest forms.

3.2 Target group

This guideline was developed for healthcare providers involved in the care of patients with adrenocortical carcinoma *i.e.*, endocrinologists, oncologists, surgeons, radiologists, nuclear medicine physicians, radio-oncologists, pathologists, specialists in general internal medicine, and nurse specialists. However, general practitioners or gynecologists or dermatologists (who are involved in the diagnostic of androgen excess) might also find the guideline useful, as might our patients. In addition, the guideline document can serve as a source document for the preparation of patient information leaflets.

3.3 Aims

The overall purpose of this guideline is to provide clinicians with practical guidance for the management of patients with adrenocortical carcinoma. In clinical practice, treatment decisions should take into account the recommendations but also the clinical judgment of the treating physician. Recommendations are thus never meant to replace clinical judgment. In

some countries not all recommended tests and treatments, or both, might be available. Thus, the recommendations have certainly be interpreted in the context of available resources/treatment in the community, in which the patient is being seen.

3.4 Summary of methods used for guideline development

The methods used have been described in more detail previously {Bollerslev, 2015 #1}. In short, the guideline used GRADE (Grading of Recommendations Assessment, Development and Evaluation) as a methodological base. The first step was to define clinical question(s) (see section 3.5), the second being a systematic literature search (see Section 3.6). After including all relevant articles, we 1), rated the quality of the evidence, and 2) estimated an average effect for specific outcomes (if possible). The quality of evidence behind the recommendations is classified as very low (+OOO), low (++OO), moderate (+++O) and strong (++++).

For the recommendations we took into account: 1) quality of the evidence, 2) balance of desirable and undesirable outcomes, 3) values and preferences (patient preferences, goals for health, costs, management inconvenience, feasibility of implementation, etc) {Andrews, 2013 #137; Andrews, 2013 #138}. The recommendations are worded as recommend (strong recommendation) and suggest (weak recommendation). The meaning of a strong recommendation can be stated as follows: reasonably informed persons (clinicians, politicians and patients) would want the management in accordance with the recommendation. For a weak recommendation, most persons would still act in accordance with the guideline, but a substantial number would not {Andrews, 2013 #138}. Formal evidence syntheses were performed and graded only for recommendations addressing our initial four questions. Recommendations based on good practice and experience of the panelists were not graded {Guyatt, 2015 #139}. Recommendations were derived from majority consensus of the guideline development committee, but if at least one member had substantial disagreements, this is acknowledged in the manuscript. If two or more panelists did not agree with a recommendation, this was considered as not consensus. For transparency, all recommendations are accompanied by text explaining why specific recommendations were made.

3.5. Clinical question, eligibility criteria and endpoint definition

At the beginning of the guideline development process, the panel agreed on 30 clinical questions in the management of patients with ACC that should be addressed in the guidelines. In a next step, we agreed on four most relevant clinical questions (Table 2), for which a detailed literature search and review was subsequently performed.

3.6 Description of search and selection of literature

A literature search of electronic medical databases was performed for all four clinical questions. As we expected that single publications could contribute to different questions (for example 2 and 4) we decided to perform one overarching search using broad search terms. The search revealed 5988 papers, of which 615 were duplicates. In summary, we included 18 publications for clinical question 1 (diagnostics for ACC), 35 studies for clinical question 2 (prognosis), 10 publications for clinical question 3 (adjuvant therapy) and 48 publications for clinical question 4 (recurrent/advanced disease). The review of hormonal overproduction as prognostic factor was published as stand-alone paper {Vanbrabant, 2018 #140}. For question 3, we included one study after having been provided with baseline characteristics and

adjusted estimates for mitotane therapy not reported in the original publication {Bertherat, 2007 #82}.

3.7. Review process and endorsement of other societies

A draft of the guideline was reviewed by four experts in the field (see “Acknowledgment” section) and has been submitted for comments by ESE and ENSAT members. In addition, the following societies and networks were asked for review and finally endorsed the guidelines: the European Society of Endocrine Surgeons, the Endocrine Society, USA, the European Society of Pathology, the American-Australian-Asian Adrenal Alliance (A5), the European Reference Network on Rare Endocrine Conditions (Endo-ERN), the European Reference Network on Rare Adult Solid Cancers (ERN EURACAN). Furthermore, patient groups were approached to review the guidelines. All comments and suggestions were then discussed and implemented as appropriate by the panel (all comments and responses are provided in Appendix 8).

187 **Table 2: Overview of the key clinical questions and predefined outcome parameters**

Clinical Question	Predefined selection criteria and key outcome parameters	Metrics of the literature search
<p>Question 1:</p> <p>Pathology - what is needed to diagnose an ACC?</p> <p>Sub-question 1A: How to make a distinction between adrenocortical/non-adrenocortical tumor?</p> <p>Sub-question 1B How to make a distinction between benign or malignant or indeterminate behavior in adrenocortical tumors</p>	<p>Population</p> <ul style="list-style-type: none"> Adrenal masses <p>Restriction</p> <ul style="list-style-type: none"> Minimum 25 ACC patients Each marker has to be reported in at least 2 independent cohorts <p>Outcome</p> <ul style="list-style-type: none"> Diagnostic accuracy (Sensitivity/specificity/NPV/PPV) <p>Diagnostic marker:</p> <ul style="list-style-type: none"> (Weiss Score), Ki67, reticulin, Helsinki, SF-1, melan A, inhibin, calretinin, chromogranin, SRC1 <p>Reference standard:</p> <ul style="list-style-type: none"> Weiss-Score¹ Recurrence 	<p>Number of papers included:</p> <p>1a: n=4</p> <p>1b: n=15</p> <p>(2 papers contributed to both)</p>
<p>Question 2:</p> <p>Which are the best prognostic markers in ACC?</p>	<p>Population (minimum 100 ACC patients):</p> <ol style="list-style-type: none"> 1) Patients after radically resected ACC 2) Patients with advanced ACC <p>Restriction:</p> <ul style="list-style-type: none"> Prognostic marker has to be reported in at least 2 independent cohorts <p>Prognostic markers to be considered:</p> <ul style="list-style-type: none"> Tumor stage (different systems: Sullivan, Lee, UICC, ENSAT, etc.), sex, age, Ki67, hormone section, Weiss score, mitotic index, R status, molecular/immunohistological markers <p>Outcome</p> <ul style="list-style-type: none"> Overall survival, disease-free and progression-free survival, prognostic ability 	<p>Number of papers included: 35</p>
<p>Question 3:</p> <p>Is adjuvant therapy able to prevent recurrent disease or reduce mortality after radical resection?</p>	<p>Population:</p> <ul style="list-style-type: none"> Diagnosis of ACC with macroscopic radical resection (R0, R1, Rx) <p>Restriction:</p> <ul style="list-style-type: none"> Studies with > 10 patients in the intervention group Only studies providing baseline data per treatment group, and providing age and stage adjusted estimates In case of >25% overlap only inclusion of the largest study 	<p>Number of papers included:</p> <p>Mitotane n=6</p> <p>Radiation therapy n=4</p>

	Intervention: <ul style="list-style-type: none"> Adjuvant treatment with either mitotane, radiation therapy or cytotoxic chemotherapy Control group: <ul style="list-style-type: none"> Without therapy or other treatment Outcomes: <ul style="list-style-type: none"> Disease-free survival, overall survival, quality of life, adverse events 	
Question 4: What is the best treatment option for macroscopically incompletely resected, recurrent or metastatic disease?	Population: <ul style="list-style-type: none"> Macroscopically incompletely resected, recurrent or metastatic ACC Restriction: <ul style="list-style-type: none"> Studies > 10 patients in the intervention group. Only studies providing baseline data per treatment group Interventions <ul style="list-style-type: none"> Cytotoxic drugs including mitotane, surgery, radiation therapy, radiofrequency ablation, chemoembolization Control <ul style="list-style-type: none"> Not mandatory (single arm cohort studies eligible) Outcome <ul style="list-style-type: none"> Overall survival, progression-free survival, tumor response, quality of life, adverse events 	Number of papers included: cytotoxic drugs including mitotane: n=27 surgery: n= 16 radiation therapy: n=1 radiofrequency ablation: n=1 radionuclide therapy: n=1

NPV negative predictive value, PPV positive predictive value, SF-1 steroidogenic factor 1, SRC1 steroid receptor coactivator 1, R status Resection status, R0 microscopically complete resection, R1 microscopically incomplete resection, Rx uncertain resection status
¹ we are aware that the Weiss score was never properly validated, but we decided that there is no other “gold standard”)

4. Summary and conclusions from systematic literature reviews

4.1. Clinical question 1: Pathology

We included 17 publications {Blanes, 2007 #141;Creemers, 2016 #142;Erickson, 2001 #143;Arola, 2000 #144;Aubert, 2002 #108;Busam, 1998 #146;Kamio, 1990 #148;Komminoth, 1995 #149;Pan, 2005 #150;Rubin, 2016 #151;Sbiera, 2010 #15;Stojadinovic, 2003 #152;Volante, 2006 #153;Wajchenberg, 2000 #154;Wang, 2014 #155;Zhang, 2008 #156;Kovach, 2015 #353} that contributed data to either the diagnosis of ACC in the context of adrenal vs. non-adrenal distinction (4 studies), or in the context of benign vs. malignant adrenocortical tumor distinction (15 studies) (two of them contributing to both subquestions {Arola, 2000 #144;Pan, 2005 #150}). Details of studies are shown in Appendix 1 (in all samples, diagnosis based on histological examination). Melan-A and inhibin-alpha were studied in three publications; all other markers were studied in one or two publications only. In total data for twenty-seven diagnostic markers were reported. Since many publications included patients who did not reflect the target population in question for this guideline (i.e. patients with a suspicion for ACC), positive or negative predictive values were not provided. A formal meta-analysis was not performed given the low number of studies per marker. Importantly, no study reported on the combined diagnostic ability of a set of markers, which actually may reflect the approach in clinical practice.

4.2. Clinical question 2: Prognostic factors

Thirty-five studies reporting on risk factors for recurrence and/or mortality, and that included more than 100 patients with histologically proven ACC, were analyzed {Amini, 2016 #157;Asare, 2014 #158;Assie, 2007 #114;Ayala-Ramirez, 2013 #160;Berruti, 2014 #35;Beuschlein, 2015 #50;Bilimoria, 2008 #80;Canter, 2013 #164;Duregon, 2017 #110;Erdogan, 2013 #55;Ettaieb, 2016 #117;Fassnacht, 2009 #58;Freire, 2013 #169;Gicquel, 2001 #170;Glover, 2015 #171;Gonzalez, 2007 #172;Icard, 2001 #79;Jouinot, 2017 #17;Kebebew, 2006 #3;Kendrick, 2002 #176;Kim, 2016 #177;Kim, 2017 #178;Libe, 2015 #29;Livhits, 2014 #180;Lucon, 2002 #181;Margonis, 2016 #182;Margonis, 2016 #183;Millis, 2015 #184;Paton, 2006 #185;Pennanen, 2015 #109;Schulick, 1999 #187;Tran, 2016 #188;Xiao, 2015 #189;Zini, 2009 #190;Ronchi, 2012 #321}(see Appendix 2 for details of studies included, and Appendix 3 for an overview of all prognostic factors studied). The threshold of 100 cases was defined upfront as with n=100 and an expected number of deaths of 50, statistical power was considered sufficient. Almost all studies reported age, sex and tumor stage as prognostic factors, although several different staging systems were used. A formal comparison of the studies was difficult due to heterogeneity regarding clinical characteristics, use of varying definitions of characteristics (e.g. stage) and different cut-offs (e.g. tumor size, age). Furthermore, the multivariable models presented include adjustment for different additional variables. We acknowledge a concern over the number of variables included in models relative to the number of events, and that this may have the potential to lead to false positive results.

The association between staging and prognosis was robust (+++O), despite different systems being used {Macfarlane, 1958 #281;Sullivan, 1978 #282;Lee, 1995 #283;DeLellis, 2004 #284;Asare, 2014 #158;Miller, 2010 #90;Lughezzani, 2010 #92;Fassnacht, 2009 #58;Libe, 2015 #29;Lam, 2017 #285}. In a formal comparison, the ENSAT staging {Fassnacht, 2009 #58} was slightly superior to the UICC staging {Lughezzani, 2010 #92}. Additionally, the association between hypercortisolism and mortality was consistent, and remained with a positive hazard ratio after adjustments for tumor stage HR 1.71, 95% CI

1.18-2.47 {Vanbrabant, 2018 #140}. Ki67 was studied in five publications, showing worse prognosis with increasing Ki67 in all studies. Other molecular markers have been studied in single cohorts only (Appendix 2+3).

It is important to mention that relative risks, even if statistically significant, cannot inform clinical decision making unless translated into predictive values or incorporated in prediction models. Only one study presented a formal prediction model (including the variables tumor size, stage, mitotic index, venous invasion, and endocrine activity), showing a sensitivity of 0.91 and a specificity of 0.90 {Freire, 2013 #169}. Another study provided nomograms to facilitate prognosis in individual patients {Kim, 2016 #177}. None of these models, however, has been validated externally.

4.3. Clinical question 3: Adjuvant therapy


No randomized clinical trial has been published yet exploring adjuvant therapies; no studies comparing quality of life after different treatment modalities were found. We included six studies that assessed the effect of mitotane on recurrence and mortality {Berruti, 2017 #22; Bertherat, 2007 #82; Beuschlein, 2015 #50; Else, 2014 #125; Grubbs, 2010 #191; Postlewait, 2016 #192}. See Appendix 4 for details and Appendix 5 for risk of bias assessment. Due to an overlap of the study population of >25% between studies {Berruti, 2017 #22; Bertherat, 2007 #82; Beuschlein, 2015 #50} only the German study cohort from Beuschlein et al. was considered, but not the validation cohort {Beuschlein, 2015 #50}. In one study, forty-seven patients were enrolled in 4 Italian centers where adjuvant mitotane was routinely recommended, 55 patients in 4 Italian centers where no adjuvant strategy was undertaken (control group 1), and 75 German patients left untreated after surgery (control group 2) {Berruti, 2017 #22; Terzolo, 2007 #33}. However, only the most recent update of these series was included in the analysis {Berruti, 2017 #22}. In order to avoid counting data twice only control group 1 was included.

In a meta-analysis the pooled hazard ratio for recurrence was 0.7, 95%CI 0.5-1.1; for mortality (5 studies) the pooled hazard ratio was 0.7, 95%CI 0.5-0.9 (Figure 1). All six studies were non-randomized with the potential of a (residual) confounding effect, meaning that treatment choices are based on prognosis (such as performance status of the patient, tumor stage etc.), which introduces imbalance in prognostic factors. It is known that when studying therapeutic effects this confounding effect is difficult to remedy statistically {Bosco, 2010 #193}. One study {Berruti, 2017 #22} circumvented the confounding effect by comparing two treatment strategies applied in different settings; such comparison relies on other assumptions {Hernan, 2006 #354}. A further bias in this context is immortal time bias, which can occur if treatment is initiated after follow-up time starts and this is not accounted for in the analysis. Such biases tend to overestimate treatment effects {Suisse, 2008 #194}, and were not explicitly accounted for in most studies. Only one study applied a landmark analysis to address this bias {Berruti, 2017 #22}. The overall quality rating was very low (+OOO).

Four studies assessed the impact of adjuvant radiation therapy {Fassnacht, 2006 #126; Habra, 2012 #123; Else, 2014 #125; Sabolch, 2015 #127}. See Appendix 4 for details and Appendix 5 for risk of bias assessment. The study by Sabolch et al. {Sabolch, 2015 #127} was only considered for data on local recurrence, not for recurrence and mortality given the overlap with another study of the same group {Else, 2014 #125}. All but one study (59 patients treated with adjuvant radiation therapy {Else, 2014 #125} were small. We found a pooled hazard ratio of 0.8 (95% CI 0.6-1.1) for recurrence and for mortality of 1.0 (95% CI 0.7-1.5) (Figure 1). The pooled hazard ratio for local recurrence (three studies) after treatment with radiotherapy was 0.3 (93% CI 0.1-1.9).

All studies were observational with the potential of (residual) confounding effects, immortal time bias was not explicitly accounted for in most studies, and the studies were small with imprecise effect estimates; the overall quality rating was therefore very low (+000).

Recurrence in the adjuvant setting



Mortality in the adjuvant setting




Figure 1 Meta-analysis of recurrence (A) and mortality (B) of included studies on adjuvant therapy after radical resection in ACC

4.4. Question 4: Therapy for advanced or recurrent disease.

A total of twenty-seven publications reported outcomes of 29 different systemic therapies for advanced or recurrent ACC {Berruti, 2005 #24; Fassnacht, 2015 #27; Fassnacht, 2012 #28; Gonzalez, 2007 #172; Hermsen, 2011 #68; Sperone, 2010 #32; Abraham, 2002 #195; Baudin, 2002 #196; Baudin, 2001 #197; Berruti, 2012 #23; Bonacci, 1998 #199; Bukowski, 1993 #200; Decker, 1991 #201; Haak, 1994 #202; Haluska, 2010 #204; Khan, 2004 #205; Kroiss, 2016 #206; Kroiss, 2012 #207; Naing, 2013 #208; O'Sullivan, 2014 #209; Quinkler, 2008 #74; Schlumberger, 1991 #211; Urup, 2013 #212; Williamson, 2000 #213; Wortmann, 2010 #214; Henning, 2017 #215; Lerario, 2014 #216}; two were randomized controlled trials ({Fassnacht, 2015 #27; Fassnacht, 2012 #28}; see Appendix 6 for details of studies included). The first randomized trial compared mitotane plus a combination of etoposide, doxorubicin, and cisplatin (EDP-M) to mitotane plus streptozocin in 204 patients with advanced ACC {Fassnacht, 2012 #28}. The trial showed a positive effect of EPD-M on progression-free survival HR 0.55 (95% CI, 0.43 to 0.69; $P < 0.001$), but failed to show a significant effect on mortality (HR 0.79; 95% CI, 0.61 to 1.02; $p = 0.07$); (+++O). The second randomized trial compared linsitinib to placebo (total 139 patients, 2:1 randomization to therapy) and did not show a clear effect on either progression free (HR 0.83, 95% CI 0.56–1.21; $p = 0.30$) or overall survival (HR 0.94; 95%CI 0.61–1.44; $p = 0.77$){Fassnacht, 2015 #27}; (+++O).


Many publications reported on single arm studies of different therapeutic regimens. These single arm studies have an inherent risk of selection bias, and direct comparison is not possible. Differences in patient characteristics, definition of response criteria and follow-up duration are a concern (+OOO). Given the uncontrolled design a final conclusion about the optimal treatment for advanced recurrent ACC cannot be given. Figure 2 shows response rates from all studies with data for at least one regimen. For most regimens at least some responses (partial or even complete) were reported; treatment merits in case of stable disease is more difficult to judge as this depends highly on duration of follow-up and biology of the disease. Adverse effects from chemotherapy, however, are common and diverse (see Appendix 6).

Study

Henning, 2017 {Henning, 2017 #215}
 Fassnacht, 2012 A {Fassnacht, 2012 #28}
 Fassnacht, 2012 B {Fassnacht, 2012 #28}
 Hermsen, 2011 {Hermsen, 2011 #68}
 Fassnacht, 2015 {Fassnacht, 2015 #27}
 Berruti, 2005 {Berruti, 2005 #24}
 Gonzalez, 2007 {Gonzalez, 2007 #172}
 Williamson, 2000 {Williamson, 2000 #213}
 Bukowski, 1993 {Bukowski, 1993 #200}
 Decker, 1991 B {Decker, 1991 #201}
 Abraham, 2002 {Abraham, 2002 #195}
 Sperone, 2010 {Sperone, 2010 #32}
 Kroiss, 2012 {Kroiss, 2012 #207}
 Naing, 2013 {Naing, 2013 #208}
 Haak, 1994 {Haak, 1994 #202}
 Kroiss, 2016 {Kroiss, 2016 #206}
 Bonacci, 1998 {Bonacci, 1998 #199}
 Urup, 2013 {Urup, 2013 #212}
 Decker, 1991 A {Decker, 1991 #201}

Therapy

Gemcitabine and capecitabine
 etoposide, doxorubicin, cisplatin, and mitotane
 Streptozocin and mitotane
 Mitotane and different cytotoxic drug
 Linsitinib
 Etoposide, doxorubicin, cisplatin, and mitotane
 Mitotane
 Cisplatin and etoposide
 Cisplatin and mitotane
 Mitotane
 Doxorubicin, etoposide, vincristine, and mitotane
 Gemcitabine and capecitabine/5-fluorouracil
 Sunitinib
 Cixutumumab and temsirolimus
 Mitotane
 Trofosfamide
 Etoposide and cisplatin
 Cisplatin and docetaxel
 Doxorubicin



Lerario, 2014 {Lerario, 2014 #216}	Cixutumumab and mitotane
Haluska, 2010 {Haluska, 2010 #204}	Figitumumab
Schlumberger, 1991 {Schlumberger, 1991 #211}	5-fluorouracil, doxorubicin, and cisplatin
O'Sullivan, 2014 {O'Sullivan, 2014 #209}	Axitinib
Baudin, 2001 {Baudin, 2001 #197}	Mitotane
Baudin, 2002 {Baudin, 2002 #196}	Irinotecan
Kahn, 2004 {Khan, 2004 #205}	Vincristine, teniposide, cisplatin, and cyclophosphamide
Wortmann, 2010 {Wortmann, 2010 #214}	Bevacizumab and capecitabine
Quinkler, 2008 {Quinkler, 2008 #74}	Erlotinib and gemcitabine
Berruti, 2012 {Berruti, 2012 #23}	Sorafenib and metronomic paclitaxel

Figure 2: Overview of the objective response rates in studies with systemic therapies in ACC

The studies are ordered by number of included patients per regimen. This figure has to be interpreted very cautiously, because study protocols, patient cohorts and characteristics as well as outcome measurements are quite different precluding a direct comparison. CR: complete response; PR: partial response; SD: stable disease; PD: Progression of the Disease. Some of the older studies did not report stable disease or progression, thus these columns don't sum up to 100%

Sixteen studies focused on surgery in recurrent and advanced ACC; six publications reported on oligo-metastasectomy (lung, liver) {Datrice, 2012 #118;Gaujoux, 2012 #218;Kemp, 2011 #219;Kwauk, 1993 #220;op den Winkel, 2011 #221;Ripley, 2011 #222}, whereas 10 publications assessed the effect of surgery in local recurrent and/or metastatic disease {Bellantone, 1997 #223;Crucitti, 1996 #83;Dy, 2013 #225;Erdogan, 2013 #55;Gonzalez, 2007 #172;Jensen, 1991 #228;Schulick, 1999 #187;Simon, 2017 #136;Tran, 2013 #231;Dy, 2015 #232}. In patients with metastasectomy 5-survival rates up to 40% were reported {Datrice, 2012 #118;Gaujoux, 2012 #218}, although control groups were lacking (+OOO). There were large differences regarding extent of disease, indication, and concurrent treatment in studies comparing a surgical approach to a non-surgical approach for recurrent or advanced disease. The reported benefit of surgery is confounded by differing indications for surgery, and this precludes firm conclusions from being drawn (+OOO). Therefore, the main conclusion is that in patients deemed radically operable by the surgeon/team operation is a treatment option. However, beside prognostic factors like Ki67 a key influencing factor in case of recurrence is the disease-free interval prior to recurrence. For radionuclide therapy {Hahner, 2012 #373}, transcatheter arterial chemoembolization {Cazejust, 2010 #233}, radiofrequency ablation {Wood, 2003 #235} and radiation {Ho, 2013 #234} only one small study per procedure was found, and no conclusions can be drawn.

5. Recommendations

5.1. General remarks

The main part of this guideline addresses the management of adult patients with ACC. We divided the 62 recommendations in 12 sections. In addition, we provide two flow-charts on the management of patients with ACC amenable to radical resection (Figure 3) and on the management of patients with advanced ACC not amenable to radical resection (Figure 4) to give an efficient overview. However, we would like to emphasize once more that none of these flow-charts nor the entire recommendations can replace clinical judgment of the treating physician and joint decision-making with the patient.

5.1. Overarching recommendations

R.1.1. We recommend that all patients with suspected and proven adrenocortical carcinoma (ACC) are discussed in a multidisciplinary expert team meeting (including health care providers experienced in care of adrenal tumors, including at least the following disciplines: endocrinology, oncology, pathology, radiology, surgery) at least at the time of initial diagnosis. In addition, this team should have access to adrenal-specific expertise in interventional radiology, radiation therapy, nuclear medicine, and genetics as well as to palliative care teams.

Reasoning:

Despite the lack of studies, the panel was convinced that patients with ACC benefit from multidisciplinary management by a team of experts with experience in care for patients with this rare disease. Ideally, all patients would be managed by such a team throughout the

course of their disease, because during the follow-up considerations of multiple diagnostic and treatment modalities might be required. However, in many health care settings this is yet an unrealistic expectation. Therefore, we envision that in the future at least one reference center, that fulfills the above-mentioned criteria, will be established in every country. We believe that it is crucial that every case of suspected ACC is discussed in detail with a panel of experts for this disease at the time of the initial diagnosis. Additionally, this expert team should be ideally requested every time progress is documented (or suspected) and new treatment options might be required. If there is no accessible center with all the required expertise in all disciplines, or the patient is not able to travel to such a center, telemedicine approaches should be encouraged to compensate for these limitations.

R.1.2. We suggest that at any time of decision-making regarding therapy, enrollment in a clinical trial (if available) should be considered. Furthermore, we encourage patients' participation in registries and the collection of biological material as part of structured research programs aimed at defining biomarkers of diagnosis, prognosis and treatment response.

Reasoning:

As described above, the evidence for almost all therapeutic strategies for ACC is very low. Furthermore, the efficacy of systemic therapies is limited, including the most commonly used treatments - mitotane and platinum-based chemotherapies, with response rates clearly less than 30% {Baudin, 2001 #197;Berruti, 2012 #20;Else, 2014 #135;Fassnacht, 2012 #28;Hermsen, 2011 #68;Hahner, 2005 #64}. Thus, improved treatment paradigms are needed urgently. Clinical trials are the best way to improve our knowledge and patient care. However, the benefits and risk for the individual patient have to be weighed against available data of agents with known or predicted efficacy in ACC.

Because of the rarity of the disease, it is crucial to include as many patients as possible in research programs for multicenter therapeutic trials, as well as studies for diagnostic, prognostic and predictive markers. A list of ongoing trials is accessible on <https://www.clinicaltrials.gov/>. Biological material may include tumor samples, ideally frozen and paraffin-embedded, blood-derived and urine samples. National and international research networks such as ENSAT (www.ensat.org){Stell, 2012 #91} and the recently founded A5 (<https://adrenal-a5.org/>) play instrumental roles in coordinating research programs. Centers providing care to patients with ACC should register as investigators with ongoing trials and also facilitate the collection of biological material and ensure appropriate consent.

5.2. Diagnostic procedures in suspected ACC

R.2.1. The diagnosis of ACC is not always obvious. We recommend establishing as soon as possible whether an adrenal mass is malignant, using all required diagnostic tools in a timely fashion.

Reasoning

Due to the potentially poor prognosis of ACC, it is critical to know as early as possible if an adrenal mass is malignant or not. Therefore, even if there is only a small likelihood that an adrenal mass is an ACC, this diagnosis should be rapidly excluded with the highest possible certainty. A particular suspicion for an ACC might arise from clinical aspects (e.g. rapidly developed features of adrenocortical hormone excess, see R.2.2), or results from hormonal work-up (see R.2.3), or indeterminate or suspicious imaging (see R.2.4). An adrenal biopsy should only be considered in those selected cases in which an adrenal metastasis of an extra-adrenal malignancy is suspected or when the tumor is considered as inoperable {Fassnacht, 2016 #46} (for details and explanation see R.2.7). The proposed diagnostic work-up is summarized in Table 3.

Table 3: Diagnostic work-up in patients with suspected or proven ACC

Hormonal work up

- Glucocorticoid excess
 - 1mg dexamethasone suppression test or free cortisol in 24-h urine¹
 - basal ACTH (plasma)²
- Sex steroids and steroid precursors³
 - DHEA-S
 - 17-OH-progesterone
 - androstenedione
 - testosterone (only in women)
 - 17-beta-estradiol (only in men and postmenopausal women)
 - 11-deoxycortisol
- Mineralocorticoid excess
 - potassium
 - aldosterone/renin ratio (only in patients with arterial hypertension and/or hypokalemia)
- Exclusion of a pheochromocytoma
 - Fractionated metanephrines in 24h urine or free plasma-metanephrines

Imaging

- CT or MRI of abdomen and pelvis,
- Chest CT
- FDG-PET/CT⁴
- Bone or brain imaging (when skeletal or cerebral metastases are suspected)

¹ The 1-mg dexamethasone test is the preferred method to exclude relevant hypercortisolism.

However, if overt Cushing syndrome is evident, then cortisol in 24-h urine might be at least as good to quantify the cortisol excess. Alternatively, salivary or serum bedtime cortisol can be used.

² ACTH can be skipped if hypercortisolism is excluded.

³ The most suitable set of precursors and sex hormones has not yet been established and local availability might be taken into account.

⁴ The panel did not agree on the systematic use of FDG-PET/CT (see R.2.4).

R.2.2. We recommend that every patient with (suspected) ACC should undergo careful assessment including case history, clinical examination for symptoms and signs of adrenal hormone excess.

Reasoning

All patients should undergo a careful evaluation with detailed history and physical examination. In particular, patients should be evaluated for rapidly developing Cushing's syndrome (which frequently presents not as 'full blown' Cushing, but rather predominantly with muscle weakness, hypokalemia, wasting and constitutional symptoms), and symptoms and signs of a large abdominal mass. Clinical evaluation should additionally focus on symptoms and signs of androgen excess, hirsutism or virilization in women or recent onset of gynecomastia in men, because these might be clinical indicators for an androgen- or estrogen-producing ACC, respectively {Fassnacht, 2004 #59;Allolio, 2006 #236;Else, 2014 #135;Fassnacht, 2009 #56;Nieman, 2008 #134;Libe, 2007 #237}. Any evidence of co-secretion of different steroids raises the suspicion of an ACC (especially if sex-hormones are involved). In contrast, mild, long standing hirsutism is usually not caused by an ACC, but rather due to (among other diagnoses) polycystic ovary syndrome and non-classical congenital adrenal hyperplasia {Legro, 2013 #238}. Primary aldosteronism is rare in ACC and usually accompanied by severe hypokalemia {Funder, 2016 #239}. However, hypokalemia in ACC is more frequently caused by massive cortisol excess overwhelming the renal 11- β hydroxysteroid dehydrogenase type 2 system.

R.2.3. We recommend that all patients with suspected ACC undergo a detailed hormonal work-up to identify potential autonomous excess of glucocorticoids, sex-hormones, mineralocorticoids and adrenocortical steroid hormone precursors (see Table 3). In addition, a pheochromocytoma must be excluded.

Reasoning

A comprehensive endocrine work-up is helpful for various reasons. (i) The diagnosis of steroid excess is frequently able to establish the adrenocortical origin of the tumor. (ii) The steroid pattern may indicate whether an adrenal lesion is an ACC. For example, autonomous co-secretion of androgens and cortisol in any patient and secretion of steroid precursors or estradiol in males are highly suspicious for ACC {Fassnacht, 2004 #59}. Furthermore, hormonal evaluation is of prognostic value as cortisol-secreting tumors generally have a worse prognosis {Vanbrabant, 2018 #140}. (iii) If undiagnosed, autonomous cortisol secretion may be followed by life-threatening adrenal insufficiency after complete resection of the primary tumor. The best test to diagnose autonomous cortisol secretion is the 1-mg overnight dexamethasone suppression test {Nieman, 2008 #134}. If hypercortisolism is present, it is crucial to prove ACTH-independency, because an adrenal metastasis of an ectopic ACTH-secreting tumor (e.g. lung cancer) can mimic an ACC. (iv) Elevated hormones prior to surgery may serve as tumor markers during follow-up. Finally, conventional imaging cannot discriminate an ACC from a pheochromocytoma. However, undiagnosed pheochromocytoma may lead to dangerous hypertensive crises (especially during invasive procedures). Therefore, a pheochromocytoma has to be ruled out in any case of an adrenal tumor whenever no obvious autonomous steroid excess is present {Fassnacht, 2016 #46}. It is important to note, however, that slightly elevated metanephrines levels (< 2-fold), particularly when inconsistent with a large tumor size, might be non-specific and can be observed in ACC.

R.2.4. We recommend adrenal-focused imaging in all patients with suspected ACC.

Reasoning

Imaging tools for adrenal tumors were carefully reviewed during the development of the ESE-ENSAT guidelines for adrenal incidentalomas {Dinnes, 2016 #54; Fassnacht, 2016 #46}. Thus, we refer to these documents for details. Briefly, there are currently three main imaging techniques available for the differentiation of malignant and benign adrenal tumors: computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography with ¹⁸F-2-deoxy-D-glucose (mostly combined with CT; FDG-PET/CT). CT and MRI are techniques mainly optimised to identify benign lesions, providing a tool for the exclusion of adrenal malignancy {Peppercorn, 1998 #244; Caoili, 2002 #243; Blake, 2006 #242; Ilias, 2007 #245}. Conversely, FDG-PET/CT is mainly used for the detection of malignant disease {Mackie, 2006 #121; Groussin, 2009 #247; Deandreis, 2011 #246}. A recently performed meta-analysis indicated that the level of evidence is low to very low for all these imaging methods {Dinnes, 2016 #54}. In the last 2 years some additional studies have been published {Cistaro, 2015 #362; Altinmakas, 2017 #254; Ciftci, 2017 #255; Bluemel, 2017 #250; Werner, 2016 #248; Wu, 2016 #249; Nakajo, 2017 #257; Guerin, 2017 #256; Marty, 2018 #251; Kim, 2018 #252; Delivanis, 2018 #253; Romeo, 2018 #258; Thomas, 2018 #259; Ng, 2018 #260; Kim, 2018 #252}. However, the panel still considers that of the available imaging

modalities, only non-contrast CT is sufficiently reliable to rule-out an ACC when the adrenal lesion is homogenous and has low CT density ≤ 10 HU. In contrast, ACCs are usually large and of inhomogeneous appearance, and characterized by low fat content (and hence higher HU density){Petersenn, 2015 #323}. Recently, FDG-PET has been proposed as possibly the best second-line test to assess indeterminate masses by unenhanced CT {Cistaro, 2015 #362;Guerin, 2017 #256;Nakajo, 2017 #257}. However, the experience shows that sensitivity and negative predictive value are much better than specificity or positive predictive value. Therefore, no consensus could be reached for a general recommendation on FDG-PET in all patients. Additional reasons in favor of systematic FDG-PET are: whole body imaging (beyond thorax and abdomen, particularly for distant bone metastasis) and in advanced disease, a reference uptake value for all metastases can be established, which can help judging the future evolution of disease. Evidence against FDG-PET includes cost, additional radiation exposure, false-positive findings, and difficult access in some countries. If adrenal imaging indicates an indeterminate mass, other parameters should be considered: For instance, in such a situation a tumor size > 4 cm, combined adrenocortical hormone excess (see also R.2.3), rapidly developing symptoms or young age (e.g. < 40 years) might point to an ACC. However, it is important to note that no single imaging method can definitively prove the diagnosis of ACC.

R.2.5. We recommend in any case where there is high suspicion for ACC performing a chest CT, in addition to an abdominal-pelvic cross-sectional imaging (CT or MRI), because the results might influence therapeutic decision-making.

Reasoning:

Since decisions for treatment strategy, particularly decisions for surgery, and prognostication rely on tumor stage, it is mandatory to systematically and rapidly evaluate for metastases, before initiation of any anti-tumor treatment. Thoraco-abdomino-pelvic imaging will cover the vast majority of metastatic locations, which most often are lung and liver, and will assess locoregional tumor extent. Imaging should include contrast-enhanced imaging. For abdominal imaging there are advantages and disadvantages for both CT and MRI, but for thoracic imaging CT is the method of choice, because it outperforms all other methods in detecting small pulmonary lesions.

Additional imaging may be required to better characterize tumor vascularization, or specific tumor extent such as a vena cava thrombus.

R.2.6. We suggest performing additional imaging (e.g. bone and brain imaging) only in case of clinical suspicion of metastatic lesions.

Reasoning:

Bone and brain metastases are rare events (especially in patients without other metastatic lesions). Therefore, additional imaging focusing on these sites is only warranted when there is increased clinical suspicion or other imaging is suggestive for bone metastases. It should be noted, however, that the basis for this advice has never been studied systematically.

R.2.7. We recommend against the use of an adrenal biopsy in the diagnostic work-up of patients with suspected ACC unless there is evidence of metastatic disease that precludes surgery and histopathologic proof is required to inform oncological management.

Reasoning:

Differentiating benign from malignant adrenocortical tumors is very challenging on a biopsy only and may lead to misdiagnosis {Bancos, 2016 #49; Fassnacht, 2016 #46}. Furthermore, the biopsy comes with significant risks such as hemorrhage {Williams, 2014 #262}. The risk of tumor dissemination precluding a R0 resection is very low {Williams, 2014 #262}. However, a biopsy might be indicated in an adrenal mass without any hormone excess in patients with a history of extra-adrenal cancers to exclude or prove an adrenal metastasis of an extra-adrenal malignancy. For details see the adrenal incidentaloma guidelines {Fassnacht, 2016 #46}.

5.3. Surgery for suspected localized ACC

R.3.1. We recommend that adrenal surgery for suspected/confirmed ACC should be performed only by surgeons experienced in adrenal and oncological surgery.

Reasoning

ACC surgery requires expertise in both adrenal and oncological surgery due to the specific anatomy, the malignant character of the disease and the potential need for multi-organ en-bloc resection to optimize the probability of a R0 resection and minimize the risk of complications.

Data comparing outcome between 'high-volume' and 'low-volume' centers for ACC are limited. Published reports from the UK, USA and Spain show an unacceptable low annual workload for the majority of surgeons involved in any adrenal surgery, with a median 1 case/year {Palazzo, 2016 #7; Park, 2009 #9; Lindeman, 2018 #264; Villar, 2010 #263}. This situation is likely to have a negative impact on patient care and contrasts significantly with the current status in other surgical specialties.

Based on the upper quartile distribution of workload of surgeons in the USA, a volume of 4 adrenalectomies/year was used to define a 'high-volume' surgeon {Park, 2009 #9} but this threshold might be too low to inspire confidence. Several studies showed that those doing more than 6-7 cases per year have shorter length of stay and fewer complications {Palazzo, 2016 #7; Park, 2009 #9; Gallagher, 2007 #265}. Despite the perceived benefit of being operated in a high-volume center, published data from Italy and the USA showed no significant association between overall survival / disease-free survival and workload even though patients operated in high-volume centers had more radical surgery, more lymph node assessment and more use of chemotherapy {Lombardi, 2012 #266; Gratian, 2014 #268}. In contrast, the creation of national centers for adrenal surgery in The Netherlands led to significantly improved disease-free survival (1y: 93% vs. 78%, 5y: 63% vs. 42 %) {Hermsen, 2012 #36; Kerkhofs, 2013 #41}. Therefore, the panel believes that a minimal annual workload of 6 adrenalectomies/year seems to be required to ensure sufficient experience in adrenal surgery, but > 20 adrenalectomies/year are desirable for those involved in surgery for ACC. Furthermore, due to the complexity of some operations, it is essential to involve surgeons

with different expertise (e.g. vascular, liver, and cardiac surgeons) for pre-surgical planning and during these complex operations.

Protocols ensuring referral to regional or national centers should be established and patients should feel empowered to ask about the previous experience of individual surgeons.

R.3.2. We recommend complete *en bloc* resection of all adrenal tumors suspected to be ACC including the peritumoral/periadrenal retroperitoneal fat. We recommend against enucleation and partial adrenal resection for suspected ACC. If adjacent organs are suspected to be invaded, we recommend *en bloc* resection. However, we suggest against the routine resection of the ipsilateral kidney in the absence of direct renal invasion.

Reasoning

Complete resection is of utmost importance for all ACCs and successful surgery is a prerequisite for cure. As the diagnosis of ACC might only become apparent after histological analysis, it remains imperative for all adrenalectomies (laparoscopic or open) in patients with a reasonable suspicion for ACC to respect the principles of oncological surgery in order to ensure complete resection (R0 status) {Gaujoux, 2017 #87;Gaujoux, 2012 #86}.

To ensure that the pathologist can judge the completeness of surgery, any fragmentation of the tumor has to be avoided. Intraoperative tumour rupture or spillage and R2 resection are associated with very high recurrence rates and poor overall survival {Bilimoria, 2008 #80} {Crucitti, 1996 #83}.

Although there are no specific studies comparing outcome of surgery with and without resection of invaded adjacent organs, it is deemed to be 'good surgical practice' to resect adjacent tissues that are/could be invaded by tumor. This holds true for involvement of spleen, distal pancreas, stomach, kidney, right liver, colon, diaphragm, the wall of the IVC or left renal vein. A cohort study compared the oncological results of patients with stage II ACC treated by radical adrenalectomy alone or by *en-bloc* resection with kidney. The results did not support the hypothesis that nephrectomy improves the oncological outcome {Porpiglia, 2016 #31}. Combined nephrectomy, however, offers a lower risk of capsular rupture and can include complete lymphadenectomy of the renal hilum, but impairs kidney function and this may limit further access to chemotherapy. Thus, in case of possible invasion in the kidney, partial nephrectomy should be considered on an individual basis.

R.3.3. Open surgery is the standard surgical approach for confirmed or highly suspected ACC. Therefore, we recommend open surgery for all tumors with radiological findings suspicious of malignancy and evidence for local invasion. However, for tumors < 6 cm without any evidence of local invasion, laparoscopic adrenalectomy (respecting the principles of oncological surgery) is reasonable if the surgeon has sufficient experience in these types of surgery.

Reasoning

There is an ongoing debate if laparoscopic adrenalectomy is an acceptable alternative for adrenal tumors with suspicion of ACC. Based on the systematic review on this topic until July 2014 {Fassnacht, 2016 #46} and an additional literature search until December 2017 {Donatini, 2014 #274;Sgourakis, 2015 #273;Autorino, 2016 #272;Langenhuijsen, 2016

#271;Lee, 2017 #6;Zheng, 2018 #269;Mpaili, 2018 #270;Huynh, 2016 #333}, we conclude that the quality of evidence from these observational studies is still very low. The main concerns with all these studies are differences of baseline characteristics between groups, and between important prognostic factors, such as tumor stage or size. The lack of any randomized trial prevents any final conclusions. However, in order to provide guidance for clinicians the panel concurs with two other recent European guidelines {Fassnacht, 2016 #46;Gaujoux, 2017 #87} and agrees that all tumors with some radiological evidence of local invasion (including enlarged lymph nodes) should undergo surgery with an open approach. The likelihood of a benign adrenal tumor is higher in the group of adrenal incidentalomas ≤ 6 cm, for whom a laparoscopic approach is reasonable. However, this cut-off is arbitrary and the experience of the surgeon is the single most important factor. Furthermore, it is advised to convert to an open procedure when obvious signs of invasion are encountered during laparoscopic surgery that would prevent complete resection. For detailed discussion we refer to the recent recommendations for the surgical management of ACC by ESES and ENSAT {Gaujoux, 2017 #87} and the guidelines on adrenal incidentaloma {Fassnacht, 2016 #46}. Although retroperitoneoscopic adrenalectomy is gaining popularity, only a small number of surgeons are likely to have completed the learning curve to reach sufficient expertise, which is estimated to be at least 20 cases {Barczynski, 2007 #275;Schreinemakers, 2010 #276}. This is a very significant issue in the context of the overall minimal experience of most surgeons offering adrenalectomy (see above). Outside specialized centers with large volume practice, retroperitoneoscopic adrenalectomy should only be considered for benign tumors <4 cm.

R.3.4. We suggest that routine locoregional lymphadenectomy should be performed with adrenalectomy for highly suspected or proven ACC. It should include (as a minimum) the periadrenal and renal hilum nodes. All suspicious or enlarged lymph nodes identified on preoperative imaging or intraoperatively should be removed.

Reasoning

Reports from several databases indicated that patients with stage III tumors and positive lymph nodes can have a 10-year overall survival rate of up to 40% after resection {Fassnacht, 2009 #58;Lughezzani, 2010 #92;Libe, 2015 #29;Nilubol, 2016 #8;Saade, 2015 #93}. However, the wide range of reported lymph node involvement in ACC (from 4 to 73%) {Icard, 2001 #79;Bilimoria, 2008 #80;Harrison, 1999 #88} demonstrates that regional lymphadenectomy is neither formally performed by all surgeons nor accurately assessed or reported by all pathologists. According to large American and French series, approximately 10-30% of patients with ACC had formal lymphadenectomy as part of the tumor resection, reflecting the heterogeneity of operative management {Icard, 2001 #79;Nilubol, 2016 #8}. A minimum of four lymph nodes should be retrieved in order to declare lymph node negative cases {Panjwani, #89} Furthermore, in an analysis of 120 cases identified from a multi-institutional database, the benefit of lymphadenectomy on overall survival persisted on multivariable analysis controlling for adverse preoperative and intraoperative factors associated with lymphadenectomy, such as tumor size, palpable mass, irregular tumor edges, suspicious nodes on imaging, and multivisceral resection {Gerry, 2016 #94}. The largest series so far included 283 patients and the resection of more than five lymph nodes reduced also the risk of local recurrence and disease-related death in a multivariate analysis

{Reibetanz, 2012 #75}.

However, the panel is not in favor of a repeat surgery if complete adrenalectomy was performed without lymphadenectomy (e.g. due to perceived benign tumor). The clinical benefit is uncertain and probably lower than the harm (e.g. delayed adjuvant therapy).

R.3.5. We recommend that individualized treatment decisions are made in cases of tumors with extension into large vessels based on multidisciplinary surgical team. Such tumors should not be regarded ‘unresectable’ until reviewed in an expert center.

Reasoning

Extension of ACC into the adrenal vein, renal vein or inferior vena cava occurs in approximately 15-25% {Chiche, 2006 #96;Turbendian, 2010 #95;Fassnacht, 2009 #58}. Venous involvement consists mostly of intravenous tumor thrombus. Thrombectomy might require vena cava cross-clamping above or below the hepatic vein confluence or cardiopulmonary bypass, depending on the upper level of extent of the thrombus. The resection might include a complete thrombectomy, a flush manoeuvre and, occasionally, vascular cuff or prosthetic IVC replacement. A 3-year overall survival rate of about 25% in a large series {Mihai, 2012 #97} encourages the performance of a venous resection in the presence of vena cava or renal vein invasion but without distant metastases.

R.3.6. If the first surgery was suboptimal and macroscopically incomplete (R2 resection), we suggest to discuss repeat surgery in a multidisciplinary expert team.

Reasoning

There has been no prospective study assessing the benefits (or the lack thereof) of early reoperation in patients whose initial adrenalectomy was incomplete (R2 status). It is the panel's view that such patients should have intensive postoperative monitoring and if local recurrence is detected radiologically, in the absence of other metastases, they should undergo surgery with a curative intent at an expert center, if it is deemed likely to lead to an R0 resection.

R.3.7. We recommend perioperative hydrocortisone replacement in all patients with hypercortisolism that undergo surgery for ACC.

Reasoning:

Overt ACTH-independent Cushing's syndrome or biochemical autonomous cortisol secretion might lead to adrenal insufficiency after removal of the adrenal source of cortisol (even in patients with incompletely suppressed ACTH) {Eller-Vainicher, 2010 #4}. Therefore, the group unanimously sees a clear indication of intra- and postoperative glucocorticoid replacement, preferably with hydrocortisone, in all patients with evidence for '(possible) autonomous cortisol secretion' (post-dexamethasone cortisol >50 nmol/L (>1.8 µg/dL)). This should follow the suggestions for major stress dose replacement as per recent international

guidelines {Bornstein, 2016 #314}. Postoperatively, the dose of glucocorticoid should be tapered on an individualized basis by a physician experienced with this clinical scenario.

5.4. Pathological work-up

R.4.1. We recommend that the diagnosis of ACC should be confirmed by histopathology (+++0).

Reasoning:

Histopathology is the gold-standard of diagnosing ACC and should in principle be obtained in all patients. For patients deemed operable this will be done on the basis of the resection specimen and for those patients who are inoperable, a biopsy will be taken in accordance with good oncological practice. However, the majority of panelists argued that in selected cases biopsy might be omitted when there is advanced disease with unequivocal ACTH-independent cortisol excess, androgen excess (testosterone, DHEAS) or estradiol excess. There is no role for biopsy in a patient who is considered suitable for surgery of the adrenal mass.

R.4.2. We suggest that all adrenal tumors, which cannot be readily classified, and all suspected ACC, should be reviewed by an expert adrenal pathologist (++OO).

Reasoning:

Diagnosing ACC can be challenging and misdiagnoses are relatively frequent events. In 21 of 161 of the patients (13%) registered with the German ACC Registry between 2006 and 2009, the diagnosis of ACC had to be revised by the reference pathologist {Johanssen, 2010 #69}. Similar results were found in a large series from Italy with a rate of misdiagnosis in 26 out of 300 cases (9%) {Duregon, 2015 #98}.

R.4.3. We suggest the use of immunohistochemistry for steroidogenic factor-1 (SF1) for the distinction of primary adrenocortical tumors and non-adrenocortical tumors (+OOO).

Reasoning:

Generally, the distinction between adrenocortical and non-adrenocortical tumors is clear and can be made on the basis of hematoxylin and eosin-stained slides. In case of doubt, on the basis of histology only, whether a tumor originates from the adrenal cortex or not, immunohistochemistry with SF1 is the most sensitive and specific marker currently available to establish if the tumor in question is of adrenocortical origin, with a sensitivity of 98% and a specificity of 100% {Sbiera, 2010 #15}. If this marker is not available, we advise a combination of markers, which should include inhibin-alpha, melan-A, and calretinin {Sangoi, 2011 #99; Weissferdt, 2014 #100}. Depending on the differential diagnosis, other immunohistochemistry markers used to make alternative diagnoses may be considered following local standard procedures.

R.4.4. We recommend the use of the Weiss system, based on a combination of 9 histological criteria that can be applied on hematoxylin and eosin-stained slides, for the distinction of benign and malignant adrenocortical tumors (++).

Reasoning:

There are many classification systems based on histology and/or a limited number of additional markers for the distinction of benign and malignant adrenocortical tumors. The Weiss system is the most widely used, and although it is not fully standardized {Tissier, 2010 #102;Tissier, 2012 #101} the panel favors use of this score. It should be noted that all scoring systems have similar inherent problems. Using the Weiss system, a score of 3 or higher (on a total of 9 criteria, see Table 4) indicates ACC {Weiss, 1984 #104;Weiss, 1989 #103}. A score of 2 and 3 may be considered as borderline between benign and malignant tumors (tumors of uncertain malignant potential). In such instance, one of several other classification systems, including the van Slooten index {van Slooten, 1985 #107}, the modified Weiss score {Aubert, 2002 #108}, the Helsinki classification {Pennanen, 2015 #109;Duregon, 2017 #110}, and the addition of reticulin stain assessment {Duregon, 2013 #26} may be used.

Special attention should be paid to histological variants of adrenocortical tumors, mainly oncocytic tumors, which, because of their specific characteristics, will always have a Weiss score of least 3, whether they are benign or malignant. For these tumors, an adapted scoring system should be used, the Lin-Weiss-Bisceglia system {Bisceglia, 2004 #111;Duregon, 2011 #112;Wong, 2011 #113}.

Table 4 Histopathologic criteria by Weiss {Weiss, 1984 #104;Weiss, 1989 #103}

The presence of three or more of the following criteria highly correlated with subsequent malignant behavior:

- High nuclear grade (Fuhrman criteria {Fuhrman, 1982 #357})
- > 5 mitoses per 50 high-power field
- Atypical mitotic figures
- < 25% of tumor cells are clear cells
- Diffuse architecture (> 33% of tumor)
- Necrosis
- Venous invasion (smooth muscle in wall)
- Sinusoidal invasion (no smooth muscle in wall)
- Capsular invasion

R.4.5. We recommend the use of Ki67 immunohistochemistry for every resection specimen of an adrenocortical tumor (++)

Ki67 immunohistochemistry has been proposed for prognostic purposes. Higher Ki67 levels are consistently associated with poor prognosis. Threshold levels of 10% and 20% have been considered for discriminating low from high Ki67 labeling index {Beuschlein, 2015 #50;Libe, 2015 #29}. However it is not clear whether any single significant threshold can be determined (see R.5.2.).

Ki67 labeling has been shown to be unevenly distributed in tumors. Therefore, determination of the labeling index should be done on whole tumors, with specific attention to the area of highest Ki67 labeling, preferably by use of an image analysis system {Lu, 2014 #115;Papathomas, 2016 #116}. If only a biopsy is available a low Ki67 labeling may not be representative and therefore can be misleading.

If Ki67 immunohistochemistry is not available, mitotic count may help in prognostic stratification of ACC. Mitotic count has been proposed for grading of ACC, using >20 mitoses per 50 high-power field to define high-grade tumors {Weiss, 1989 #103;Assie, 2007 #114;Miller, 2010 #90}. However, the precise correlation between mitotic count and Ki67 labeling is undetermined.

R.4.6. We recommend that the pathology report of a suspected ACC should at least contain the following information: Weiss score (including the exact mitotic count), exact Ki67 index, resection status, and pathological tumor stage (indicating invasion or not of the capsule and/or surrounding tissue and organs) and nodal status (+++).

Reasoning

The importance of Weiss score and Ki67 index has been discussed in R4.4 and R4.5, respectively. It is important that the exact values are given, because this is of prognostic relevance. Resection status is a major prognostic factor (see R 5.2.). Tumor stage, including nodal involvement, is discussed below (see R.5.1).

5.5. Staging classification and prognostic factors

R.5.1. At initial diagnosis, we recommend using the ENSAT staging classification (Table 5) (+++O).

Reasoning

Tumor staging is the most important prognostic factor. Specifically, the presence of metastases is by far the strongest indicator of poor prognosis. Several staging classifications have been proposed {Macfarlane, 1958 #281; Sullivan, 1978 #282; Lee, 1995 #283; DeLellis, 2004 #284; Asare, 2014 #158; Miller, 2010 #90; Lughezzani, 2010 #92; Fassnacht, 2009 #58; Libe, 2015 #29; Lam, 2017 #285}. Among these, the ENSAT staging classification appears to be the most discriminant, but the differences between staging systems are minor {Fassnacht, 2016 #46} (see also section 4.2.). The panel felt strongly that a one unique staging classification should be adopted across centers in order to improve standardization and documentation of clinical data, and so improve patient care and enhance clinical research.

The ENSAT classification requires extensive imaging prior to surgery (see R.2.4.), systematic lymph node resection, a complete surgical report (see R.3.3 and R.3.4.), and a complete pathological report (see R.4.6.).

Table 5: ENSAT staging classification {Fassnacht, 2016 #46}

ENSAT stage	Definition
I	T1, N0, M0
II	T2, N0, M0
III	T1-T2, N1, M0 T3-T4, N0-N1, M0
IV	T1-T4, N0-N1, M1

T1: tumor ≤ 5cm; T2: tumor > 5cm; T3: infiltration into surrounding tissue; T4: tumor invasion into adjacent organs or venous tumor thrombus in vena cava or renal vein; N0: no positive lymph node; N1: positive lymph node; M0: no distant metastases; M1: presence of distant metastases.

R.5.2. At initial diagnosis, we recommend taking the following factors into account when assessing the prognosis and treatment options: tumor stage, resection status, Ki67 index (or mitotic count), autonomous cortisol secretion and the patient's general condition (++OO).

Reasoning

Of the many reported prognostic factors tumor stage is the most important, because it reflects tumor extent. Especially the presence of metastases is strongly pejorative (see R.5.1.). Resection status is also a strong prognostic factor {Bilimoria, 2008 #80; Johanssen, 2010 #69; Libe, 2015 #29}, and should be carefully documented in the surgical and pathology reports. Furthermore, several studies have identified Ki67 immunostaining (or mitotic index) as major prognostic factors {Morimoto, 2008 #278; Weiss, 1989 #103; Miller, 2010 #90; Beuschlein, 2015 #50; Libe, 2015 #29}. As revealed by our systemic literature search,

hypercortisolism was also one of the most consistent prognostic factors (see section 4.2; {Abiven, 2006 #279;Berruti, 2014 #35;Vanbrabant, 2018 #140}).

Finally, the patient's general condition is an obvious prognostic factor, especially at advanced age {Asare, 2014 #158}. It is, however, noticeable that ACC patients often do not show altered general condition despite advanced disease.

From a patient perspective, the panel felt it important to consider two distinct scenarios. First, the risk of recurrence of patients with a localized (stage I-III) disease. For these patients, tumor stage, resection status and Ki67 labeling index are currently the main prognostic factors. This panel proposes to define two classes of localized ACC: low/moderate risk ACC includes stage I-II and R0 and Ki67 $\leq 10\%$, whereas high risk ACC includes stage III, R1, or Ki67 $>10\%$. However, the panel is aware that the dichotomy is arbitrary.

The second scenario to consider deals with the prognosis of patients with advanced disease (stage IV or recurrent disease not amenable to complete resection or R2 resection). In this situation, high tumor burden, high tumor grade, high Ki67 index, and uncontrolled symptoms are major factors associated with worse prognosis {Assie, 2007 #114;Libe, 2015 #29}. However, there is consensus that the kinetics of tumor growth might be also relevant, particularly when making the decision for initiation of cytotoxic chemotherapy. However, this parameter has not been formally assessed. Although a correlation of tumor growth and tumor grade exists, it is not true for all tumors.

R.5.3. During follow-up, we recommend re-assessing prognosis at each evaluation, to guide treatment strategy (++)

Reasoning

After complete surgery, the major prognostic factor is whether there is any tumor recurrence. At the time of recurrence the main prognostic factors are time between initial surgery and recurrence, tumor burden and resectability {Datrice, 2012 #118;Erdogan, 2013 #55;Ettaieb, 2016 #117;Simon, 2017 #136}.

For patients with advanced disease, prognostic factors include Ki67 index, tumor burden, general patient condition, and kinetics of tumor growth, as well as response to treatment. Limited evidence is available, but these factors make clinical sense and are corroborated by this panel's experience.

5.6. Methods and time interval for imaging and hormonal assessment during follow-up

R.6.1. We recommend following patients with regular cross-sectional imaging of the abdomen, pelvis and chest for disease recurrence or progression.

Reasoning

A majority of disease recurrence and progression occurs either loco-regionally, or with metastases to lung or liver and therefore should be identified by thoraco-abdomino-pelvic imaging. Bone metastases are infrequent and brain involvement is exceptional {Fassnacht, 2009 #56;Libe, 2015 #29;Burotto, 2015 #119}. In general, 18-FDG-PET/CT might provide additional information (see R.2.4.) particularly prior to any surgical intervention {Leboulleux,

2006 #120;Mackie, 2006 #121;Ardito, 2015 #122}. In addition, change in tracer uptake might inform about disease evolution.

R.6.2. After complete resection, we suggest radiological imaging every 3 months for 2 years, then every 3-6 months for a further 3 years. The majority of the panel suggests continuation of follow-up imaging beyond 5 years, but surveillance should then be adapted.

Reasoning

There are no published studies that address specifically this issue. Therefore, the suggested imaging interval is in accordance with the practice at many expert centers, and with standards for other malignant tumors. In the experience of the panel few tumors with initial curative surgery will recur after more than five years and therefore a 5-yr surveillance is likely to include >90% of the ACC population that will experience disease recurrence. However, the majority of the panel felt uncomfortable with the notion of complete cessation of imaging after 5 years and preferred for instance an annual imaging for another 5 years. After stopping regular imaging, patients and primary care physicians should remain vigilant in terms of potential symptoms or signs of late recurrences (see also R.6.4.).

R.6.3. For advanced ACC, we recommend surveillance based on prognostic factors, expected treatment efficacy and treatment-related toxicity, as well as the available alternative treatment options.

Reasoning

The imaging interval in advanced ACC depends on the ongoing treatment and the overall prognosis, but will usually be in 2-3 monthly intervals. For patients receiving mitotane alone, imaging intervals might be even more individualized (e.g. 2-5 months) based on tolerability and tumor kinetics. For patients undergoing loco-regional treatments, specific surveillance following procedures must be determined by the team performing these procedures, both to assess efficacy and adverse effects. For patients opting for entirely palliative management, without any anti-neoplastic therapy, no systematic imaging is advised.

R.6.4. In all patients, we recommend regular screening for hormone secretion.

Reasoning

Biochemical evaluation together with clinical evaluation fulfills two purposes: (i) it allows in a few patients the early detection of recurrences and (ii) it also identifies patients that might benefit from early anti-hormonal therapy. Biochemical evaluation should focus on steroid hormones or metabolites that were present at the time of diagnosis of the initial tumor. However, some panelists favored a more complete hormonal evaluation, because some tumors might change their steroid secretion pattern over time.

5.7. Adjuvant therapy

R.7.1. For adrenal tumors with uncertain malignant potential, we recommend against adjuvant therapy (+OOO).

Reasoning:

In certain tumors it is difficult to define if the tumor is truly malignant (see R.4.4.). Since all adjuvant therapies are associated with potential toxicity, only patients with a definitive diagnosis of ACC should be considered for adjuvant treatment.

R.7.2. We suggest adjuvant mitotane treatment in those patients without macroscopic residual tumor after surgery but who have a perceived high risk of recurrence (+OOO). However, we cannot suggest for or against adjuvant therapy for patients at low/moderate risk of recurrence (stage I-II, R0 resection and Ki67 ≤ 10%) and adjuvant therapy options should be discussed on an individual basis.

Reasoning:

The panel is in favor of offering mitotane to patients with high risk of recurrence (stage III, or R1 resection, or Ki67 >10%; see R.5.2.) despite the absence of completely convincing evidence (see section 4.3). The panel decided on the use of mitotane in the adjuvant setting based on three arguments: (i) the perceived effects {Terzolo, 2007 #33;Berruti, 2010 #21;Berruti, 2017 #22;Bertherat, 2007 #82;Else, 2014 #125;Fassnacht, 2010 #57;Grubbs, 2010 #191;Postlewait, 2016 #192} (acknowledging this is based on low quality evidence), see Figures 1A + B; (ii) published data showing a tumor response in ~20% of patients with advanced disease treated with mitotane {Baudin, 2001 #197;Else, 2014 #135;Hahner, 2005 #64;Megerle, 2018 #294}; (iii) clinical experience of the panelists. For details on mitotane management see section 5.9.

Ki67 has emerged as the most powerful predictor of recurrence, and tumors with Ki67 ≤10% might represent a subset of patients with a good prognosis. For these patients mitotane might be considered overtreatment. For this subset of patients (<30% of all localized ACCs) the ongoing ADIUVO trial, a prospective study where patients are randomized to adjuvant mitotane vs. observation, will provide guidance in a few years.

There is no clinical, histopathological, or molecular marker that reliably predicts response to mitotane although several markers have been proposed {Volante, 2012 #327;Ronchi, 2014 #322}. A study showed that mitotane levels may influence patient outcome in adjuvant setting {Terzolo, 2013 #313} as it has been reported in advanced ACC. The secretory status of the tumor has a negative prognostic value but does not seem to influence response to treatment {Berruti, 2014 #35;Berruti, 2017 #22;Megerle, 2018 #294}.

In patients who undergo surgery for recurrence of ACC but who have not previously had medical therapy, the decision on adjuvant mitotane should follow the same lines of reasoning.

R.7.3. Once the decision for mitotane treatment is established, we recommend starting mitotane as soon as clinically possible after surgery (+OOO).

Reasoning:

The ideal timing to start adjuvant mitotane is unknown; however, by analogy with other oncological adjuvant treatments we are convinced that starting mitotane within six weeks is ideal, and would not initiate the treatment later than 3 months. This reasoning is sound with the biological concept of adjuvant therapy in general, and with the latency of mitotane to

reach effective levels and anti-tumor activity. However, no published data are available to demonstrate the superiority of an early start of treatment or the lack of efficacy when started later than 3 months.

R.7.4. In patients without recurrence who tolerate mitotane in an acceptable manner, we suggest to administer adjuvant mitotane for at least 2 years, but not longer than 5 years (+OOO).

Reasoning:

The optimal duration of mitotane treatment is unknown and practice varies among different centers. Some members of the panel continue treatment for 3 to 5 years if tolerated {Terzolo, 2014 #363}, while others discontinue after 2 to 3 years {Fassnacht, 2011 #61;Berruti, 2012 #20;Else, 2014 #135}. Prognostic factors at diagnosis, patient compliance with treatment and plasma mitotane levels reached during treatment are factors that influence duration of treatment. Mitotane may possibly act as an oncostatic measure in those patients {Huang, 2008 #350;Terzolo, 2009 #328}. However, the rate of recurrence 5 years after surgery is potentially too low to advise continuation of therapy treatment beyond this time point. Treatment-related toxicity, lack of experience in long-term administration are additional factors portending against indefinite treatment.

R.7.5. The panel did not come to a definitive consensus on adjuvant radiation therapy. However, we suggest against the routine use of radiation therapy in patients with stage I-II and R0 resection (+OOO). The panel suggests considering radiation in addition to mitotane therapy on an individualized basis therapy in patients with R1 or Rx resection or in stage III.

Reasoning:

The systematic literature search indicated that radiation therapy is able to prevent local recurrence but does not significantly affect distant recurrences or overall survival {Else, 2014 #125;Fassnacht, 2006 #126;Habra, 2012 #123;Polat, 2009 #73;Sabolch, 2015 #127;Sabolch, 2013 #124} (see section 4.3. and Figure 1). However, distant metastases account for about 40-60% of tumor relapses {Berruti, 2017 #22;Amini, 2016 #157;Erdogan, 2013 #55} and have large impact on the patient prognosis, and are more difficult to treat effectively. Conversely, prevention of the complications due to local recurrence argues in favor of radiation therapy. Adjuvant radiation therapy might be particularly reasonable in patients with R1 resection. This was already suggested by earlier studies, but also by a very recent study that was published after the meta-analysis associated with this report {Nelson, 2018 #358}.

Radiation therapy is not advised for patients who experienced widespread tumor spillage during surgery. The combination of radiation therapy and mitotane is biologically sound {Cerquetti, 2008 #330;Cerquetti, 2010 #329} and possible but at the cost of greater toxicity (e.g. constitutional, gastrointestinal and liver toxicity). In addition, there is concern that radiation therapy may delay systemic therapy or prevent effective mitotane administration resulting in lower drug levels.

R.7.6. If adjuvant radiation therapy is administered, we recommend starting treatment as soon as clinically possible after surgery and to deliver radiation therapy at the dose of 50-60 Gy to the previous tumor bed in fractionated doses of approximately 2 Gy each (+000).

Reasoning:

Radiation therapy was delivered following this scheme in previous observational studies {Fassnacht, 2006 #126;Habra, 2012 #123;Sabolch, 2013 #124;Else, 2014 #125;Sabolch, 2015 #127} and lower dosage seems to be less effective {Polat, 2009 #73}.

R.7.7. The panel did not come to a definitive consensus on adjuvant use of cytotoxic drugs. We suggest against the routine use of cytotoxic drugs in the adjuvant setting. However, the panel suggests considering adjuvant chemotherapy in selected patients with very high risk for recurrence.


Reasoning:

Scant data are available on the use of cytotoxic drugs in an adjuvant setting and the studies did not control the results of treatment with a matched control group of untreated patients, or patients treated undergoing mitotane therapy {Khan, 2000 #296}. However, the majority of panelists favors discussion of this option with patients with high risk of recurrence (ideally in the setting of clinical trials). Despite the lack of published data, some members of the panel are currently using cisplatin, with or without etoposide, in patients at perceived very high risk of recurrence (e.g. Ki67 >30%. large tumor thrombus in the vena cava, stage IV, or R1 resection).

In patients with R2 resection or tumor spillage, the same considerations for treatment of (locally) advanced disease should apply (see section 5.8.).

Figure 3: Treatment for ACC amenable to complete resection

Figure 3



DFI disease-free interval between complete resection and recurrence

¹ All patients with stage I+II and most patients with stage III should be amenable to radical resection. If complete resection is not feasible, consider neo-adjuvant treatment (e.g. cisplatin or EDP). In selected patients with stage IV and oligo-metastatic disease complete resection might be possible as well and should be aimed at.

² In patients with R2 resection, consider re-surgery by an expert surgeon (see R.3.6) or see Figure 1B

³ If Ki67 staining is not available, a low (<20 mitoses / 50 high power fields) or a high mitotic rate (> 20 mitoses / 50 high power fields) may be used for risk stratification.

⁴ Individual decision (see R.7.2.). If possible enroll in clinical trial like ADIUVO (www.adiuvo-trial.org).

⁵ In some patients (e.g. Ki67 >30%, large tumor thrombus in the vena cava, stage IV, or R1 resection) consider additional cytotoxic therapy (e.g. 3-4 cycle of cisplatin + etoposide).

⁶ After two years the time intervals are gradually extended.

⁷ If the disease-free interval is between 6 and 12 months or in patients with DFI > 12, in whom complete resection is not possible, an individual approach is required (see R.8.7.)

5.8. Treatment of recurrent and/or advanced ACC

Clinical scenarios of patients with recurrent and/or advanced ACC are highly variable. Therefore, we try to provide recommendations for at least the most frequent presentations (see also Figure 4). Although a (small) proportion of patients experience a relatively long survival {Hermesen, 2008 #128; Fassnacht, 2009 #58; Libe, 2015 #29; Else, 2014 #135}, the prognosis of advanced/metastatic ACC is generally limited. The goal of any therapy is to palliate symptoms and prolong survival. In this situation it is even more important than in other scenarios to tailor treatment on an individual basis taking into account the disease extent, the patient performance status and particularly the preference of the patient.

R.8.1. For patients presenting at time of initial diagnosis with limited intra-abdominal metastases we suggest surgical therapy if complete resection of all lesions seems feasible (+OOO). In case of limited extra-abdominal lesions, we suggest adrenal tumor resection in conjunction with therapy aiming at long-term tumor control of the other lesions (+OOO). In all patients, we recommend to start mitotane therapy as soon as clinically possible (+OOO).

Reasoning:

Complete surgery is the best chance to reach long-term disease control although the likelihood of complete tumor removal in advanced ACC is low. If clinically possible, a single surgical approach should be planned. If a one-time surgical approach is impossible (e.g. due to extra-abdominal metastases), other loco-regional approaches (see R.8.2) should be discussed within a multidisciplinary expert team and the patient on an individual basis. Local expertise and preference of the patient should be taken into account. Any initial treatment (surgery, local and/or medical therapy) should be initiated in a timely fashion (\leq 4-6 weeks following initial diagnosis).

In general, prognostic parameters (see R.5.2 + 5.3) should influence the overall treatment strategy. If the disease has an aggressive behavior (i.e. increase in tumor burden [e.g. increasing size of existing tumors or new metastasis] observed in subsequent imaging performed within a few weeks) systemic options (chemotherapy plus mitotane) may be favored. If partial responses or prolonged stabilization are then observed, surgery and/or additional loco-regional options might be particularly useful ("neo-adjuvant approach", see also R.8.3). This strategy could also be potentially advantageous in patients for whom tumor shrinkage might allow a more conservative surgical approach (i.e. patients in whom radical surgery would imply the complete or partial removal of neighboring organs such as kidney, spleen and part of the pancreas){Bednarski, 2014 #334}.

These patients are at high risk for recurrence and therefore adjuvant mitotane seems to be justified {Wangberg, 2010 #361}. Addition of cytotoxic drugs might be a possible option (although data are lacking; see also R.7.7.).

R.8.2. The panel is convinced that in addition to surgery other local therapeutic measures (e.g. radiation therapy, radiofrequency ablation, cryoablation, microwave ablation, chemo-embolization) are of value for therapy of advanced ACC. We suggest individualization of the decision on the method of choice

based on the localization of the tumor lesion(s), local expertise, prognostic factors, and patient's preference (+OOO).

Reasoning:

Published data on local therapies in advanced ACC are very limited {Cazejust, 2010 #233;Ho, 2013 #234;Polat, 2009 #73;Wood, 2003 #235} and summarized in Appendix 6. However, the experience of many panelists provides additional support of efficacy of these local measures. Nevertheless, it is impossible to indicate which method is superior. Most important, the expertise of the local team in applying these methods should be taken into account when discussing this issue with patients in a shared decision-making process.

R.8.3. We suggest against the routine use of adrenal surgery in case of widespread metastatic disease at the time of first diagnosis (+OOO).

Reasoning: Despite the lack of large studies addressing this particular question, a majority of the panel agreed that patients with widespread and unresectable disease will usually not benefit from surgery. However, a few panelists suggested that adrenalectomy could be an option if technically possible.

In patients who respond very well to systemic therapy, surgery should be considered at an appropriate time point; especially if complete resection becomes feasible ("neo-adjuvant approach"). However, the published evidence for such an approach is scant {Rangel, 2013 #331;Bednarski, 2014 #334}.

In selected cases (e.g. patients with severe hormone excess) debulking surgery might be an option, although anti-hormonal drugs (see R.10.1) should be considered here. In these cases, surgery might be especially reasonable if > 80% of the tumor burden can be removed safely. In patients with a poor clinical condition and significant localized metastatic burden, additional localized therapies (see R.8.2) may be considered as an alternative.

R.8.4. In patients with advanced ACC at the time of diagnosis not qualifying for local treatment, we recommend either mitotane monotherapy or mitotane + EDP depending on prognostic parameters (+++O).

Reasoning:

Mitotane is the treatment of choice for patients with advanced ACC (for details about the management of mitotane see section 5.9). However, a very recent cohort study suggests that patients with metastatic disease at the time of primary diagnosis might not be the ideal candidates for mitotane monotherapy {Megerle, 2018 #294}. Furthermore, unfavorable prognostic parameters (e.g. high tumor burden, uncontrolled symptoms, high proliferative index, clinical evidence of a fast growing tumor) are important factors favoring a more aggressive/more rapidly active therapeutic approach. If more aggressive therapy is indicated, then the combination of EDP in addition to mitotane (EDP-M) is the most validated regimen {Fassnacht, 2012 #28}. EDP-M is the only treatment approach in ACC that is successfully evaluated in a randomized trial, the FIRM-ACT study. It has to be highlighted, however, that only progression-free survival was significantly improved in comparison to the alternative therapy (in this case streptozotocin plus mitotane; 5.0 vs. 2.1 months; HR 0.55; 95% CI 0.43

to 0.69; $P < 0.001$)), whereas for overall survival the crossover design might have diluted the results (14.8 vs 12.0 months, HR 0.79; 95% CI, 0.61 to 1.02; $P = 0.07$).

The administration of EDP-M comes with risk of adverse events and it is important that the treatment will be administered by physicians with sufficient experience in oncology treatments. All cytotoxic drugs induce asthenia, nausea, vomiting and reversible myelotoxicity. In addition, etoposide might lead (among other adverse effects) to liver toxicity and reversible alopecia, doxorubicin to congestive heart failure and reversible alopecia; cisplatin to renal toxicity, ototoxicity, peripheral neuropathy. In some patients, the risks might even outweigh the benefits (especially in patients with reduced performance status). If there are concerns about the use of doxorubicin, cisplatin/carboplatin with or without etoposide (EP or P) might be an alternative option. Carboplatin may be an alternative to cisplatin, particularly when cardiac or renal function is compromised. Again, in this cohort, loco-regional treatment options may be particularly applicable.


Several studies have tried to find biomarkers that predict response to cytotoxic therapy in ACC {Ronchi, 2009 #320; Malandrino, 2010 #335; Roca, 2017 #319; Laufs, 2018 #336}. However, no reliable marker could be identified yet.

A few centers prefer the combination of etoposide and cisplatin (EP), because there is no single study proving that EDP is truly superior to EP. In patients with poor overall health cisplatin with mitotane may be an option. However, the evidence for etoposide + cisplatin or cisplatin alone is based only on small phase II studies {Bonacci, 1998 #199; Bukowski, 1993 #200; Williamson, 2000 #213}.

There is limited evidence that standard chemotherapeutic agents may be more active in the presence of elevated mitotane concentrations {Bates, 1991 #295; Fassnacht, 2012 #28; Sperone, 2010 #32}, but the panel is not in favor in delaying cytotoxic therapy for this reason for more than 14 days. Several centers start mitotane and cytotoxic therapy in parallel.

Figure 4: Treatment of advanced ACC

Figure 4



EDP Etoposide, Doxorubicin, cisPlatin

¹ only in selected patients (e.g. with severe hormone excess)

² The following factors might guide the decision: site of disease involvement, tumor burden, symptoms, tumor grade/Ki67 index

³ The following factors might guide the decision: site of disease involvement, tumor burden, symptoms, tumor grade/Ki67 index, and importantly kinetics of tumor growth

⁴ radiotherapy, radiofrequency ablation, cryo ablation, microwave ablation, (chemo-)embolization

⁵ Few panelist favored cisplatin + etoposide

⁶ For the currently available cytotoxic regimens see Table 6 and contact specialized center.

R.8.5. In patients with recurrent disease and a disease-free interval of at least 12 months, in whom a complete resection/ablation seems feasible, we recommend surgery or alternatively other local therapies (+OOO). We recommend starting mitotane as soon as possible after the intervention.

R.8.6. We recommend EDP-M as first line treatment if the time interval between last surgery/loco-regional therapy and recurrence is less than 6 months (++OO), rather than repeat loco-regional measures.

R.8.7. For all other patients with recurrent disease an individualized approach is needed.

Reasoning:

It has been suggested that patients with a disease-free interval of 12 months or more have a significantly better prognosis and long-term disease control is achievable, if loco-regional measures are successful {Datrice, 2012 #118;Erdogan, 2013 #55}. The choice of different loco-regional therapies depends again on benefit/risk ratio, local availability and expertise, and the clinical scenario in a given individual patient. Most panelists favor surgery (if complete resection is feasible) followed by mitotane therapy.

If the recurrence occurs during adjuvant mitotane therapy, additional measures could be considered. In patients with local recurrence, adjuvant radiation therapy after surgery should be discussed. In other scenarios, additional administration of cytotoxic drugs should be discussed with the patient, particularly when mitotane blood levels were in the recommended range > 14 mg/l.

Patients with early recurrence usually suffer from a very aggressive tumor, which most likely cannot be controlled by surgery or localized therapies. Decision-making should incorporate the concern that any local measure will only delay the administration of systemic therapy. Similar to the discussion to R.9.3, the FIRM-ACT data indicate EDP-M as the most effective form of therapy. An exception might be patients in whom incomplete initial surgery is the most likely cause for early progression. In these selected patients repeat surgery at an expert center might be an appropriate alternative (see R.3.6).

Patients with recurrence between 6 and 12 months after primary surgery usually have a poor prognosis and would, therefore, benefit from a more aggressive therapeutic approach (e.g. EDP-M). However, this decision should be discussed with the patient taking into account prognostic parameters (see section 5.5.), the feasibility of a R0 resection and patient's general condition. Patients with a disease-free interval > 12 months, in whom complete resection or loco-regional therapy is not feasible and who are currently not treated with mitotane, might be good candidates for mitotane monotherapy {Megerle, 2018 #294}.

R.8.8. In patients who progress under mitotane monotherapy, we recommend to add EDP (+++O).

Reasoning:

Mitotane is a slow-acting drug and in patients with rapidly progressing tumor, it might be too slow or not effective enough. In these patients, based on the FIRM-ACT data {Fassnacht, 2012 #28}, additional administration of EDP is the first choice (for alternatives see Reasoning R.8.4.). However, if the tumor burden is limited despite obvious progression, another 2-3 months mitotane monotherapy could also be justified, particularly if adequate mitotane levels have not been achieved. In these cases, additional loco-regional options should be considered.

R.8.9. In patients who respond to medical therapy (including achievement of long-term stable disease), we suggest re-considering local measures aiming at long-term tumor control. Such an approach could be also considered in patients attaining a generally good control of the disease, in which a limited number of lesions are progressing.

Reasoning:

In some patients, in whom long-term disease control could be achieved, loco-regional measures (in addition to ongoing medical therapy) might be able to reach complete remission or at least significantly reduce tumor burden {Berruti, 2005 #24}. In patients with "mixed responses"; e.g. progressive disease limited to few lesions, loco-regional options might be reasonable to add to the ongoing medical therapy.

R.8.10. In patients who progress under EDP-M we suggest considering additional therapies including clinical trials on an individual basis (+OOO).

Reasoning:

Several drugs and drug combinations have been tested in advanced ACC. However, except EDP-M none of them has been successfully evaluated in large randomized trials. Figure 2 outlines the outcomes of the different approaches. However, this figure has to be interpreted with great caution, because differences in the characteristics of the patients included in the different cohorts preclude direct comparison between studies. Therefore, it is not possible to draw definitive conclusions. Due to the limited treatment options, the panel clearly favors enrollment of patients with progressing tumors in clinical trials investigating experimental therapies including phase I trials. However, the panel felt that despite the lack of convincing data, some guidance might be helpful for patients that cannot be enrolled in clinical trials (Table 6). Beyond cisplatin-based therapies, the two reasonably well-studied second-line cytotoxic regimens are gemcitabine + capecitabine (+/- mitotane) {Henning, 2017 #215; Sperone, 2010 #32} and streptozotocin + mitotane {Khan, 2000 #296; Fassnacht, 2012 #28}. However, objective response rates are clearly below 10% and median progression-free survival (PFS) is generally <4 months, but a few patients with long-term disease control and even complete responses in single patients are described. Nevertheless, a few panelists argued against the use of streptozotocin, because median PFS in the FIRM-ACT trial was only two months {Fassnacht, 2012 #28}. As for EDP, these cytotoxic drugs should be administered only by physicians experienced with chemotherapy. Typical adverse effects of streptozotocin are nausea, vomiting, diarrhea, renal and liver toxicity and of the association gemcitabine and capecitabine nausea, vomiting and reversible myelotoxicity.

Loco-regional measures can be particularly useful when progression is limited, or only affects limited areas (e.g. single organs). In these cases, such localized therapies (see R.8.2) might be able to provide higher response rates for these specific organ/tissue areas than second line systemic options.

Several tyrosine kinase inhibitors have been investigated in advanced ACC {Berruti, 2012 #23; Fassnacht, 2015 #27; Kroiss, 2012 #207; O'Sullivan, 2014 #209}, but the results were largely disappointing. However, in retrospect, drug efficacy could have been hampered by increased metabolism of the TKI due to mitotane-induced CYP3A4 activity. Nevertheless, currently no specific TKI can be suggested for the treatment of advanced ACC. Targeting the IGF2/IGF receptor signaling pathway was pathophysiologically a very promising approach and initial small studies suggested some efficacy {Almeida, 2008 #303; Boulle, 1998 #304; Gicquel, 1994 #305; Giordano, 2003 #306; Weber, 2000 #307; Haluska, 2010 #204; Jones, 2015 #299; Lerario, 2014 #216; Naing, 2011 #301; Naing, 2013 #208}. However, the large placebo-controlled phase III GALACCTIC trial demonstrated that the IGF1R inhibitor linsitinib did not improve progression-free or overall survival {Fassnacht, 2015 #27}. Therefore, monotherapy with drugs targeting this pathway are not reasonable for therapy in an unselected patient population.

Table 6: Systemic therapies for recurrent / advanced ACC

First-line therapies (see text for details)

- Surgery +/- other local measures (see R.8.1 and R.8.4)

- **Mitotane monotherapy**
- details on the management see section 5.9.
- **Etoposide, Doxorubicin and Cisplatin (EDP) plus Mitotane (EDP/M)** {Fassnacht, 2012 #28}
every 28 days:
 day 1 40mg/m² doxorubicin (D)
 day 2 100mg/m² etoposide (E)
 day 3+4 100mg/m² etoposide (E) + 40mg/m² cisplatin (P)
 plus oral mitotane aiming at a blood level between 14-20mg/l.

 In patients unfit for the EDP-M regimen, (E)P-M may constitute a reasonable alternative.
 Every 28 days
 day 1 100mg/m² etoposide (E)
 day 2+3 100mg/m² etoposide (E) + 40mg/m² cisplatin (P)

Additional therapeutic options

- **Consider enrollment of patients in clinical trials (www.clinicaltrial.gov)**
- **Consider loco-regional therapies**
- **Gemcitabine plus capecitabine** {Henning, 2017 #215; Sperone, 2010 #32}
 800 mg/m² gemcitabine on day 1 and 8 (repeated every 3 weeks)
 1,500 mg capecitabine orally per day in a continuous fashion
 Mitotane can be continued (individualized decision)
- **Streptozotocin plus Mitotane (Sz/M)** {Fassnacht, 2012 #28}
 induction: day 1-5: 1g Sz/d
 afterwards 2g/d Sz every 21 days
 plus oral mitotane aiming at a blood level between 14-20mg/l

R.8.11. The optimal timing of mitotane discontinuation is currently unknown and the panel could not come to a specific recommendation on this issue.

Reasoning:

A recent cohort study reported that discontinuation of mitotane should be considered in patients who experienced progressive disease after one year of mitotane therapy {Vezzosi, 2018 #308}. Part of the panel considers mitotane discontinuation when there is progressive disease despite mitotane blood levels above 14 mg/L while others often continue mitotane indefinitely in their practice. Tolerability of treatment is an important issue to consider in this decision. Moreover, it has to be considered that CYP3A4 induction by mitotane can greatly enhance metabolism of many drugs {Kroiss, 2011 #72}, including a number of experimental anti-ACC compounds, and so potentially limit their effectiveness.

5.9. Special considerations on mitotane

If mitotane therapy is started (independent of the clinical scenario) the following issues have to be considered.

R.9.1. We recommend starting therapy with mitotane in an escalating regimen depending on the performance status of the patient as well as the tolerability in the first weeks.

Reasoning

There are different regimens to administer mitotane, but none of them has been proven to be superior. In patients with good performance status some panelists use a high starting dose approach: mitotane is administered at a starting dose of 1.5 g/day and if well-tolerated from a gastrointestinal perspective the dose is increased on day two to 3 g/day, on day three to 4.5 g/day, and on day four to 6 g/day {Faggiano, 2006 #309;Mauclere-Denost, 2011 #310}. This dosage will be administered until first mitotane blood level is assessed. In this high dose regimen, it is strongly recommended to measure mitotane blood levels 2-3 weeks after initiation of therapy. Afterwards dosage will be adjusted according to blood concentrations and tolerability. Other panelists prefer a low starting dose approach. With this approach, mitotane is administered at a starting dose of 1 g/day and increased when there is good gastrointestinal tolerance every 3 days by 0.5 g up to a total dose of 3.0 - 4.0 g/day and then adjusted according to blood concentrations and tolerability {Terzolo, 2000 #311;Terzolo, 2008 #364;Terzolo, 2014 #363}.

In a formal comparative pharmacokinetic study, the high-dose starting regimen led to slightly higher mitotane plasma levels within 12 weeks of treatment, and more patients reached the target level of 14 mg/L {Kerkhofs, 2013 #38}. However, these results were not statistically significant due to lack of power. Beyond these two regimens, there is a variety of other possibilities and choice depends on personal practice, clinical scenario and patient conditions.

Mitotane is a lipophilic drug and is supposed to be better absorbed from the gut with a high fat content of the diet, e.g. with milk or chocolate. {Moolenaar, 1981 #374}. In case of limited gastrointestinal tolerance, symptomatic treatments of nausea and or diarrhea may be proposed.

R.9.2. We recommend monitoring of blood concentration of mitotane. The general aim is to reach a mitotane blood level above 14 mg/L (+000).

Reasoning

As long as mitotane plasma levels are increasing and have not yet reached a plateau at >14mg/L, mitotane plasma levels will be assessed every 3-4 weeks. Mitotane plasma level determination is best done as morning trough sampling, at least 12 hours after the last dose, preventing false high levels {Kerkhofs, 2014 #351}. When mitotane plasma levels have reached a plateau, it is usually sufficient to measure blood levels every 6-12 weeks.

Usually it takes several weeks (sometimes months) to reach mitotane levels > 14 mg/L. As long as the concentration is < 14 mg/L it is reasonable to continue to increase the dosage if this is tolerated by the patient. Due to slow pharmacokinetic characteristics, the dose of mitotane can be reduced in most patients as soon as a plasma level of > 14mg/L is reached. Over time, mitotane dosage will be titrated to the best tolerable dose while maintaining a

plasma level >14mg/L. Most patients experience adverse effects to a certain extent and these usually correlate with the plasma mitotane level (although there is major inter-individual variability) (see Table 7). However, some gastrointestinal adverse effects (like diarrhea) seem to correlate more with the oral dosage than with the plasma level and occur more frequently in the first phase of treatment {Terzolo, 2000 #311;Allolio, 2006 #236;Daffara, 2008 #25;Terzolo, 2008 #364;Terzolo, 2014 #363}. Several studies {van Slooten, 1984 #312;Baudin, 2001 #197;Haak, 1994 #202} have shown that CNS-related adverse events in particular occur more frequently when the plasma mitotane is > 20 mg/L. Therefore, many experts recommend aiming to keep plasma concentrations below 20 mg/L. However, it can be speculated that higher plasma levels may also be associated with better clinical efficacy. Furthermore, some patients do not experience relevant adverse events even at plasma levels well above 20 mg/L. Regarding the lower limit it has to be acknowledged that in at least a few patients objective responses are seen even though plasma levels of >14 mg/l were not achieved {Megerle, 2018 #294}. Therefore, some panelists favored a target range of plasma mitotane of 8-30 mg/L, whereas others aim at an individualized target level of mitotane.

Most studies addressing plasma mitotane levels analyze patients with advanced disease. However, there is one study suggesting that the same target level is also reasonable for the adjuvant setting {Terzolo, 2013 #313}. Therefore, the panel is in favor to use the same approach for both patient groups.

R.9.3. We recommend glucocorticoid replacement in all patients treated with mitotane (except those with ongoing cortisol excess). We suggest to using hydrocortisone/cortisone acetate for this purpose. Due to increased steroid clearance and increase cortisol-binding globulin at least twice the standard replacement dose is usually required.

Reasoning

A possible strategy is to start concomitant treatment on day one of mitotane treatment with hydrocortisone 20 mg/d. Alternatively, patients can be instructed to start hydrocortisone later (e.g. after 2-3 weeks or in case they experience adrenal insufficiency), because impairment of glucocorticoid effectiveness is rarely observed within the first few weeks. Due to the increased clearance and increased cortisol-binding globulin {Daffara, 2008 #25;Chortis, 2013 #52;Reimondo, 2017 #349;Kerkhofs, 2015 #39} with increasing mitotane plasma levels and based on clinical symptoms, the total hydrocortisone replacement dose will usually increased to a typical total daily dose of 50 mg in two or three divided doses. However, some patients require daily dosages up to 100 mg. There is no reliable laboratory marker to guide the optimal dosage of hydrocortisone {Reimondo, 2017 #349}, which has to be based on clinical judgment similar to the management of patients with adrenal insufficiency {Bornstein, 2016 #314}. Mitotane-induced increase in cortisol-binding globulin may confound interpretation of serum cortisol measurement. The measurement of free cortisol may offer additional information, but more studies are required to clarify the value of this method {Alexandraki, 2010 #325}. Some panelists measure plasma ACTH and use ACTH levels more than 2-fold of the upper limit of normal as evidence for insufficient glucocorticoid replacement. Other centers prefer a combined measurement of plasma ACTH and 24-hour urine free cortisol levels to assess adequacy of and optimize glucocorticoid replacement for patients receiving

mitotane. However, when urinary cortisol is measured by immunoassays, interference by cortisol metabolites induced by mitotane might occur.

In case of acute adverse events and/or hospital admission, patients should be treated intravenously with high-dose hydrocortisone (e.g. 100 mg TID) until resolution of symptoms.

Some patients experience symptoms and signs of insufficient mineralocorticoid activity (hyperkalemia, hyponatremia, hypotension, decreased wellbeing) despite full-dose substitution with hydrocortisone. In these patients, addition of fludrocortisone should be considered. Clinical judgment, electrolytes, and plasma renin concentration can be used for decision making whether to start fludrocortisone {Allolio, 2006 #236;Daffara, 2008 #25;Terzolo, 2008 #364;Terzolo, 2014 #363}.

R.9.4. We recommend regular monitoring of mitotane-induced adverse effects (Table 7) and to treat them appropriately (Table 8). To increase tolerability of mitotane, we suggest starting supportive therapy ideally before severe toxicity occurs.

Reasoning

In addition to adrenal insufficiency (see R.9.3.) mitotane treatment comes with a plethora of potential adverse events {Daffara, 2008 #25}(Table 2). Therefore, it is important to evaluate the patients regularly (e.g. in the first 6 months every 3-4 weeks, thereafter every 6-12 weeks).

Gastrointestinal adverse effects are frequent, particularly in the first months of therapy. Supportive therapy should include antiemetic and anti-diarrheal medication, as needed. Some centers even start supportive therapy at initiation of mitotane therapy. However, one has to be aware that nausea may also be a sign of adrenal insufficiency that needs recognition and appropriate treatment. Nevertheless, it should be emphasized that despite optimization of dosing schedules, the key factor influencing build-up of appropriate mitotane plasma levels is patient tolerability, so efforts should be made in order to optimize this.

In case of central nervous system (CNS) adverse effects grade 2 (moderate) and/or gastrointestinal adverse effects grade 3 (severe, but not life-threatening), mitotane dose should be reduced by 1-1.5 gram/day. In case of CNS severe, but not life-threatening (grade 3) adverse effects or any relevant grade 4 toxicity (life-threatening), and/or increase of liver enzymes >5 times baseline (except GGT), mitotane should be interrupted until significant improvement of symptoms occurs and be restarted at 50–75% of the last dose.

Assessment of thyroid hormone status (TSH, FT4, every 3 months) is advised as mitotane may induce a clinical picture similar to central hypothyroidism {Daffara, 2008 #25;Russo, 2016 #365}, possibly through a direct effect on the pituitary gland or induction of thyroid hormone metabolism. Replacement therapy with levothyroxine can be considered for these patients.

In men with signs of hypogonadism, assessment of testosterone and sex hormone-binding globulin levels is warranted, as hypogonadism is common {Daffara, 2008 #25}. Mitotane-induced increase in SHBG may confound interpretation of testosterone measurement. Testosterone supplementation may be considered in patients with low testosterone and symptoms of hypogonadism, but inhibition of 5- α reductase might prevent full activity of testosterone {Chortis, 2013 #52}.

Ovarian steroid synthesis is less affected but women in childbearing age treated with mitotane may develop multiple, and sometimes huge, ovarian cysts that may be painful and sometimes require treatment.

Cholesterol levels very frequently increase during mitotane treatment {Tada, 2014 #332}. Hypercholesterolemia can be treated with statin therapy using agents not metabolized by CYP3A4 (e.g. rosuvastatine or pravastatine). However, HDL cholesterol is usually also elevated significantly and this should be taken in consideration. Thus, statin therapy might only be beneficial in selected patients (e.g. with good prognosis in an adjuvant setting, high LDL cholesterol and additional high cardiovascular risk factors). Therefore, an individual decision making regarding the benefits of any lipid lowering therapy is necessary. Psychological and social aspects of treatment should not be neglected, i.e., professional counseling may be warranted. Follow-up on patient's well-being may be performed by questionnaire-based assessment of toxicity upon the start of the treatment and by repeating this assessment every 3 months.

R.9.5. We recommend being aware of significant drug interactions of mitotane (e.g. due to strong induction of CYP3A4). All concomitant medication should be checked for CYP3A4 interactions and substituted for an alternative if necessary and available. Other care-providers should be advised not to initiate other drug therapies without consultation.

Reasoning

A comprehensive (but not exhaustive) summary of relevant drug interactions with mitotane is provided in Kroiss et al. {Kroiss, 2011 #72} and in the Appendix 7.

Table 7: Adverse effects during mitotane treatment*

Adverse Effect	Frequency
• Gastrointestinal: nausea, vomiting, diarrhea, anorexia	very common
• Adrenal insufficiency	very common
• CNS: lethargy, somnolence, vertigo, ataxia	common
• Confusion, depression, dizziness, decreased memory	common
• Increase of hepatic enzymes (in particular gamma-GT)	very common
• Liver failure	rare
• Hepatic microsomal enzyme induction with increased metabolism of glucocorticoids and other steroids and barbiturates, phenytoin, warfarin, and many other drugs (see Appendix 7)	very common
• Increase in hormone-binding globulins (CBG, SHBG, TBG, etc.)	common
• Disturbance of thyroid parameters (interference with binding of T4 to TBG, total T4↓, free T4↓, TSH↓)	very common
• Hypercholesterolemia, hypertriglyceridemia	very common
• Gynecomastia	very common
• Skin rash	common
• Primary hypogonadism in men	common
• Prolonged bleeding time	common
• Leucopenia	common
• Thrombocytopenia, anemia	rare
• Autoimmune hepatitis	rare
• Cardiovascular: hypertension	not known
• Ocular: blurred or double vision, toxic retinopathy, cataract, macular edema	not known
• Hemorrhagic cystitis	not known

**modified by the authors based on information published by the European Medicine Agency (EMA):*

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000521/human_med_000895.jsp&mid=WC0b01ac058001d124 and clinical experience

1585 *Frequency is defined according to the following convention: very common ($\geq 1/10$), common*
1586 *($\geq 1/100$ to $< 1/10$), uncommon ($\geq 1/1,000$ to $< 1/100$), rare ($\geq 1/10,000$ to $< 1/1,000$), very rare*
1587 *(< $1/10,000$), Not known (cannot be estimated from the available data)*
1588
1589
1590

Table 8: Monitoring during mitotane treatment

Parameter	Interval	Comment
Recommended monitoring		
Mitotane blood level	Every 3-4 weeks, as soon as plateau of blood level is reached every 2-3 months	Target blood level > 14 mg/L (details see R.9.2)
GOT, GPT, bilirubin, (gGT)	Initially every 3-4 weeks, after 6 months every 2-3 months	GGT is invariably elevated without clinical consequences. If other liver enzymes are rapidly increasing (> 5-fold of baseline), there is risk of liver failure: interrupt mitotane
Blood count	Initially after 3-4 weeks, then every 3-4 months	Check for rare and in most cases not significant leucopenia, thrombocytopenia, and anemia
Suggested monitoring		
ACTH	Suspected glucocorticoid deficiency or excess	Glucocorticoid status is difficult to determine Target: ACTH in the normal range or slightly above
TSH, fT4	Every 3 – 4 months	Disturbance of thyroid hormones is frequent. Thyroid hormone replacement is only recommended in patients with clinical symptoms of hypothyroidism
Renin	Every 6 months	If renin ↑ and clinical symptoms of hypoaldosteronism are present, add fludrocortisone
Cholesterol (HDL, LDL)	Every 3-4 months (in adjuvant setting)	If LDL / HDL cholesterol ↑↑ consider treatment with statins in selected cases.
Testosterone and SHBG in men	Every 3-4 months (in adjuvant setting)	If testosterone is low and clinical symptoms of hypogonadism are present add testosterone

5.10. Other supportive therapies

R.10.1. We recommend medical therapy to control hormone excess in all patients with clinically relevant hormone-producing ACC.

Reasoning

Overt glucocorticoid excess causes significant morbidity, such as diabetes, osteoporosis, muscle weakness and immunosuppression, conditions that can impact quality of life and increase mortality. Mitotane is effective in controlling adrenocortical hormone excess syndromes, but its efficacy is delayed by several weeks. In general, mild hormone secretion can be effectively managed by mitotane alone. However, severe Cushing syndrome needs a more rapid control. Furthermore, these patients should receive appropriate anticoagulation and also pneumocystis directed antibiotic prophylaxis until cortisol levels are safely controlled {Nieman, 2015 #133}. In selected patients, surgery might even be postponed for few weeks until Cushing's syndrome is partly under control with the use of rapid agents inhibiting steroidogenesis (i.e. metyrapone). However, some panelists argued that surgery might be the fastest way to control severe hypercortisolism.

Available steroidogenic enzyme inhibitors and steroid receptor antagonists are able to attain quick reduction of cortisol effects. Anti-hormonal agents can be initiated together with mitotane. Once therapeutic mitotane levels are established, anti-steroidogenic action is also maximized, and other anti-hormonal drugs can be reduced guided by tolerability, symptoms and biochemical measurements. If possible doses should be titrated to normalization of hormone levels, or in the case of receptor antagonists to improved well-being, accepting that assessment of this can be challenging in cancer patients.

Despite the lack of comparative studies, the majority of panel members considers that metyrapone is the first therapeutic choice for the management advanced ACC patients with severe Cushing syndrome. The drug is well tolerated and can be safely administered in

association with mitotane and cytotoxic chemotherapy {Claps, 2017 #131}. Moreover, its metabolism and elimination are not altered by concomitant mitotane. Ketoconazole an inhibitor of several key cytochrome P450 (CYP) enzymes involved in multiple steps of steroidogenesis in the adrenal cortex, is another alternative, but often less effective than metyrapone and requires regular monitoring of liver function tests. Its advantage is that it also inhibits androgen production. Ketoconazole should be avoided at initiation of mitotane therapy because both substances are potentially hepatotoxic and it will be difficult to attribute the hepatotoxicity to one or the other drug. Hypercortisolemia can also be treated with mifepristone, a glucocorticoid antagonist, but dosing is based on clinical judgement as cortisol levels remain elevated or rise further on therapy {Castinetti, 2009 #132}. Moreover, the high circulating cortisol levels when on mifepristone may cause mineralocorticoid effects, including hypertension and hypokalemia that necessitate treatment with high doses of spironolactone. Patients treated with enzyme inhibitors or receptor antagonists need to be educated about symptoms and signs of adrenal insufficiency. All patients at risk for adrenal insufficiency need to be supplied with emergency medication and instructions. Intravenous etomidate can be used for seriously ill patients with severe hypercortisolemia who cannot take oral medication.

In the management of severe Cushing's syndrome, locoregional options (see R.8.2.) should also be discussed, in selected cases.

Androgen excess in women can impact quality of life due to hirsutism and virilization. It can be treated with androgen receptor antagonists, such as bicalutamide, flutamide, or spironolactone.

Only a small fraction of all tumors produce aldosterone, leading to hypertension and hypokalemia. Mineralocorticoid excess is best treated with mineralocorticoid receptor antagonists, such as spironolactone or eplerenone. However, patients with severe Cushing's syndrome may also experience hypokalemia, related to mineralocorticoid receptor activation. In case of severe hypokalemia, spironolactone and epithelial sodium channel inhibitors such as amiloride can be used, potentially at high doses, along with potassium supplementation. In such cases, frequent serum electrolyte measurement, initially several times a week, are mandatory, as there is a risk of rapid occurrences of hyperkalemia and hyponatremia.

In the rare situation of estradiol production by tumors in male patients, therapy with estrogen receptor antagonists or aromatase inhibitors could be considered.

R.10.2. We recommend therapy with anti-resorptive treatment in patients with bone metastasis.

Reasoning

Bone metastasis in cancer patients are associated with poor quality of life due to bone pain and increased risk of adverse skeletal-related events (SREs) such as pathological fractures, spinal cord compression and hypercalcemia. Several randomized phase III trials have demonstrated that bone resorption inhibitors such as bisphosphonates and denosumab are efficacious in the prevention of skeletal-related events in patients with bone metastasis from breast, prostate, lung and others primary malignancies. No data are available for ACC patients. However, based on these results, it has become general practice to treat patients with any kind of bone metastasis with anti-resorptive therapies. The administration of denosumab or bisphosphonates in 'oncological doses' in association with calcium intake and vitamin D supplementation are therefore advisable in ACC patients with metastatic bone

disease, with the aim to prevent adverse skeletal-related events and improve control of bone pain.

In patients with ACC with Cushing's syndrome that cannot be otherwise controlled anti-resorptive treatment, using 'anti-osteoporotic doses', should be considered, because it is well established that glucocorticoid-excess increases the risk of osteoporotic fractures. Since fracture risk declines rapidly after lowering excess cortisol, or antagonizing its effects, anti-osteoporotic therapies are usually not required once cortisol secretion is controlled (either by surgery or medical therapy).

R.10.3. We recommend palliative radiation for symptom palliation in advanced/metastatic ACC patients

Reasoning

Palliative radiation therapy is a commonly utilized intervention for symptom relief among patients with metastatic cancer. Two schedules of irradiation are commonly used, which include 8 Gy in a single fraction or 30 Gy in ten fractions. This treatment modality is highly effective in achieving relief of symptoms arising from bone metastases, with positive responses in up to 50% - 90% of cancer patients {Chow, 2012 #355;Pin, 2018 #356}. Painful bone metastases are, therefore, the main indication of palliative radiation in metastatic ACC patients {Polat, 2009 #73}. Other indications are symptomatic recurrences, severe mass effect and the rare case of brain metastases.

R.10.4. We recommend integrating palliative care into standard oncology care for all patients with advanced ACC

Reasoning

According to the WHO palliative care is defined as 'an approach that improves the quality of life of patients and their families facing the problems associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychosocial and spiritual' (WHO: WHO definition of palliative care. <http://www.who.int/cancer/palliative/definition/en/>).

As previously stated, the goal of care for metastasized ACC is to obtain long-term disease control and prolong patient survival. Although prognosis of patients with advanced ACC is often poor, there is a patient subset destined to obtain a relatively long survival, while treated with antineoplastic therapies. The needs of patients with cancer and their families have changed over time. According to the ASCO guidelines the best model to manage metastatic patients is to integrate palliative care early in the course of the disease and throughout the trajectory of care, extending to long-term survivorship as well as end-of-life (hospice) care. In this integrated approach the primary endocrinologists and oncologists focus on the primary oncologic disease, and the palliative care team addresses the majority of the patient's physical and psychological concerns. The team plans all therapy aiming to integrate patient wishes and employ treatment options balancing quality of life and increased survival with therapy associated risks and complications {Ferrell, 2017 #316}.

R.10.5. We suggest counseling for fertility protection in female patients in reproductive age. Fertility counseling should not only be restricted to patients undergoing cytotoxic chemotherapy, but also given to patients who plan to embark on mitotane therapy.

Reasoning

A considerable proportion of patients are diagnosed with ACC during their reproductive years. Several drugs used to treat ACC harbor significant risk for impairment of fertility or the exact risks are unknown (e.g. mitotane). On the other hand, in recent years several treatment options for preservation of fertility have been introduced. However, none of them has gained general acceptance. Therefore, we just advise to discuss this topic with every patient. This discussion should include the consideration given in section 5.12. on pregnancy and ACC in general.

5.11. Genetic counseling

R.11.1. For adults with ACC, we recommend at least a basic clinical genetic evaluation, exploring personal and family history for evidence of a hereditary predisposition syndrome.

Reasoning

The detection of germline mutations impacts on the clinical care and surveillance of index patients and offers the possibility to identify at risk family members. Probably, up to 5% of adult ACC arise in patients with germline *TP53* mutations {Herrmann, 2012 #287;Raymond, 2013 #289;Waldmann, 2012 #77} and about 3% of all ACC patients have an underlying diagnosis of Lynch syndrome {Raymond, 2013 #288;Zheng, 2016 #16}. Special attention should be given to these two hereditary syndromes, because for them there are well-established screening guidelines available {Stoffel, 2015 #367;Daly, 2017 #368;Kratz, 2017 #370;Ballinger, 2017 #369;Gupta, 2017 #366}. Up to 13% of all adrenal lesions in patients with MEN1 represent adrenal cancer (22084155). Cases of ACC have been reported in patients with Beckwith-Wiedemann syndrome (children), Familial Adenomatous Polyposis (APC) and Carney Complex {Petr, 2016 #34}.

Germline genetic testing for ACC patients should primarily be considered for the genes related to Li-Fraumeni syndrome and Lynch syndrome. ACC is an integral part of Li-Fraumeni syndrome and when considering germline genetic testing, it is important to keep in mind that at least 20% of germline *TP53* pathogenic variants occur as de novo mutations in the absence of any family history. Lynch syndrome is present in the same fraction of ACC patients as in colorectal cancer patients (3-5%), where general screening for Lynch syndrome is recommended {Stoffel, 2015 #367;Stoffel, 2015 #372}. Both, Li-Fraumeni syndrome and Lynch syndrome have well established surveillance guidelines for carriers of pathogenic variants {Stoffel, 2015 #367;Daly, 2017 #368;Kratz, 2017 #370;Ballinger, 2017 #369;Gupta, 2017 #366}. Evaluation for Lynch syndrome can be initiated by immunohistochemistry for MSH2, MLH1, PMS2, MSH6 and microsatellite instability testing, or direct genetic germline analysis of *MSH2*, *MLH1*, *PMS2*, *MSH6* and *EPCAM*. Genetic diagnosis of Li-Fraumeni syndrome is usually done by germline analysis for variants in *TP53*.

For other syndromes (depending on family history and clinical suspicion) we refer to other sources {Petr, 2016 #34;Else, 2012 #290}.

Although not the topic of this guideline, all children with a diagnosis of ACC should undergo a systematic search of germline *TP53* pathogenic variants, because 50-90% of ACC in children are related to germline pathogenic *TP53* variants {McDonnell, 2003 #291;Custodio, 2013 #293;Wasserman, 2015 #292}

R.11.2. The panel does not recommend for or against genetic tumor testing for somatic alterations.

Reasoning

While the panel recognizes that there is great hope that testing for somatic mutations and other markers in cancers general may allow tailoring of therapy and personalized approaches for therapy, for ACCs this approach is not yet established in routine clinical practice. Therefore, molecular testing should be offered within the framework of structured and systematic research projects.

5.12. Pregnancy and ACC

R.12.1. When an adrenal mass suspected to be an ACC is diagnosed during pregnancy, we recommend prompt surgical resection regardless of pregnancy trimester.

Reasoning

Considering the poor prognosis of ACC and the importance of a prompt and complete surgical removal for prognosis, adrenal surgery should be pursued independent of the term of the pregnancy {Eschler, 2015 #129}. Preterm delivery (especially in the third trimester) and pregnancy loss are obvious risks when surgery is performed. Therefore, the patient and their family, obstetric providers and the ACC care team must engage in an informed discussion considering disease prognosis and the risk to the mother and fetus as related to the underlying disease and interventional procedures. A shared decision-making after discussion of all options is imperative.

R.12.2. Patients should be informed on pregnancy-related concerns specific to the current or past diagnosis of ACC.

Reasoning

No evidence is available regarding how long patients should wait after the treatment of an ACC before they can safely consider pregnancy.

Importantly, the main concern is the poor prognosis of the malignant tumor and the potential that pregnancy could be a negative prognostic factor, possibly increasing the risk of recurrence. There is limited evidence that ACC occurring during pregnancy or in the postpartum period is associated with a worse prognosis than in non-pregnant women

{Abiven-Lepage, 2010 #315}. The hypothesis that pregnancy could favor the development of a more aggressive variant of ACC was raised.

Due to the extreme paucity of information about this issue, it seems prudent to relay the information to the patient that there is a substantial risk of disease recurrence in the first years following the diagnosis of ACC.

Since ACC may express estrogen receptors and there are preclinical data showing that estrogen may facilitate tumor development and progression through cross-talk with the IGF pathway {Sirianni, 2012 #317}, contraceptive measures other than estrogen-containing preparations are preferred.

R.12.3. We recommend avoiding pregnancy while being on mitotane treatment.

Reasoning

The main concern with mitotane therapy is the potential of teratogenic effects, due to the suspicion that the drug may cross the placenta and cause adrenolytic activity on the human fetus. However, there are only few case reports of pregnancies when on mitotane therapy {Tripto-Shkolnik, 2013 #130}. Therefore, it is impossible to draw definitive conclusions about the safety of mitotane treatment or its associated risks. Woman treated with mitotane should be informed about these risks, and ensure effective contraception to avoid pregnancy. Moreover, when mitotane treatment is discontinued, it seems wise to ensure undetectable mitotane plasma levels before considering pregnancy {de Corbiere, 2015 #318}, which might take 3-12 months. In case a patient becomes pregnant while on mitotane therapy, the uncertainty regarding risks of mitotane for the fetus should be discussed. In case the patient wishes to continue pregnancy mitotane therapy should be withheld.

6. Future directions and recommended research

Due to the fact that the evidence for most of the recommendations provided in these guidelines is weak or even very weak, there are no doubts that major efforts are needed to improve diagnosis, treatment, and quality of life for patients with ACC.

Among many important research questions, we selected ten topics as particularly important. All of them can only be addressed in an international collaborative interdisciplinary manner.

1) Clinical response to the best available therapy (i.e. EDP + mitotane) for advanced ACC is very limited with an objective response rate of less than 25%. Therefore, we undeniably lack efficient drugs for treating this disease. Thus, identifying new therapeutic targets and options is a high priority. Here is a comprehensive but by far not complete list of emerging therapies: internal radionuclide therapy, such as metomidate-based therapies; drugs targeting the following pathways or targets: Wnt/beta-catenin; CDKN2A / TP53 / RB; IGF2 / mTOR; telomeres; drugs targeting histone modifications. In general, a combined approach seems to be reasonable. There is a growing notion that individual patients and individual tumors might respond better to certain therapies, depending on their molecular landscape. Therefore, studies focusing on subgroup classification and identification are important. Due to the mitotane-associated pharmacological issues (e.g.

- CYP3A4 induction), it might be reasonable to test experimental drugs in mitotane-naïve patients within clinical studies.
- 2) Immunotherapy is the latest revolution in cancer therapy, however preliminary data with single immune check point inhibitors showed a modest activity in ACC patients. Molecular and oncogenic pathways either in tumor cells or tumor microenvironment that can impair induction or execution of a local antitumor immune response should be carefully studied in ACC.
 - 3) Since currently available systemic therapies have limited efficacy, but a subgroup of patient is destined to obtain a consistent benefit from them, the identification of predictive markers of efficacy (either clinical or molecular) of standard treatments is of paramount importance in order to spare toxic regimens to patients not destined to obtain a disease response.
 - 4) With regards to improvement of surgery for ACC, standardization of procedures (e.g. laparoscopic vs. open surgery, lymph node dissection) should be promoted and tested in clinical trials.
 - 5) The high recurrence rate in the majority of patients even after complete resection calls for improvement of adjuvant therapy. There are significant gaps in our understanding, which patients might truly benefit from the different adjuvant therapies and prospective trials are urgently needed. The ongoing ADIUVO trial will hopefully provide important information for low/intermediate risk patients, but a trial in high-risk patients (e.g. mitotane vs. mitotane + cisplatin + etoposide) is equally important.
 - 6) Despite extensive efforts, the mechanism of action and pharmacodynamics of mitotane remain poorly understood {Hescot, 2015 #338;Hescot, 2013 #339;Sbiera, 2015 #337;Hescot, 2017 #340}. In addition, mitotane is a strong inducer of xenobiotics metabolism, probably negatively impacting subsequent and parallel therapies. Therefore, further understanding and improving the pharmacology and mechanism of action of mitotane with the goal of development of mitotane related drugs that do not share the negative adverse-effects would be a significant goal.
 - 7) Translational research with the goal of rational treatment stratification should be promoted. Recent molecular classifications, identifying distinct molecular subtypes with different outcomes, should be tested prospectively. These markers could provide a cornerstone for stratifying treatment strategies. This would mean that some patients of the 'better outcome' molecular group might benefit from forgoing any adjuvant therapy. Reversely, patients in the "poor outcome" molecular group could be included in a randomized trial testing mitotane + cytotoxic drugs as an adjuvant therapy. In addition, it will be important to define differences in pharmacogenomics or tumor genomics that define exceptional responders to mitotane and/or EDP. This data can fuel further sub-stratification of ACC patients for certain therapies.
 - 8) In addition to improving treatment, other future research directions may include the use of artificial intelligence in diagnostic work-up of adrenal tumors and the improvement of screening and follow-up procedures using non-invasive techniques such as urine or serum steroid metabolomics {Arlt, 2011 #48;Kerkhofs, 2015 #40;Taylor, 2017 #341;Hines, 2017 #342} or 'liquid biopsies' with circulating tumor cells {Pinzani, 2013 #343}, circulating miRNAs {Chabre, 2013 #344;Szabo, 2014 #345;Perge, 2017 #346}, or circulating cell-free tumor DNA {Creemers, 2017 #347;Garinet, 2018 #348} for early diagnosis or detection of recurrence.
 - 9) In the long term, a better understanding of the pathogenesis of ACC is needed to pave the way for future progress. Therefore, basic research efforts have to continue. Preclinical

models are needed, to test new treatments, including additional new cell lines, tumor organoids, and new animal models. Mechanisms of tumorigenesis, tumor evolution (genetic heterogeneity, clonal evolution) and further definition of known and future therapeutic targets should be encouraged.

10) No studies so far have revealed the wishes and experiences of patients. Given the poor prognosis and the toxic therapies, there is a definite need for 'Patient Related Outcomes'. PRO's should be measured (PROM's) and incorporated in our strategy for value based cure and care.

In general, it is our common task to overcome the major limitation in ACC research – the rarity of this disease. Therefore, beyond proofs of concept requiring few patients, clinical trials can only be performed if a large number of centers gather multicenter studies. This underscores the critical role of adrenal research networks, such as ENSAT or A5, to coordinate these efforts. Ideally a limited number of large prospective trials should continuously be ongoing, in order to allow for sufficient patient recruitment. In the same context we envision that at least one reference center in every country will be established to provide multidisciplinary expertise for this rare disease to all patients.

Altogether, owing to its rarity and its severity, ACC should continue to mobilize researchers, physicians and patients in a coordinated engaged effort.

Appendices

- Appendix 1: Question 1: Pathology - what is needed to diagnose an ACC? Summary of included studies (1a: distinguishing adrenal from non-adrenal tumors; 1b: distinguishing benign from malignant behavior in adrenal tumors)
- Appendix 2: Question 2: Which are the best prognostic markers in ACC? Summary of included studies
- Appendix 3: Question 2: Prognostic factors in ACC - overview of studies markers
- Appendix 4: Question 3: Is adjuvant therapy able to prevent recurrent disease or reduce mortality after radical resection? Summary of included studies (3a: Adjuvant mitotane after surgery; 3b: Adjuvant radiotherapy after surgical resection)
- Appendix 5: Evidence tables Question 3 (adjuvant therapy)
- Appendix 6: Question 4: What is the best treatment option for macroscopically incompletely resected, recurrent or metastatic disease? Summary of included studies
- Appendix 7: Summary of relevant drug interactions with mitotane
- Appendix 8: Comments to this Guidelines by invited reviewers and members of the European Society of Endocrinology (ESE) and the European Network for the Study of Adrenal Tumors (ENSAT), representatives of associated societies of ESE, and patient representatives

Funding

This guideline was sponsored by the European Society of Endocrinology with support by the European Network for the Study of Adrenal Tumors.

Acknowledgements

The authors of the guideline would like to thank and acknowledge Mouhammed Habra, Electron Kebebe, and Britt Skogseid for their expert review and additional members of the European Society of Endocrinology, the European Network for the Study of Adrenal Tumors

or representatives of national endocrine societies for valuable and critical comments. In addition, we thank 3 patient representatives who provided valuable feedback for the guideline. The comments of the reviewers as well as the authors' responses are available as Appendix 8. Furthermore, we thank John Newell-Price for very helpful English proof-reading. Finally we would like to thank Annemarie Venemans for her support in the systematic literature search.

Declaration of potential conflict of interests (in the last 5 years)

Guillaume Assié

- Speakers fee / travel support for congresses from: HRA Pharma (2016); Ipsen Pharma (2013, 2014); Novartis (2012, 2013, 2014, 2015, 2016)

Eric Baudin

- Speakers fee: HRA Pharma
- Research support by HRA Pharma

Alfredo Berruti

- Member to remunerated Advisory Boards of Astellas, Sanofi, Janssen, Merck Sharp and Dome, Novartis, Ipsen
- Speakers fee / travel support for congresses from: Astellas, Sanofi, Janssen, Novartis, Ipsen
- Research support by Janssen (Phase II trial of Abiraterone in the management of Cushing Syndrome induced by Adrenocortical Carcinoma; 2016); Sanofi: Phase II trial of Cabazitaxel as second line treatment in the treatment of patients with advanced Adrenocortical Carcinoma; 2014)

Martin Fassnacht

- Advisory board member: of HRA Pharma (2015; not remunerated); Atterocor (2013); Astellas Pharma (2012)
- Speakers fee / travel support for congresses from: HRA Pharma (2013); Ipsen Pharma (2011, 2012)

Harm Haak

- Research support by HRA Pharma (2016)

Massimo Terzolo -

- Advisory Board member of HRA Pharma (2013; not remunerated), Atterocor-Millendo (2013-2015)
- Research support by HRA Pharma (2016)
- Speaker fee/travel support from HRA Pharma (2014, 2015)

The other authors declare no conflict of interest.

References

- 1 Kebebew E, Reiff E, Duh QY, Clark OH & McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? *World Journal of Surgery* 2006 30 872–878. (<https://doi.org/10.1007/s00268-005-0329-x>)
- 2 Kerkhofs TM, Verhoeven RH, Van der Zwan JM, Dieleman J, Kerstens MN, Links TP, Van de Poll-Franse LV & Haak HR. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. *European Journal of Cancer* 2013 49 2579–2586. (<https://doi.org/10.1016/j.ejca.2013.02.034>)
- 3 Berruti A, Baudin E, Gelderblom H, Haak HR, Porpiglia F, Fassnacht M & Pentheroudakis G. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology* 2012 23 131–138.
- 4 Petr EJ & Else T. Genetic predisposition to endocrine tumors: diagnosis, surveillance and challenges in care. *Seminars in Oncology* 2016 43 582–590. (<https://doi.org/10.1053/j.seminoncol.2016.08.007>)
- 5 de Reynies A, Assie G, Rickman DS, Tissier F, Groussin L, Rene- Corail F, Dousset B, Bertagna X, Clauser E & Bertherat J. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. *Journal of Clinical Oncology* 2009 27 1108–1115. (<https://doi.org/10.1200/JCO.2008.18.5678>)
- 6 Fragoso MC, Almeida MQ, Mazzuco TL, Mariani BM, Brito LP, Goncalves TC, Alencar GA, Lima L de O, Faria AM, Bourdeau I et al. Combined expression of BUB1B, DLGAP5, and PINK1 as predictors of poor outcome in adrenocortical tumors: validation in a Brazilian cohort of adult and pediatric patients. *European Journal of Endocrinology* 2012 166 61–67. (<https://doi.org/10.1530/EJE-11-0806>)
- 7 Ronchi CL, Sbiera S, Leich E, Henzel K, Rosenwald A, Allolio B & Fassnacht M. Single nucleotide polymorphism array profiling of adrenocortical tumors – evidence for an adenoma carcinoma sequence? *PLoS ONE* 2013 8 e73959. (<https://doi.org/10.1371/journal.pone.0073959>)
- 8 Jouinot A, Assie G, Libe R, Fassnacht M, Papathomas T, Barreau O, de la Villeon B, Faillot S, Hamzaoui N, Neou M et al. DNA methylation is an independent prognostic marker of survival in adrenocortical cancer. *Journal of Clinical Endocrinology and Metabolism* 2017 102 923–932.
- 9 Assie G, Letouze E, Fassnacht M, Jouinot A, Luscap W, Barreau O, Omeiri H, Rodriguez S, Perlemoine K, Rene-Corail F et al. Integrated genomic characterization of adrenocortical carcinoma. *Nature Genetics* 2014 46 607–612. (<https://doi.org/10.1038/ng.2953>)
- 10 Juhlin CC, Goh G, Healy JM, Fonseca AL, Scholl UI, Stenman A, Kunstman JW, Brown TC, Overton JD, Mane SM et al. Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma. *Journal of Clinical Endocrinology and Metabolism* 2015 100 E493–E502. (<https://doi.org/10.1210/jc.2014-3282>)
- 11 Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, Lerario AM, Else T, Knijnenburg TA, Ciriello G et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma. *Cancer Cell* 2016 29 723–736. (<https://doi.org/10.1016/j.ccell.2016.04.002>)

- 2052 12 Assie G, Jouinot A & Bertherat J. The 'omics' of adrenocortical tumours for
2053 personalized medicine. *Nature Reviews Endocrinology* 2014 10 215–228.
2054 (<https://doi.org/10.1038/nrendo.2013.272>)
- 2055 13 Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, Jolly S, Miller BS,
2056 Giordano TJ & Hammer GD. Adrenocortical carcinoma. *Endocrine Reviews* 2014 35 282–
2057 326. (<https://doi.org/10.1210/er.2013-1029>)
- 2058 14 Faillot S & Assie G. ENDOCRINE TUMOURS: The genomics of adrenocortical
2059 tumors. *European Journal of Endocrinology* 2016 174 R249–R265.
2060 (<https://doi.org/10.1530/EJE-15-1118>)
- 2061 15 Terzolo M, Ali A, Osella G & Mazza E. Prevalence of adrenal carcinoma among
2062 incidentally discovered adrenal masses. A retrospective study from 1989 to 1994. Gruppo
2063 Piemontese Incidentalomi Surrenali. *Archives of Surgery* 1997 132 914–919.
2064 (<https://doi.org/10.1001/archsurg.1997.01430320116020>)
- 2065 16 Cawood TJ, Hunt PJ, O'Shea D, Cole D & Soule S. Recommended evaluation of
2066 adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal
2067 cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink?
2068 *European Journal of Endocrinology* 2009 161 513–527. (<https://doi.org/10.1530/EJE-09-0234>)
2069
- 2070 17 Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, Tabarin A,
2071 Terzolo M, Tsagarakis S & Dekkers OM. Management of adrenal incidentalomas: European
2072 Society of Endocrinology Clinical Practice Guideline in collaboration with the European
2073 Network for the Study of Adrenal Tumors. *European Journal of Endocrinology* 2016 175 G1–
2074 G34. (<https://doi.org/10.1530/EJE-16-0467>)
- 2075 18 Seccia TM, Fassina A, Nussdorfer GG, Pessina AC & Rossi GP. Aldosterone-
2076 producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous
2077 clinical course. *Endocrine-Related Cancer* 2005 12 149–159.
2078 (<https://doi.org/10.1677/erc.1.00867>)
- 2079 19 Fassnacht M, Libe R, Kroiss M & Allolio B. Adrenocortical carcinoma: a clinician's
2080 update. *Nature Reviews Endocrinology* 2011 7 323–335.
2081 (<https://doi.org/10.1038/nrendo.2010.235>)
- 2082 20 Berruti A, Fassnacht M, Haak H, Else T, Baudin E, Sperone P, Kroiss M, Kerkhofs T,
2083 Williams AR, Ardito A et al. Prognostic role of overt hypercortisolism in completely operated
2084 patients with adrenocortical cancer. *European Urology* 2014 65 832–838.
2085 (<https://doi.org/10.1016/j.eururo.2013.11.006>)
- 2086 21 Kerkhofs TM, Ettaieb MH, Hermesen IG & Haak HR. Developing treatment for
2087 adrenocortical carcinoma. *Endocrine-Related Cancer* 2015 22 R325–R338.
2088 (<https://doi.org/10.1530/ERC-15-0318>)
- 2089 22 Fassnacht M, Kroiss M & Allolio B. Update in adrenocortical carcinoma. *Journal of*
2090 *Clinical Endocrinology and Metabolism* 2013 98 4551–4564. (<https://doi.org/10.1210/jc.2013-3020>)
2091
- 2092 23 Fassnacht M & Allolio B. Clinical management of adrenocortical carcinoma. *Best*
2093 *Practice and Research Clinical Endocrinology and Metabolism* 2009 23 273–289.
- 2094 24 Johanssen S, Hahner S, Saeger W, Quinkler M, Beuschlein F, Dralle H, Haaf M,
2095 Kroiss M, Jurowich C, Langer P et al. Deficits in the management of patients with

- 2096 adrenocortical carcinoma in germany. *Deutsches Arzteblatt International* 2010 107 U885–
2097 U889.
- 2098 25 Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y, Cougard P,
2099 Henry JF & Proye C. Adrenocortical carcinomas: surgical trends and results of a 253-patient
2100 series from the French Association of Endocrine Surgeons study group. *World Journal of*
2101 *Surgery* 2001 25 891–897. (<https://doi.org/10.1007/s00268-001-0047-y>)
- 2102 26 Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E &
2103 Sturgeon C. Adrenocortical carcinoma in the United States: treatment utilization and
2104 prognostic factors. *Cancer* 2008 113 3130–3136. (<https://doi.org/10.1002/cncr.23886>)
- 2105 27 Sturgeon C, Shen WT, Clark OH, Duh QY & Kebebew E. Risk assessment in 457
2106 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy?
2107 *Journal of the American College of Surgeons* 2006 202 423–430. (<https://doi.org/10.1016/j.jamcollsurg.2005.11.005>)
- 2109 28 Fassnacht M, Johanssen S, Fenske W, Weismann D, Agha A, Beuschlein F, Fuhrer
2110 D, Jurowich C, Quinkler M, Petersenn S et al. Improved survival in patients with stage II
2111 adrenocortical carcinoma followed up prospectively by specialized centers. *Journal of Clinical*
2112 *Endocrinology and Metabolism* 2010 95 4925–4932.
- 2113 29 Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F,
2114 Terzolo M, Mueller HH, Hahner S & Allolio B. Limited prognostic value of the 2004
2115 International Union Against Cancer staging classification for adrenocortical carcinoma:
2116 proposal for a Revised TNM Classification. *Cancer* 2009 115 243–250. (<https://doi.org/10.1002/cncr.24030>)
- 2118 30 Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-
2119 Brittinger C, Lacroix A, Jarzab B et al. Combination chemotherapy in advanced
2120 adrenocortical carcinoma. *New England Journal of Medicine* 2012 366 2189–2197.
2121 (<https://doi.org/10.1056/NEJMoa1200966>)
- 2122 31 Bollerslev J, Rejnmark L, Marcocci C, Shoback DM, Sitges-Serra A, van Biesen W &
2123 Dekkers OM. European Society of Endocrinology Clinical Guideline: treatment of chronic
2124 hypoparathyroidism in adults. *European Journal of Endocrinology* 2015 173 G1–G20.
2125 (<https://doi.org/10.1530/EJE-15-0628>)
- 2126 32 Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, Nasser M,
2127 Meerpohl J, Post PN, Kunz R et al. GRADE guidelines: 14. Going from evidence to
2128 recommendations: the significance and presentation of recommendations. *Journal of Clinical*
2129 *Epidemiology* 2013 66 719–725. (<https://doi.org/10.1016/j.jclinepi.2012.03.013>)
- 2130 33 Andrews JC, Schunemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, Rind D,
2131 Montori VM, Brito JP, Norris S et al. GRADE guidelines: 15. Going from evidence to
2132 recommendation- determinants of a recommendation's direction and strength. *Journal of*
2133 *Clinical Epidemiology* 2013 66 726–735. (<https://doi.org/10.1016/j.jclinepi.2013.02.003>)
- 2134 34 Guyatt GH, Schunemann HJ, Djulbegovic B & Akl EA. Guideline panels should not
2135 GRADE good practice statements. *Journal of Clinical Epidemiology* 2015 68 597–600.
2136 (<https://doi.org/10.1016/j.jclinepi.2014.12.011>)
- 2137 35 Vanbrabant T, Fassnacht M, Assie G & Dekkers OM. Influence of hormonal functional
2138 status on survival in adrenocortical carcinoma: systematic review and meta-analysis.
2139 *European Journal of Endocrinology* 2018.

2140 36 Bertherat J, Coste J & Bertagna X. Adjuvant mitotane in adrenocortical carcinoma.
 2141 New England Journal of Medicine 2007 357 1256–1257; author reply 1259.
 2142 (<https://doi.org/10.1056/NEJMc076267>)

2143 37 Blanes A & Diaz-Cano SJ. Histologic criteria for adrenocortical proliferative lesions –
 2144 value of mitotic figure variability. American Journal of Clinical Pathology 2007 127 398–408.
 2145 (<https://doi.org/10.1309/MCGUQ3R4A4WWN3LB>)

2146 38 Creemers SG, van Koetsveld PM, van Kemenade FJ, Papathomas TG, Franssen GJ,
 2147 Dogan F, Eekhoff EM, van der Valk P, de Herder WW, Janssen JA et al. Methylation of IGF2
 2148 regulatory regions to diagnose adrenocortical carcinomas. Endocrine-Related Cancer 2016
 2149 23 727–737. (<https://doi.org/10.1530/ERC-16-0266>)

2150 39 Erickson LA, Jin L, Sebo TJ, Lohse C, Pankratz VS, Kendrick ML, van Heerden JA,
 2151 Thompson GB, Grant CS & Lloyd RV. Pathologic features and expression of insulin-like
 2152 growth factor-2 in adrenocortical neoplasms. Endocrine Pathology 2001 12 429–435.
 2153 (<https://doi.org/10.1385/EP:12:4:429>)

2154 40 Arola J, Liu J, Heikkila P, Ilvesmaki V, Salmenkivi K, Voutilainen R & Kahri AI.
 2155 Expression of inhibin alpha in adrenocortical tumours reflects the hormonal status of the
 2156 neoplasm. Journal of Endocrinology
 2157 2000 165 223–229. (<https://doi.org/10.1677/joe.0.1650223>)

2158 41 Aubert S, Wacrenier A, Leroy X, Devos P, Carnaille B, Proye C, Wemeau JL, Lecomte-
 2159 Houcke M & Leteurre E. Weiss system revisited: a clinicopathologic and
 2160 immunohistochemical study of 49 adrenocortical tumors. American Journal of Surgical
 2161 Pathology 2002 26 1612–1619. (<https://doi.org/10.1097/0000478-200212000-00009>)

2162 42 Busam KJ, Iversen K, Coplan KA, Old LJ, Stockert E, Chen YT, McGregor D &
 2163 Jungbluth A. Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical
 2164 and other steroid tumors. American Journal of Surgical Pathology 1998 22 57–63.
 2165 (<https://doi.org/10.1097/0000478-199801000-00007>)

2166 43 Kamio T, Shigematsu K, Sou H, Kawai K & Tsuchiyama H. Immunohistochemical
 2167 expression of epidermal growth factor receptors in human adrenocortical carcinoma. Human
 2168 Pathology 1990 21 277–282. ([https://doi.org/10.1016/0046-8177\(90\)90227-V](https://doi.org/10.1016/0046-8177(90)90227-V))

2169 44 Komminoth P, Roth J, Schroder S, Saremaslani P & Heitz PU. Overlapping
 2170 expression of immunohistochemical markers and synaptophysin mRNA in
 2171 pheochromocytomas and adrenocortical carcinomas. Implications for the differential
 2172 diagnosis of adrenal gland tumors. Laboratory Investigation 1995 72 424–431.

2173 45 Pan CC, Chen PCH, Tsay SH & Ho DMT. Differential immunoprofiles of
 2174 hepatocellular carcinoma, renal cell carcinoma, and adrenocortical carcinoma: a systemic
 2175 immunohistochemical survey using tissue array technique. Applied Immunohistochemistry
 2176 and Molecular Morphology 2005 13 347–352. (<https://doi.org/10.1097/01.pai.0000146525.72531.19>)

2178 46 Rubin B, Regazzo D, Redaelli M, Mucignat C, Citton M, Iacobone M, Scaroni C,
 2179 Betterle C, Mantero F, Fassina A et al. Investigation of N-cadherin/beta-catenin expression in
 2180 adrenocortical tumors. Tumour Biology 2016 37 13545–13555. (<https://doi.org/10.1007/s13277-016-5257-x>)

2182 47 Sbiera S, Schmull S, Assie G, Voelker HU, Kraus L, Beyer M, Ragazzon B,
 2183 Beuschlein F, Willenberg HS, Hahner S et al. High diagnostic and prognostic value of

2184 steroidogenic factor-1 expression in adrenal tumors. *Journal of Clinical Endocrinology and*
2185 *Metabolism* 2010 95 E161–E171.

2186 48 Stojadinovic A, Brennan MF, Hoos A, Omeroglu A, Leung DH, Dudas ME, Nissan A,
2187 Cordon-Cardo C & Ghossein RA. Adrenocortical adenoma and carcinoma: histopathological
2188 and molecular comparative analysis. *Modern Pathology* 2003 16 742–751.
2189 (<https://doi.org/10.1097/01.MP.0000081730.72305.81>)

2190 49 Volante M, Sperone P, Bollito E, Frangipane E, Rosas R, Daffara F, Terzolo M,
2191 Berruti A & Papotti M. Matrix metalloproteinase type 2 expression in malignant adrenocortical
2192 tumors: Diagnostic and prognostic significance in a series of 50 adrenocortical carcinomas.
2193 *Modern Pathology* 2006 19 1563–1569. (<https://doi.org/10.1038/modpathol.3800683>)

2194 50 Wajchenberg BL, Albergaria Pereira MA, Medonca BB, Latronico AC, Campos
2195 Carneiro P, Alves VA, Zerbini MC, Liberman B, Carlos Gomes G & Kirschner MA.
2196 Adrenocortical carcinoma: clinical and laboratory observations. *Cancer* 2000 88 711–736.
2197 ([https://doi.org/10.1002/\(SICI\)1097-0142\(20000215\)88:4<711::AID-CNCR1>3.0.CO;2-W](https://doi.org/10.1002/(SICI)1097-0142(20000215)88:4<711::AID-CNCR1>3.0.CO;2-W))

2198 51 Wang C, Sun Y, Wu H, Zhao D & Chen J. Distinguishing adrenal cortical carcinomas
2199 and adenomas: a study of clinicopathological features and biomarkers. *Histopathology* 2014
2200 64 567–576. (<https://doi.org/10.1111/his.12283>)

2201 52 Zhang HY, Bu H, Chen HJ, Wei B, Liu WP, Guo J, Li FY, Liao DY, Tang Y & Zhang Z.
2202 Comparison of immunohistochemical markers in the differential diagnosis of adrenocortical
2203 tumors – immunohistochemical analysis of adrenocortical tumors. *Applied*
2204 *Immunohistochemistry and Molecular Morphology* 2008 16 32–39.

2205 53 Kovach AE, Nucera C, Lam QT, Nguyen A, Dias-Santagata D & Sadow PM. Genomic
2206 and immunohistochemical analysis in human adrenal cortical neoplasia reveal beta-catenin
2207 mutations as potential prognostic biomarker. *Discoveries* 2015 3 e40.

2208 54 Amini N, Margonis GA, Kim Y, Tran TB, Postlewait LM, Maithel SK, Wang TS, Evans
2209 DB, Hatzaras I, Shenoy R et al. Curative resection of adrenocortical carcinoma: rates and
2210 patterns of postoperative recurrence. *Annals of Surgical Oncology* 2016 23 126–133.
2211 (<https://doi.org/10.1245/s10434-015-4810-y>)

2212 55 Asare EA, Wang TS, Winchester DP, Mallin K, Kebebew E & Sturgeon C. A novel
2213 staging system for adrenocortical carcinoma better predicts survival in patients with stage I/II
2214 disease. *Surgery* 2014 156 1378–1386. (<https://doi.org/10.1016/j.surg.2014.08.018>)

2215 56 Assie G, Antoni G, Tissier F, Caillou B, Abiven G, Gicquel C, Leboulleux S, Travagli
2216 JP, Dromain C, Bertagna X et al. Prognostic parameters of metastatic adrenocortical
2217 carcinoma. *Journal of Clinical Endocrinology and Metabolism* 2007 92 148–154.

2218 57 Ayala-Ramirez M, Jasim S, Feng L, Ejaz S, Deniz F, Busaidy N, Waguespack SG,
2219 Naing A, Sircar K, Wood CG et al. Adrenocortical carcinoma: clinical outcomes and
2220 prognosis of 330 patients at a tertiary care center. *European Journal of Endocrinology* 2013
2221 169 891–899. (<https://doi.org/10.1530/EJE-13-0519>)

2222 58 Beuschlein F, Weigel J, Saeger W, Kroiss M, Wild V, Daffara F, Libe R, Ardito A,
2223 Ghuzlan AA, Quinkler M et al. Major prognostic role of Ki67 in localized adrenocortical
2224 carcinoma after complete resection. *Journal of Clinical Endocrinology and Metabolism* 2015
2225 100 841–849. (<https://doi.org/10.1210/jc.2014-3182>)

2226 59 Canter DJ, Mallin K, Uzzo RG, Egleston BL, Simhan J, Walton J, Smaldone MC,
2227 Master VA, Bratslaysky G & Kutikov A. Association of tumor size with metastatic potential

2228 and survival in patients with adrenocortical carcinoma: an analysis of the National Cancer
2229 Database. *Canadian Journal of Urology* 2013 20 6915–6921.

2230 60 Duregon E, Cappellesso R, Maffei V, Zaggia B, Ventura L, Berruti A, Terzolo M,
2231 Fassina A, Volante M & Papotti M. Validation of the prognostic role of the 'Helsinki Score' in
2232 225 cases of adrenocortical carcinoma. *Human Pathology* 2017 62 1–7.
2233 (<https://doi.org/10.1016/j.humpath.2016.09.035>)

2234 61 Erdogan I, Deutschbein T, Jurowich C, Kroiss M, Ronchi C, Quinkler M, Waldmann J,
2235 Willenberg HS, Beuschlein F, Fottner C et al. The role of surgery in the management of
2236 recurrent adrenocortical carcinoma. *Journal of Clinical Endocrinology and Metabolism* 2013
2237 98 181–191.

2238 62 Ettaieb MH, Duker JC, Feelders RA, Corssmit EP, Menke-van der Houven van Oordt
2239 CW, Timmers HJ, Kerstens MN, Wilmsink JW, Zelissen PM, Havekes B et al. Synchronous vs
2240 metachronous metastases in adrenocortical carcinoma: an analysis of the dutch adrenal
2241 network. *Hormones and Cancer* 2016 7 336–344. (<https://doi.org/10.1007/s12672-016-0270-5>)
2242 5)

2243 63 Freire DS, Siqueira SAC, Zerbini MCN, Wajchenberg BL, Correa- Giannella ML,
2244 Lucon AM & Pereira MAA. Development and internal validation of an adrenal cortical
2245 carcinoma prognostic score for predicting the risk of metastasis and local recurrence. *Clinical*
2246 *Endocrinology* 2013 79 468–475. (<https://doi.org/10.1111/cen.12174>)

2247 64 Gicquel C, Bertagna X, Gaston V, Coste J, Louvel A, Baudin E, Bertherat J, Chapuis
2248 Y, Duclos JM, Schlumberger M et al. Molecular markers and long-term recurrences in a large
2249 cohort of patients with sporadic adrenocortical tumors. *Cancer Research* 2001 61 6762–
2250 6767.

2251 65 Glover AR, Zhao JT, Ip JC, Lee JC, Robinson BG, Gill AJ, Soon PS & Sidhu SB.
2252 Long noncoding RNA profiles of adrenocortical cancer can be used to predict recurrence.
2253 *Endocrine-Related Cancer* 2015 22 99–109. (<https://doi.org/10.1530/ERC-14-0457>)

2254 66 Gonzalez RJ, Tamm EP, Ng C, Phan AT, Vassilopoulou-Sellin R, Perrier ND, Evans
2255 DB & Lee JE. Response to mitotane predicts outcome in patients with recurrent adrenal
2256 cortical carcinoma. *Surgery* 2007 142 867–874. (<https://doi.org/10.1016/j.surg.2007.09.006>)

2257 67 Kendrick ML, Curlee K, Lloyd R, Farley DR, Grant CS, Thompson GB, Rowland C,
2258 Young WF Jr, Van Heerden JA, Duh QY et al. Aldosterone-secreting adrenocortical
2259 carcinomas are associated with unique operative risks and outcomes. *Surgery* 2002 132
2260 1008–1012. (<https://doi.org/10.1067/msy.2002.128476>)

2261 68 Kim Y, Margonis GA, Prescott JD, Tran TB, Postlewait LM, Maithel SK, Wang TS,
2262 Evans DB, Hatzaras I, Shenoy R et al. Nomograms to predict recurrence-free and overall
2263 survival after curative resection of adrenocortical carcinoma. *JAMA Surgery* 2016 151 365–
2264 373. (<https://doi.org/10.1001/jamasurg.2015.4516>)

2265 69 Kim Y, Margonis GA, Prescott JD, Tran TB, Postlewait LM, Maithel SK, Wang TS,
2266 Glenn JA, Hatzaras I, Shenoy R et al. Curative surgical resection of adrenocortical
2267 carcinoma: determining long-term outcome based on conditional disease-free probability.
2268 *Annals of Surgery* 2017 265 197–204. (<https://doi.org/10.1097/SLA.0000000000001527>)

2269 70 Libe R, Borget I, Ronchi CL, Zaggia B, Kroiss M, Kerkhofs T, Bertherat J, Volante M,
2270 Quinkler M, Chabre O et al. Prognostic factors in stage III-IV adrenocortical carcinomas
2271 (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. *Annals of*
2272 *Oncology* 2015 26 2119–2125. (<https://doi.org/10.1093/annonc/mdv329>)

2273 71 Livhits M, Li N, Yeh MW & Harari A. Surgery is associated with improved survival for
2274 adrenocortical cancer, even in metastatic disease. *Surgery* 2014 156 1531–1540; discussion
2275 1540–1531. (<https://doi.org/10.1016/j.surg.2014.08.047>)

2276 72 Lucon AM, Pereira MA, Mendonca BB, Zerbini MC, Saldanha LB & Arap S.
2277 Adrenocortical tumors: results of treatment and study of Weiss's score as a prognostic factor.
2278 *Revista do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo*
2279 2002 57 251–256. (<https://doi.org/10.1590/S0041-87812002000600002>)

2280 73 Margonis GA, Kim Y, Prescott JD, Tran TB, Postlewait LM, Maithel SK, Wang TS,
2281 Evans DB, Hatzaras I, Shenoy R et al. Adrenocortical carcinoma: impact of surgical margin
2282 status on long-term outcomes. *Annals of Surgical Oncology* 2016 23 134–141. (<https://doi.org/10.1245/s10434-015-4803-x>)

2284 74 Margonis GA, Kim Y, Tran TB, Postlewait LM, Maithel SK, Wang TS, Glenn JA,
2285 Hatzaras I, Shenoy R, Phay JE et al. Outcomes after resection of cortisol-secreting
2286 adrenocortical carcinoma. *American Journal of Surgery* 2016 211 1106–1113.
2287 (<https://doi.org/10.1016/j.amjsurg.2015.09.020>)

2288 75 Millis SZ, Ejadi S & Demeure MJ. Molecular profiling of refractory adrenocortical
2289 cancers and predictive biomarkers to therapy. *Biomarkers in Cancer* 2015 7 69–76.
2290 (<https://doi.org/10.4137/BIC.S34292>)

2291 76 Paton BL, Novitsky YW, Zerey M, Harrell AG, Norton HJ, Asbun H, Kercher KW &
2292 Heniford BT. Outcomes of adrenal cortical carcinoma in the United States. *Surgery* 2006 140
2293 914–920; discussion 919–920. (<https://doi.org/10.1016/j.surg.2006.07.035>)

2294 77 Pennanen M, Heiskanen I, Sane T, Remes S, Mustonen H, Haglund C & Arola J.
2295 Helsinki score-a novel model for prediction of metastases in adrenocortical carcinomas.
2296 *Human Pathology* 2015 46 404–410. (<https://doi.org/10.1016/j.humpath.2014.11.015>)

2297 78 Schulick RD & Brennan MF. Long-term survival after complete resection and repeat
2298 resection in patients with adrenocortical carcinoma. *Annals of Surgical Oncology* 1999 6 719-
2299 726. (<https://doi.org/10.1007/s10434-999-0719-7>)

2300 79 Tran TB, Postlewait LM, Maithel SK, Prescott JD, Wang TS, Glenn J, Phay JE,
2301 Keplinger K, Fields RC, Jin LDX et al. Actual 10-year survivors following resection of
2302 adrenocortical carcinoma. *Journal of Surgical Oncology* 2016 114 971–976.
2303 (<https://doi.org/10.1002/jso.24439>)

2304 80 Xiao WJ, Zhu Y, Dai B, Zhang HL, Shi GH, Shen YJ, Zhu YP & Ye DW. Conditional
2305 survival among patients with adrenal cortical carcinoma determined using a national
2306 population-based surveillance, epidemiology, and end results registry. *Oncotarget* 2015 6
2307 44955–44962.

2308 81 Zini L, Capitanio U, Jeldres C, Lughezzani G, Sun M, Shariat SF, Isbarn H, Arjane P,
2309 Widmer H, Perrotte P et al. External validation of a nomogram predicting mortality in patients
2310 with adrenocortical carcinoma. *BJU International* 2009 104 1661–1667. (<https://doi.org/10.1111/j.1464-410X.2009.08660.x>)

2312 82 Ronchi CL, Sbiera S, Leich E, Tissier F, Steinhauer S, Deutschbein T, Fassnacht M &
2313 Allolio B. Low SGK1 expression in human adrenocortical tumors is associated with ACTH-
2314 independent glucocorticoid secretion and poor prognosis. *Journal of Clinical Endocrinology*
2315 and Metabolism 2012 97 E2251–E2260. (<https://doi.org/10.1210/jc.2012-2669>)

- 2316 83 Macfarlane DA. Cancer of the adrenal cortex; the natural history, prognosis and
2317 treatment in a study of fifty-five cases. *Annals of the Royal College of Surgeons of England*
2318 1958 23 155–186.
- 2319 84 Sullivan M, Boileau M & Hodges CV. Adrenal cortical carcinoma. *Journal of Urology*
2320 1978 120 660–665. ([https://doi.org/10.1016/S0022-5347\(17\)57317-6](https://doi.org/10.1016/S0022-5347(17)57317-6))
- 2321 85 Lee JE, Berger DH, el-Naggar AK, Hickey RC, Vassilopoulou-Sellin R, Gagel RF,
2322 Burgess MA & Evans DB. Surgical management, DNA content, and patient survival in
2323 adrenal cortical carcinoma. *Surgery* 1995 118 1090–1098. ([https://doi.org/10.1016/S0039-](https://doi.org/10.1016/S0039-6060(05)80119-9)
2324 6060(05)80119-9)
- 2325 86 DeLellis RA, Lloyd RV, Heitz PU & Eng C. World Health Organization classification of
2326 tumours. *Pathology and Genetics of Tumours of Endocrine Organs* 2004 136.
- 2327 87 Miller BS, Gauger PG, Hammer GD, Giordano TJ & Doherty GM. Proposal for
2328 modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade.
2329 *Langenbecks Archives of Surgery* 2010 395 955–961. ([https://doi.org/10.1007/s00423-010-](https://doi.org/10.1007/s00423-010-0698-y)
2330 0698-y)
- 2331 88 Lughezzani G, Sun M, Perrotte P, Jeldres C, Alasker A, Isbarn H, Budaus L, Shariat
2332 SF, Guazzoni G, Montorsi F et al. The European Network for the Study of Adrenal Tumors
2333 staging system is prognostically superior to the international union against cancer- staging
2334 system: a North American validation. *European Journal of Cancer* 2010 46 713–719.
2335 (<https://doi.org/10.1016/j.ejca.2009.12.007>)
- 2336 89 Lam AK. Update on adrenal tumours in 2017 World Health Organization (WHO) of
2337 endocrine tumours. *Endocrine Pathology* 2017 28 213–227. ([https://doi.org/10.1007/s12022-](https://doi.org/10.1007/s12022-017-9484-5)
2338 017-9484-5)
- 2339 90 Berruti A, Grisanti S, Pulzer A, Claps M, Daffara F, Loli P, Mannelli M, Boscaro M,
2340 Arvat E, Tiberio G et al. Long-term outcomes of adjuvant mitotane therapy in patients with
2341 radically resected adrenocortical carcinoma. *Journal of Clinical Endocrinology and*
2342 *Metabolism* 2017 102 1358–1365. (<https://doi.org/10.1210/jc.2016-2894>)
- 2343 91 Else T, Williams AR, Sabolch A, Jolly S, Miller BS & Hammer GD. Adjuvant therapies
2344 and patient and tumor characteristics associated with survival of adult patients with
2345 adrenocortical carcinoma. *Journal of Clinical Endocrinology and Metabolism* 2014 99 455–
2346 461. (<https://doi.org/10.1210/jc.2013-2856>)
- 2347 92 Grubbs EG, Callender GG, Xing Y, Perrier ND, Evans DB, Phan AT & Lee JE.
2348 Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve
2349 results equal to surgery plus mitotane. *Annals of Surgical Oncology* 2010 17 263–270.
2350 (<https://doi.org/10.1245/s10434-009-0716-x>)
- 2351 93 Postlewait LM, Ethun CG, Tran TB, Prescott JD, Pawlik TM, Wang TS, Glenn J,
2352 Hatzaras I, Shenoy R, Phay JE et al. Outcomes of adjuvant mitotane after resection of
2353 adrenocortical carcinoma: a 13-institution study by the US Adrenocortical Carcinoma Group.
2354 *Journal of the American College of Surgeons* 2016 222 480–490. (<https://doi.org/10.1016/j.jamcollsurg.2015.12.013>)
- 2356 94 Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto
2357 R, Buci L, Sperone P, Grossrubatscher E et al. Adjuvant mitotane treatment for
2358 adrenocortical carcinoma. *New England Journal of Medicine* 2007 356 2372–2380.
2359 (<https://doi.org/10.1056/NEJMoa063360>)

- 2360 95 Bosco JL, Silliman RA, Thwin SS, Geiger AM, Buist DS, Prout MN, Yood MU, Haque
2361 R, Wei F & Lash TL. A most stubborn bias: no adjustment method fully resolves confounding
2362 by indication in observational studies. *Journal of Clinical Epidemiology* 2010 63 64–74.
2363 (<https://doi.org/10.1016/j.jclinepi.2009.03.001>)
- 2364 96 Hernan MA & Robins JM. Instruments for causal inference: an epidemiologist's
2365 dream? *Epidemiology* 2006 17 360–372. (<https://doi.org/10.1097/01.ede.0000222409.00878.37>)
- 2367 97 Suissa S. Immortal time bias in pharmaco-epidemiology. *American Journal of*
2368 *Epidemiology* 2008 167 492–499. (<https://doi.org/10.1093/aje/kwm324>)
- 2369 98 Fassnacht M, Hahner S, Polat B, Koschker AC, Kenn W, Flentje M & Allolio B.
2370 Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical
2371 carcinoma. *Journal of Clinical Endocrinology and Metabolism* 2006 91 4501–4504.
- 2372 99 Habra MA, Ejaz S, Feng L, Das P, Deniz F, Grubbs EG, Phan AT, Waguespack S,
2373 Montserrat AR, Jimenez C et al. A Retrospective Cohort Analysis of the Efficacy of Adjuvant
2374 Radiotherapy after Primary Surgical Resection in Patients with Adrenocortical Carcinoma.
2375 *Journal of Clinical Endocrinology and Metabolism* 2013 98 192–197.
2376 (<https://doi.org/10.1210/jc.2012-2367>)
- 2377 100 Sabolch A, Else T, Griffith KA, Ben-Josef E, Williams A, Miller BS, Worden F,
2378 Hammer GD & Jolly S. Adjuvant radiation therapy improves local control after surgical
2379 resection in patients with localized adrenocortical carcinoma. *International Journal of*
2380 *Radiation Oncology, Biology, Physics* 2015 92 252–259. (<https://doi.org/10.1016/j.ijrobp.2015.01.007>)
- 2382 101 Berruti A, Terzolo M, Sperone P, Pia A, Della Casa S, Gross DJ, Carnaghi C, Casali
2383 P, Porpiglia F, Mantero F et al. Etoposide, doxorubicin and cisplatin plus mitotane in the
2384 treatment of advanced adrenocortical carcinoma: a large prospective phase II trial.
2385 *Endocrine-Related Cancer* 2005 12 657–666. (<https://doi.org/10.1677/erc.1.01025>)
- 2386 102 Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn
2387 DI, Hesseltine E, Ronchi CL et al. Linsitinib (OSI- 906) versus placebo for patients with
2388 locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase
2389 3 study. *Lancet Oncology* 2015 16 426–435. ([https://doi.org/10.1016/S1470-2045\(15\)70081-](https://doi.org/10.1016/S1470-2045(15)70081-1)
2390 1)
- 2391 103 Hermesen IG, Fassnacht M, Terzolo M, Houterman S, den Hartigh J, Leboulleux S,
2392 Daffara F, Berruti A, Chadarevian R, Schlumberger M et al. Concentrations of o,p' DDD, o,p'
2393 DDA, and o,p' DDE as predictors of tumor response to mitotane in adrenocortical carcinoma:
2394 results of a retrospective ENS@T multicenter study. *Journal of Clinical Endocrinology and*
2395 *Metabolism* 2011 96 1844–1851.
- 2396 104 Sperone P, Ferrero A, Daffara F, Priola A, Zaggia B, Volante M, Santini D, Vincenzi
2397 B, Badalamenti G, Intrivici C et al. Gemcitabine plus metronomic 5-fluorouracil or
2398 capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a
2399 multicenter phase II study. *Endocrine-Related Cancer* 2010 17 445–453.
2400 (<https://doi.org/10.1677/ERC-09-0281>)
- 2401 105 Abraham J, Bakke S, Rutt A, Meadows B, Merino M, Alexander R, Schrupp D,
2402 Bartlett D, Choyke P, Robey R et al. A phase II trial of combination chemotherapy and
2403 surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous
2404 infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein
2405 antagonist. *Cancer* 2002 94 2333–2343. (<https://doi.org/10.1002/cncr.10487>)

2406 106 Baudin E, Docao C, Gicquel C, Vassal G, Bachelot A, Penfornis A & Schlumberger
2407 M. Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical
2408 carcinoma. *Annals of Oncology* 2002 13 1806–1809.
2409 (<https://doi.org/10.1093/annonc/mdf291>)

2410 107 Baudin E, Pellegriti G, Bonnay M, Penfornis A, Laplanche A, Vassal G & Schlumberger
2411 M. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p' DDD) levels on the
2412 treatment of patients with adrenocortical carcinoma. *Cancer* 2001 92 1385–1392.
2413 ([https://doi.org/10.1002/1097-0142\(20010915\)92:6<1385::AID-CNCR1461>3.0.CO;2-2](https://doi.org/10.1002/1097-0142(20010915)92:6<1385::AID-CNCR1461>3.0.CO;2-2))

2414 108 Berruti A, Sperone P, Ferrero A, Germano A, Ardito A, Priola AM, De Francia S,
2415 Volante M, Daffara F, Generali D et al. Phase II study of weekly paclitaxel and sorafenib as
2416 second/third-line therapy in patients with adrenocortical carcinoma. *European Journal of*
2417 *Endocrinology* 2012 166 451–458. (<https://doi.org/10.1530/EJE-11-0918>)

2418 109 Bonacci R, Gigliotti A, Baudin E, Wion-Barbot N, Emy P, Bonnay M, Cailleux AF,
2419 Nakib I & Schlumberger M. Cytotoxic therapy with etoposide and cisplatin in advanced
2420 adrenocortical carcinoma. *British Journal of Cancer* 1998 78 546–549.
2421 (<https://doi.org/10.1038/bjc.1998.530>)

2422 110 Bukowski RM, Wolfe M, Levine HS, Crawford DE, Stephens RL, Gaynor E & Harker
2423 WG. Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest
2424 Oncology Group study. *Journal of Clinical Oncology* 1993 11 161–165. (<https://doi.org/10.1200/JCO.1993.11.1.161>)

2426 111 Decker RA, Elson P, Hogan TF, Citrin DL, Westring DW, Banerjee TK, Gilchrist KW &
2427 Horton J. Eastern-Cooperative-Oncology-Group Study 1879 – mitotane and adriamycin in
2428 patients with advanced adrenocortical carcinoma. *Surgery* 1991 110 1006–1013.

2429 112 Haak HR, Hermans J, van de Velde CJ, Lentjes EG, Goslings BM, Fleuren GJ &
2430 Krans HM. Optimal treatment of adrenocortical carcinoma with mitotane: results in a
2431 consecutive series of 96 patients. *British Journal of Cancer* 1994 69 947–951. (<https://doi.org/10.1038/bjc.1994.183>)

2433 113 Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GN, Paccagnella ML,
2434 de Bono JS, Gualberto A & Hammer GD. Safety, tolerability, and pharmacokinetics of the
2435 anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical
2436 carcinoma. *Cancer Chemotherapy and Pharmacology* 2010 65 765–773.
2437 (<https://doi.org/10.1007/s00280-009-1083-9>)

2438 114 Khan TS, Sundin A, Juhlin C, Wilander E, Oberg K & Eriksson B. Vincristine,
2439 cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or
2440 metastatic adrenocortical cancer. *Medical Oncology* 2004 21 167–177. (<https://doi.org/10.1385/MO:21:2:167>)

2442 115 Kroiss M, Deutschbein T, Schlotelburg W, Ronchi CL, Neu B, Muller HH, Quinkler M,
2443 Hahner S, Heidemeier A & Fassnacht M. Salvage treatment of adrenocortical carcinoma with
2444 trofosfamide. *Hormones and Cancer* 2016 7 211–218. (<https://doi.org/10.1007/s12672-016-0260-7>)

2446 116 Kroiss M, Quinkler M, Johanssen S, van Erp NP, Lankheet N, Pollinger A, Laubner K,
2447 Strasburger CJ, Hahner S, Muller HH et al. Sunitinib in refractory adrenocortical carcinoma: a
2448 phase II, single-arm, open-label trial. *Journal of Clinical Endocrinology and Metabolism* 2012
2449 97 3495–3503. (<https://doi.org/10.1210/jc.2012-1419>)

2450 117 Naing A, LoRusso P, Fu S, Hong D, Chen HX, Doyle LA, Phan AT, Habra MA &
2451 Kurzrock R. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with
2452 the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. *British*
2453 *Journal of Cancer* 2013 108 826–830. (<https://doi.org/10.1038/bjc.2013.46>)

2454 118 O'Sullivan C, Edgerly M, Velarde M, Wilkerson J, Venkatesan AM, Pittaluga S, Yang
2455 SX, Nguyen D, Balasubramaniam S & Fojo T. The VEGF inhibitor axitinib has limited
2456 effectiveness as a therapy for adrenocortical cancer. *Journal of Clinical Endocrinology and*
2457 *Metabolism* 2014 99 1291–1297.

2458 119 Quinkler M, Hahner S, Wortmann S, Johanssen S, Adam P, Ritter C, Strasburger C,
2459 Allolio B & Fassnacht M. Treatment of advanced adrenocortical carcinoma with erlotinib plus
2460 gemcitabine. *Journal of Clinical Endocrinology and Metabolism* 2008 93 2057–2062. (<https://doi.org/10.1210/jc.2007-2564>)

2462 120 Schlumberger M, Brugieres L, Gicquel C, Travagli JP, Droz JP & Parmentier C. 5-
2463 Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal-cortical carcinoma. *Cancer*
2464 1991 67 2997–3000. ([https://doi.org/10.1002/1097-0142\(19910615\)67:12<2997::AID-](https://doi.org/10.1002/1097-0142(19910615)67:12<2997::AID-CNCR2820671211>3.0.CO;2-#)
2465 [CNCR2820671211>3.0.CO;2-#](https://doi.org/10.1002/1097-0142(19910615)67:12<2997::AID-CNCR2820671211>3.0.CO;2-#))

2466 121 Urup T, Pawlak WZ, Petersen PM, Pappot H, Rorth M & Daugaard G. Treatment with
2467 docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study. *British*
2468 *Journal of Cancer* 2013 108 1994–1997. (<https://doi.org/10.1038/bjc.2013.229>)

2469 122 Williamson SK, Lew D, Miller GJ, Balcerzak SP, Baker LH & Crawford ED. Phase II
2470 evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients
2471 with locally advanced or metastatic adrenocortical carcinoma – a Southwest Oncology Group
2472 study. *Cancer* 2000 88 1159–1165. ([https://doi.org/10.1002/\(SICI\)1097-](https://doi.org/10.1002/(SICI)1097-0142(20000301)88:5<1159::AID-CNCR28>3.0.CO;2-R)
2473 [0142\(20000301\)88:5<1159::AID-CNCR28>3.0.CO;2-R](https://doi.org/10.1002/(SICI)1097-0142(20000301)88:5<1159::AID-CNCR28>3.0.CO;2-R))

2474 123 Wortmann S, Quinkler M, Ritter C, Kroiss M, Johanssen S, Hahner S, Allolio B &
2475 Fassnacht M. Bevacizumab plus capecitabine as a salvage therapy in advanced
2476 adrenocortical carcinoma. *European Journal of Endocrinology* 2010 162 349–356.
2477 (<https://doi.org/10.1530/EJE-09-0804>)

2478 124 Henning JEK, Deutschbein T, Altieri B, Steinhauer S, Kircher S, Sbiera S, Wild V,
2479 Schlotelburg W, Kroiss M, Perotti P et al. Gemcitabine-based chemotherapy in
2480 adrenocortical carcinoma: a multicenter study of efficacy and predictive factors. *Journal of*
2481 *Clinical Endocrinology and Metabolism* 2017 102 4323–4332. ([https://doi.](https://doi.org/10.1210/jc.2017-01624)
2482 [org/10.1210/jc.2017-01624](https://doi.org/10.1210/jc.2017-01624))

2483 125 Lerario AM, Worden FP, Ramm CA, Hesseltine EA, Stadler WM, Else T, Shah MH,
2484 Agamah E, Rao K & Hammer GD. The combination of insulin-like growth factor receptor 1
2485 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with
2486 recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial.
2487 *Hormones and Cancer* 2014 5 232–239. (<https://doi.org/10.1007/s12672-014-0182-1>)

2488 126 Datrice NM, Langan RC, Ripley RT, Kemp CD, Steinberg SM, Wood BJ, Libutti SK,
2489 Fojo T, Schrupp DS & Avital I. Operative management for recurrent and metastatic
2490 adrenocortical carcinoma. *Journal of Surgical Oncology* 2012 105 709–713. ([https://doi.](https://doi.org/10.1002/jso.23015)
2491 [org/10.1002/jso.23015](https://doi.org/10.1002/jso.23015))

2492 127 Gaujoux S, Al-Ahmadie H, Allen PJ, Gonen M, Shia J, D'Angelica M, Dematteo R,
2493 Fong Y, Blumgart L & Jarnagin WR. Resection of adrenocortical carcinoma liver metastasis:
2494 is it justified? *Annals of Surgical Oncology* 2012 19 2643–2651. ([https://doi.org/10.1245/](https://doi.org/10.1245/s10434-012-2358-7)
2495 [s10434-012-2358-7](https://doi.org/10.1245/s10434-012-2358-7))

2496 128 Kemp CD, Ripley RT, Mathur A, Steinberg SM, Nguyen DM, Fojo T & Schrupp DS.
2497 Pulmonary resection for metastatic adrenocortical carcinoma: the National Cancer Institute
2498 experience. *Annals of Thoracic Surgery* 2011 92 1195–1200. (<https://doi.org/10.1016/j.athoracsur.2011.05.013>)
2499

2500 129 Kwauk S & Burt M. Pulmonary metastases from adrenal cortical carcinoma: results of
2501 resection. *Journal of Surgical Oncology* 1993 53 243–246.
2502 (<https://doi.org/10.1002/jso.2930530411>)

2503 130 op den Winkel J, Pfannschmidt J, Muley T, Grunewald C, Dienemann H, Fassnacht M
2504 & Allolio B. Metastatic adrenocortical carcinoma: results of 56 pulmonary metastasectomies
2505 in 24 patients. *Annals of Thoracic Surgery* 2011 92 1965–1970. (<https://doi.org/10.1016/j.athoracsur.2011.07.088>)
2506

2507 131 Ripley RT, Kemp CD, Davis JL, Langan RC, Royal RE, Libutti SK, Steinberg SM,
2508 Wood BJ, Kammula US, Fojo T et al. Liver resection and ablation for metastatic
2509 adrenocortical carcinoma. *Annals of Surgical Oncology* 2011 18 1972–1979.
2510 (<https://doi.org/10.1245/s10434-011-1564-z>)

2511 132 Bellantone R, Ferrante A, Boscherini M, Lombardi CP, Crucitti P, Crucitti F, Favia G,
2512 Borrelli D, Boffi L, Capussotti L et al. Role of reoperation in recurrence of adrenal cortical
2513 carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal
2514 Cortical Carcinoma. *Surgery* 1997 122 1212–1218. ([https://doi.org/10.1016/S0039-6060\(97\)90229-4](https://doi.org/10.1016/S0039-6060(97)90229-4))
2515

2516 133 Crucitti F, Bellantone R, Ferrante A, Boscherini M, Crucitti P, Carbone G, Casaccia
2517 M, Campisi C, Cavallaro A, Sapienza P et al. The Italian registry for adrenal cortical
2518 carcinoma: analysis of a multiinstitutional series of 129 patients. *Surgery* 1996 119 161–170.
2519 ([https://doi.org/10.1016/S0039-6060\(96\)80164-4](https://doi.org/10.1016/S0039-6060(96)80164-4))

2520 134 Dy BM, Wise KB, Richards ML, Young WE, Grant CS, Bible KC, Rosedahl J,
2521 Harmsen WS, Farley DR & Thompson GB. Operative intervention for recurrent
2522 adrenocortical cancer. *Surgery* 2013 154 1292–1299.
2523 (<https://doi.org/10.1016/j.surg.2013.06.033>)

2524 135 Jensen JC, Pass HI, Sindelar WF & Norton JA. Recurrent or metastatic disease in
2525 select patients with adrenocortical carcinoma – aggressive resection vs chemotherapy.
2526 *Archives of Surgery* 1991 126 457–461.
2527 (<https://doi.org/10.1001/archsurg.1991.01410280059008>)

2528 136 Simon G, Pattou F, Mirallie E, Lifante JC, Nomine C, Arnault V, de Calan L, Gaillard
2529 C, Carnaille B, Brunaud L et al. Surgery for recurrent adrenocortical carcinoma: a multicenter
2530 retrospective study. *Surgery* 2017 161 249–255. (<https://doi.org/10.1016/j.surg.2016.08.058>)

2531 137 Tran TB, Liou D, Menon VG & Nissen NN. Surgical management of advanced
2532 adrenocortical carcinoma: a 21-year population-based analysis. *American Surgeon* 2013 79
2533 1115–1118.

2534 138 Dy BM, Strajina V, Cayo AK, Richards ML, Farley DR, Grant CS, Harmsen WS,
2535 Evans DB, Grubbs EG, Bible KC et al. Surgical resection of synchronously metastatic
2536 adrenocortical cancer. *Annals of Surgical Oncology* 2015 22 146–151.
2537 (<https://doi.org/10.1245/s10434-014-3944-7>)

2538 139 Hahner S, Kreissl MC, Fassnacht M, Haenscheid H, Knoedler P, Lang K, Buck AK,
2539 Reiners C, Allolio B & Schirbel A. [131I] Iodometomidate for targeted radionuclide therapy of

2540 advanced adrenocortical carcinoma. *Journal of Clinical Endocrinology and Metabolism* 2012
 2541 97 914–922. (<https://doi.org/10.1210/jc.2011-2765>)

2542 140 Cazejust J, De Baere T, Auperin A, Deschamps F, Hechelhammer L, Abdel-Rehim M,
 2543 Schlumberger M, Leboulleux S & Baudin E. Transcatheter arterial chemoembolization for
 2544 liver metastases in patients with adrenocortical carcinoma. *Journal of Vascular and*
 2545 *Interventional Radiology* 2010 21 1527–1532.

2546 141 Wood BJ, Abraham J, Hvizda JL, Alexander HR & Fojo T. Radiofrequency ablation of
 2547 adrenal tumors and adrenocortical carcinoma metastases. *Cancer* 2003 97 554–560.
 2548 (<https://doi.org/10.1002/cncr.11084>)

2549 142 Ho J, Turkbey B, Edgerly M, Alimchandani M, Quezado M, Camphausen K, Fojo T &
 2550 Kaushal A. Role of radiotherapy in adrenocortical carcinoma. *Cancer Journal* 2013 19 288–
 2551 294. (<https://doi.org/10.1097/PPO.0b013e31829e3221>)

2552 143 Hahner S & Fassnacht M. Mitotane for adrenocortical carcinoma treatment. *Current*
 2553 *Opinion in Investigational Drugs* 2005 6 386–394.

2554 144 Stell A & Sinnott R. The ENSAT registry: a digital repository supporting adrenal
 2555 cancer research. *Studies in Health Technology and Informatics* 2012 178 207–212.

2556 145 Fassnacht M, Kenn W & Allolio B. Adrenal tumors: how to establish malignancy?
 2557 *Journal of Endocrinological Investigation* 2004 27 387–399.
 2558 (<https://doi.org/10.1007/BF03351068>)

2559 146 Allolio B & Fassnacht M. Clinical review: adrenocortical carcinoma: clinical update.
 2560 *Journal of Clinical Endocrinology and Metabolism* 2006 91 2027–2037.
 2561 (<https://doi.org/10.1210/jc.2005-2639>)

2562 147 Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM &
 2563 Montori VM. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice
 2564 Guideline. *Journal of Clinical Endocrinology and Metabolism* 2008 93 1526–1540.
 2565 (<https://doi.org/10.1210/jc.2008-0125>)

2566 148 Libe R, Fratticci A & Bertherat J. Adrenocortical cancer: pathophysiology and clinical
 2567 management. *Endocrine-Related Cancer* 2007 14 13–28.
 2568 (<https://doi.org/10.1677/erc.1.01130>)

2569 149 Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R & Welt
 2570 CK. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical
 2571 practice guideline. *Journal of Clinical Endocrinology and Metabolism* 2013 98 4565–4592.
 2572 (<https://doi.org/10.1210/jc.2013-2350>)

2573 150 Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M &
 2574 Young WF Jr. The management of primary aldosteronism: case detection, diagnosis, and
 2575 treatment: an Endocrine Society Clinical Practice Guideline. *Journal of Clinical Endocrinology*
 2576 *and Metabolism* 2016 101 1889–1916. (<https://doi.org/10.1210/jc.2015-4061>)

2577 151 Dinnes J, Bancos I, Ferrante di Ruffano L, Chortis V, Davenport C, Bayliss S, Sahdev
 2578 A, Guest P, Fassnacht M, Deeks JJ et al. MANAGEMENT OF ENDOCRINE DISEASE:
 2579 Imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a
 2580 systematic review and meta-analysis. *European Journal of Endocrinology* 2016 175 R51–
 2581 R64. (<https://doi.org/10.1530/EJE-16-0461>)

2582 152 Peppercorn PD, Grossman AB & Reznek RH. Imaging of incidentally discovered
2583 adrenal masses. *Clinical Endocrinology* 1998 48 379–388. (<https://doi.org/10.1046/j.1365-2265.1998.00475.x>)
2584

2585 153 Caoili EM, Korobkin M, Francis IR, Cohan RH, Platt JF, Dunnick NR & Raghupathi KI.
2586 Adrenal masses: characterization with combined unenhanced and delayed enhanced CT.
2587 *Radiology* 2002 222 629–633. (<https://doi.org/10.1148/radiol.2223010766>)

2588 154 Blake MA, Kalra MK, Sweeney AT, Lucey BC, Maher MM, Sahani DV, Halpern EF,
2589 Mueller PR, Hahn PF & Boland GW. Distinguishing benign from malignant adrenal masses:
2590 multi-detector row CT protocol with 10-minute delay. *Radiology* 2006 238 578–585. (<https://doi.org/10.1148/radiol.2382041514>)
2591

2592 155 Ilias I, Sahdev A, Reznek RH, Grossman AB & Pacak K. The optimal imaging of
2593 adrenal tumours: a comparison of different methods. *Endocrine-Related Cancer* 2007 14
2594 587–599. (<https://doi.org/10.1677/ERC-07-0045>)

2595 156 Mackie GC, Shulkin BL, Ribeiro RC, Worden FP, Gauger PG, Mody RJ, Connolly LP,
2596 Kunter G, Rodriguez-Galindo C, Wallis JW et al. Use of [18F]fluorodeoxyglucose positron
2597 emission tomography in evaluating locally recurrent and metastatic adrenocortical
2598 carcinoma. *Journal of Clinical Endocrinology and Metabolism* 2006 91 2665–2671.
2599 (<https://doi.org/10.1210/jc.2005-2612>)

2600 157 Groussin L, Bonardel G, Silvera S, Tissier F, Coste J, Abiven G, Libe R, Bienvenu M,
2601 Alberini JL, Salenave S et al. 18F-Fluorodeoxyglucose positron emission tomography for the
2602 diagnosis of adrenocortical tumors: a prospective study in 77 operated patients. *Journal of*
2603 *Clinical Endocrinology and Metabolism* 2009 94 1713–1722. (<https://doi.org/10.1210/jc.2008-2302>)
2604

2605 158 Deandreis D, Leboulleux S, Caramella C, Schlumberger M & Baudin E. FDG PET in
2606 the management of patients with adrenal masses and adrenocortical carcinoma. *Hormones*
2607 *and Cancer* 2011 2 354–362. (<https://doi.org/10.1007/s12672-011-0091-5>)

2608 159 Cistaro A, Niccoli Asabella A, Coppolino P, Quartuccio N, Altini C, Cucinotta M,
2609 Alongi P, Balma M, Sanfilippo S, Buschiazzi A et al. Diagnostic and prognostic value of 18F-
2610 FDG PET/CT in comparison with morphological imaging in primary adrenal gland
2611 malignancies – a multicenter experience. *Hellenic Journal of Nuclear Medicine* 2015 18 97–
2612 102.

2613 160 Altinmakas E, Hobbs BP, Ye H, Grubbs EG, Perrier ND, Prieto VG, Lee JE & Ng CS.
2614 Diagnostic performance of (18-)F-FDG-PET-CT in adrenal lesions using histopathology as
2615 reference standard. *Abdominal Radiology* 2017 42 577–584. (<https://doi.org/10.1007/s00261-016-0915-4>)
2616

2617 161 Ciftci E, Turgut B, Cakmakcilar A & Erturk SA. Diagnostic importance of 18F-FDG
2618 PET/CT parameters and total lesion glycolysis in differentiating between benign and
2619 malignant adrenal lesions. *Nuclear Medicine Communications* 2017 38 788–794. (<https://doi.org/10.1097/MNM.0000000000000712>)
2620

2621 162 Bluemel C, Hahner S, Heinze B, Fassnacht M, Kroiss M, Bley TA, Wester HJ, Kropf
2622 S, Lapa C, Schirbel A et al. Investigating the chemokine receptor 4 as potential theranostic
2623 target in adrenocortical cancer patients. *Clinical Nuclear Medicine* 2017 42 e29–e34.
2624 (<https://doi.org/10.1097/RLU.0000000000001435>)

2625 163 Werner RA, Kroiss M, Nakajo M, Mugge DO, Hahner S, Fassnacht M, Schirbel A,
2626 Bluemel C, Higuchi T, Papp L et al. Assessment of tumor heterogeneity in treatment-naïve

2627 adrenocortical cancer patients using 18F-FDG positron emission tomography. *Endocrine*
2628 2016 53 791–800. (<https://doi.org/10.1007/s12020-016-0970-1>)

2629 164 Wu YW & Tan CH. Determination of a cutoff attenuation value on single-phase
2630 contrast-enhanced CT for characterizing adrenal nodules via chemical shift MRI. *Abdominal*
2631 *Radiology* 2016 41 1170–1177. (<https://doi.org/10.1007/s00261-016-0654-6>)

2632 165 Nakajo M, Jinguji M, Shinaji T, Nakabeppu Y, Fukukura Y & Yoshiura T. Texture
2633 analysis of FDG PET/CT for differentiating between FDG-avid benign and metastatic adrenal
2634 tumors: efficacy of combining SUV and texture parameters. *Abdominal Radiology* 2017 42
2635 2882–2889. (<https://doi.org/10.1007/s00261-017-1207-3>)

2636 166 Guerin C, Pattou F, Brunaud L, Lifante JC, Mirallie E, Haissaguerre M, Huglo D,
2637 Olivier P, Houzard C, Ansquer C et al. Performance of 18F- FDG PET/CT in the
2638 characterization of adrenal masses in noncancer patients: a prospective study. *Journal of*
2639 *Clinical Endocrinology and Metabolism* 2017 102 2465–2472.
2640 (<https://doi.org/10.1210/jc.2017-00254>)

2641 167 Marty M, Gaye D, Perez P, Auder C, Nunes ML, Ferriere A, Haissaguerre M &
2642 Tabarin A. Diagnostic accuracy of computed tomography to identify adenomas among
2643 adrenal incidentalomas in an endocrinological population. *European Journal of*
2644 *Endocrinology* 2018 178 439–446. (<https://doi.org/10.1530/EJE-17-1056>)

2645 168 Kim SJ, Lee SW, Pak K, Kim IJ & Kim K. Diagnostic accuracy of (18) F-FDG PET or
2646 PET/CT for the characterization of adrenal masses: a systematic review and meta-analysis.
2647 *British Journal of Radiology* 2018 91 20170520. (<https://doi.org/10.1259/bjr.20170520>)

2648 169 Delivanis DA, Bancos I, Atwell TD, Schmit GD, Eiken PW, Natt N, Erickson D,
2649 Maraka S, Young WF & Nathan MA. Diagnostic performance of unenhanced computed
2650 tomography and (18) F-fluorodeoxyglucose positron emission tomography in indeterminate
2651 adrenal tumours. *Clinical Endocrinology* 2018 88 30–36. (<https://doi.org/10.1111/cen.13448>)

2652 170 Romeo V, Maurea S, Cuocolo R, Petretta M, Mainenti PP, Verde F, Coppola M,
2653 Dell'Aversana S & Brunetti A. Characterization of adrenal lesions on unenhanced MRI using
2654 texture analysis: a machine-learning approach. *Journal of Magnetic Resonance Imaging*
2655 2018 48 198–204. (<https://doi.org/10.1002/jmri.25954>)

2656 171 Thomas AJ, Habra MA, Bhosale PR, Qayyum AA, Ahmed K, Vicens R & Elsayes KM.
2657 Interobserver agreement in distinguishing large adrenal adenomas and adrenocortical
2658 carcinomas on computed tomography. *Abdominal Radiology* 2018 Epub. (<https://doi.org/10.1007/s00261-018-1603-3>)

2660 172 Ng CS, Altinmakas E, Wei W, Ghosh P, Li X, Grubbs EG, Perrier NA, Prieto VG, Lee
2661 JE & Hobbs BP. Combining washout and noncontrast data from adrenal protocol CT:
2662 improving diagnostic performance. *Academic Radiology* 2018 25 861–868.
2663 (<https://doi.org/10.1016/j.acra.2017.12.005>)

2664 173 Petersenn S, Richter PA, Broemel T, Ritter CO, Deutschbein T, Beil FU, Allolio B &
2665 Fassnacht M. Computed tomography criteria for discrimination of adrenal adenomas and
2666 adrenocortical carcinomas: analysis of the German ACC registry. *European Journal of*
2667 *Endocrinology* 2015 172 415–422. (<https://doi.org/10.1530/EJE-14-0916>)

2668 174 Bancos I, Tamhane S, Shah M, Delivanis DA, Alahdab F, Arlt W, Fassnacht M &
2669 Murad MH. DIAGNOSIS OF ENDOCRINE DISEASE: The diagnostic performance of adrenal
2670 biopsy: a systematic review and meta-analysis. *European Journal of Endocrinology* 2016 175
2671 R65–R80. (<https://doi.org/10.1530/EJE-16-0297>)

- 2672 175 Williams AR, Hammer GD & Else T. Transcutaneous biopsy of adrenocortical
2673 carcinoma is rarely helpful in diagnosis, potentially harmful, but does not affect patient
2674 outcome. *European Journal of Endocrinology* 2014 170 829–835.
2675 (<https://doi.org/10.1530/EJE-13-1033>)
- 2676 176 Palazzo F, Dickinson A, Phillips B, Sahdev A, Bliss R, Rasheed A, Krukowski Z &
2677 Newell-Price J. Adrenal surgery in England: better outcomes in high-volume practices.
2678 *Clinical Endocrinology* 2016 85 17–20. (<https://doi.org/10.1111/cen.13021>)
- 2679 177 Park HS, Roman SA & Sosa JA. Outcomes from 3144 adrenalectomies in the United
2680 States: which matters more, surgeon volume or specialty? *Archives of Surgery* 2009 144
2681 1060–1067. (<https://doi.org/10.1001/archsurg.2009.191>)
- 2682 178 Lindeman B, Hashimoto DA, Bababekov YJ, Stapleton SM, Chang DC, Hodin RA &
2683 Phitayakorn R. Fifteen years of adrenalectomies: impact of specialty training and operative
2684 volume. *Surgery* 2018 163 150–156. (<https://doi.org/10.1016/j.surg.2017.05.024>)
- 2685 179 Villar JM, Moreno P, Ortega J, Bollo E, Ramirez CP, Munoz N, Martinez C,
2686 Dominguez-Adame E, Sancho J, Del Pino JM et al. Results of adrenal surgery. Data of a
2687 Spanish National Survey. *Langenbecks Archives of Surgery* 2010 395 837–843.
2688 (<https://doi.org/10.1007/s00423-010-0697-z>)
- 2689 180 Gallagher SF, Wahi M, Haines KL, Baksh K, Enriquez J, Lee TM, Murr MM & Fabri
2690 PJ. Trends in adrenalectomy rates, indications, and physician volume: a statewide analysis
2691 of 1816 adrenalectomies. *Surgery* 2007 142 1011–1021; discussion 1011–1021. (<https://doi.org/10.1016/j.surg.2007.09.024>)
- 2693 181 Lombardi CP, Raffaelli M, Boniardi M, De Toma G, Marzano LA, Miccoli P, Minni F,
2694 Morino M, Pelizzo MR, Pietrabissa A et al. Adrenocortical carcinoma: effect of hospital
2695 volume on patient outcome. *Langenbecks Archives of Surgery* 2012 397 201–207. (<https://doi.org/10.1007/s00423-011-0866-8>)
- 2697 182 Gratian L, Pura J, Dinan M, Reed S, Scheri R, Roman S & Sosa JA. Treatment
2698 patterns and outcomes for patients with adrenocortical carcinoma associated with hospital
2699 case volume in the United States. *Annals of Surgical Oncology* 2014 21 3509–3514.
2700 (<https://doi.org/10.1245/s10434-014-3931-z>)
- 2701 183 Hermesen IG, Kerkhofs TM, den Butter G, Kievit J, van Eijck CH, Nieveen van Dijkum
2702 EJ & Haak HR. Surgery in adrenocortical carcinoma: Importance of national cooperation and
2703 centralized surgery. *Surgery* 2012 152 50–56. (<https://doi.org/10.1016/j.surg.2012.02.005>)
- 2704 184 Kerkhofs TM, Verhoeven RH, Bonjer HJ, van Dijkum EJ, Vriens MR, De Vries J, Van
2705 Eijck CH, Bonsing BA, Van de Poll-Franse LV & Haak HR. Surgery for adrenocortical
2706 carcinoma in The Netherlands: analysis of the national cancer registry data. *European*
2707 *Journal of Endocrinology* 2013 169 83–89. (<https://doi.org/10.1530/EJE-13-0142>)
- 2708 185 Gaujoux S & Mihai R. European Society of Endocrine Surgeons (ESES) and
2709 European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the
2710 surgical management of adrenocortical carcinoma. *British Journal of Surgery* 2017 104 358–
2711 376. (<https://doi.org/10.1002/bjs.10414>)
- 2712 186 Gaujoux S & Brennan MF. Recommendation for standardized surgical management
2713 of primary adrenocortical carcinoma. *Surgery* 2012 152 123–132.
2714 (<https://doi.org/10.1016/j.surg.2011.09.030>)
- 2715 187 Porpiglia F, Fiori C, Daffara FC, Zaggia B, Ardito A, Scarpa RM, Papotti M, Berruti A,
2716 Scagliotti GV & Terzolo M. Does nephrectomy during radical adrenalectomy for stage II

2717 adrenocortical cancer affect patient outcome? *Journal of Endocrinological Investigation* 2016
2718 39 465–471. (<https://doi.org/10.1007/s40618-015-0422-4>)

2719 188 Donatini G, Caiazzo R, Do Cao C, Aubert S, Zerrweck C, El-Kathib Z, Gauthier T,
2720 Leteurtre E, Wemeau JL, Vantighem MC et al. Long-term survival after adrenalectomy for
2721 stage I/II adrenocortical carcinoma (ACC): a retrospective comparative cohort study of
2722 laparoscopic versus open approach. *Annals of Surgical Oncology* 2014 21 284–291.
2723 (<https://doi.org/10.1245/s10434-013-3164-6>)

2724 189 Sgourakis G, Lanitis S, Kouloura A, Zaphiriadou P, Karkoulas K, Raptis D,
2725 Anagnostara A & Caraliotas C. Laparoscopic versus open adrenalectomy for stage I/II
2726 adrenocortical carcinoma: meta-analysis of outcomes. *Journal of Investigative Surgery* 2015
2727 28 145–152. (<https://doi.org/10.3109/08941939.2014.987886>)

2728 190 Autorino R, Bove P, De Sio M, Miano R, Micali S, Cindolo L, Greco F, Nicholas J,
2729 Fiori C, Bianchi G et al. Open versus laparoscopic adrenalectomy for adrenocortical
2730 carcinoma: a meta-analysis of surgical and oncological outcomes. *Annals of Surgical
2731 Oncology* 2016 23 1195–1202. (<https://doi.org/10.1245/s10434-015-4900-x>)

2732 191 Langenhuijsen J, Birtle A, Klatte T, Porpiglia F & Timsit MO. Surgical management of
2733 adrenocortical carcinoma: impact of laparoscopic approach, lymphadenectomy, and surgical
2734 volume on outcomes-a systematic review and meta-analysis of the current literature.
2735 *European Urology Focus* 2016 1 241–250. (<https://doi.org/10.1016/j.euf.2015.12.001>)

2736 192 Lee CW, Salem AI, Schneider DF, Levenson GE, Tran TB, Poultides GA, Postlewait
2737 LM, Maithel SK, Wang TS, Hatzaras I et al. Minimally invasive resection of adrenocortical
2738 carcinoma: a multi- institutional study of 201 patients. *Journal of Gastrointestinal Surgery*
2739 2017 21 352–362. (<https://doi.org/10.1007/s11605-016-3262-4>)

2740 193 Zheng GY, Li HZ, Deng JH, Zhang XB & Wu XC. Open adrenalectomy versus
2741 laparoscopic adrenalectomy for adrenocortical carcinoma: a retrospective comparative study
2742 on short-term oncologic prognosis. *OncoTargets and Therapy* 2018 11 1625–1632.
2743 (<https://doi.org/10.2147/OTT.S157518>)

2744 194 Mpaili E, Moris D, Tsilimigras DI, Oikonomou D, Pawlik TM, Schizas D, Papalampros
2745 A, Felekouras E & Dimitroulis D. Laparoscopic versus open adrenalectomy for
2746 localized/locally advanced primary adrenocortical carcinoma (ENSAT I-III) in adults: is
2747 margin-free resection the key surgical factor that dictates outcome? A review of the literature.
2748 *Journal of Laparoendoscopic and Advanced Surgical Techniques Part A* 2018 28 408–414.
2749 (<https://doi.org/10.1089/lap.2017.0546>)

2750 195 Huynh KT, Lee DY, Lau BJ, Flaherty DC, Lee J & Goldfarb M. Impact of laparoscopic
2751 adrenalectomy on overall survival in patients with nonmetastatic adrenocortical carcinoma.
2752 *Journal of the American College of Surgeons* 2016 223 485–492. (<https://doi.org/10.1016/j.jamcollsurg.2016.05.015>)

2754 196 Barczynski M, Konturek A, Golkowski F, Cichon S, Huszno B, Peitgen K & Walz MK.
2755 Posterior retroperitoneoscopic adrenalectomy: a comparison between the initial experience
2756 in the invention phase and introductory phase of the new surgical technique. *World Journal
2757 of Surgery* 2007 31 65–71. (<https://doi.org/10.1007/s00268-006-0083-8>)

2758 197 Schreinemakers JM, Kiela GJ, Valk GD, Vriens MR & Rinkes IH. Retroperitoneal
2759 endoscopic adrenalectomy is safe and effective. *British Journal of Surgery* 2010 97 1667–
2760 1672. (<https://doi.org/10.1002/bjs.7191>)

2761 198 Nilubol N, Patel D & Kebebew E. Does lymphadenectomy improve survival in patients
2762 with adrenocortical carcinoma? A population- based study. *World Journal of Surgery* 2016 40
2763 697–705. (<https://doi.org/10.1007/s00268-015-3283-2>)

2764 199 Saade N, Sadler C & Goldfarb M. Impact of regional lymph node dissection on
2765 disease specific survival in adrenal cortical carcinoma. *Hormone and Metabolic Research*
2766 2015 47 820–825. (<https://doi.org/10.1055/s-0035-1549877>)

2767 200 Harrison LE, Gaudin PB & Brennan MF. Pathologic features of prognostic
2768 significance for adrenocortical carcinoma after curative resection. *Archives of Surgery* 1999
2769 134 181–185. (<https://doi.org/10.1001/archsurg.134.2.181>)

2770 201 Panjwani S, Moore MD, Gray KD, Finnerty BM, Beninato T, Brunaud L, Fahey TJ 3rd
2771 & Zarnegar R. The impact of nodal dissection on staging in adrenocortical carcinoma. *Annals*
2772 *of Surgical Oncology* 2017 24 3617–3623. (<https://doi.org/10.1245/s10434-017-6064-3>)

2773 202 Gerry JM, Tran TB, Postlewait LM, Maithel SK, Prescott JD, Wang TS, Glenn JA,
2774 Phay JE, Keplinger K, Fields RC et al. Lymphadenectomy for adrenocortical carcinoma: is
2775 there a therapeutic benefit? *Annals of Surgical Oncology* 2016 23 708–713.
2776 (<https://doi.org/10.1245/s10434-016-5536-1>)

2777 203 Reibetanz J, Jurowich C, Erdogan I, Nies C, Rayes N, Dralle H, Behrend M, Allolio B
2778 & Fassnacht M. Impact of lymphadenectomy on the oncologic outcome of patients with
2779 adrenocortical carcinoma. *Annals of Surgery* 2012 255 363–369. (<https://doi.org/10.1097/SLA.0b013e3182367ac3>)

2781 204 Chiche L, Dousset B, Kieffer E & Chapuis Y. Adrenocortical carcinoma extending into
2782 the inferior vena cava: presentation of a 15-patient series and review of the literature.
2783 *Surgery* 2006 139 15–27. (<https://doi.org/10.1016/j.surg.2005.05.014>)

2784 205 Turbendian HK, Strong VE, Hsu M, Ghossein RA & Fahey TJ. Adrenocortical
2785 carcinoma: the influence of large vessel extension. *Surgery* 2010 148 1057–1064.
2786 (<https://doi.org/10.1016/j.surg.2010.09.024>)

2787 206 Mihai R, Iacobone M, Makay O, Moreno P, Frilling A, Kraimps JL, Soriano A, Villar del
2788 Moral J, Barczynski M, Duran MC et al. Outcome of operation in patients with adrenocortical
2789 cancer invading the inferior vena cava – a European Society of Endocrine Surgeons (ESES)
2790 survey. *Langenbecks Archives of Surgery* 2012 397 225–231. (<https://doi.org/10.1007/s00423-011-0876-6>)

2792 207 Eller-Vainicher C, Morelli V, Salcuni AS, Battista C, Torlontano M, Coletti F, Iorio L,
2793 Cairoli E, Beck-Peccoz P, Arosio M et al. Accuracy of several parameters of hypothalamic-
2794 pituitary-adrenal axis activity in predicting before surgery the metabolic effects of the removal
2795 of an adrenal incidentaloma. *European Journal of Endocrinology* 2010 163 925–935.
2796 (<https://doi.org/10.1530/EJE-10-0602>)

2797 208 Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, Husebye
2798 ES, Merke DP, Murad MH, Stratakis CA et al. Diagnosis and treatment of primary adrenal
2799 insufficiency: an Endocrine Society Clinical Practice Guideline. *Journal of Clinical*
2800 *Endocrinology and Metabolism* 2016 101 364–389. (<https://doi.org/10.1210/jc.2015-1710>)

2801 209 Duregon E, Volante M, Bollito E, Goia M, Buttigliero C, Zaggia B, Berruti A, Scagliotti
2802 GV & Papotti M. Pitfalls in the diagnosis of adrenocortical tumors: a lesson from 300
2803 consultation cases. *Human Pathology* 2015 46 1799–1807. (<https://doi.org/10.1016/j.humpath.2015.08.012>)

2805 210 Sangoi AR, Fujiwara M, West RB, Montgomery KD, Bonventre JV, Higgins JP, Rouse
2806 RV, Gokden N & McKenney JK. Immunohistochemical distinction of primary adrenal cortical
2807 lesions from metastatic clear cell renal cell carcinoma: a study of 248 cases. American
2808 Journal of Surgical Pathology 2011 35 678–686. ([https://doi.
2809 org/10.1097/PAS.0b013e3182152629](https://doi.org/10.1097/PAS.0b013e3182152629))

2810 211 Weissferdt A, Phan A, Suster S & Moran CA. Adrenocortical carcinoma: a
2811 comprehensive immunohistochemical study of 40 cases. Applied Immunohistochemistry and
2812 Molecular Morphology 2014 22 24–30. (<https://doi.org/10.1097/PAI.0b013e31828a96cf>)

2813 212 Tissier F, Aubert S, Leteurtre E, Alghuzlan A, Patey M, Decaussin M, Dousset L,
2814 Gobet F, Hoang C, Mazerolles C et al. Adrenocortical tumors (ACT): evaluation and
2815 harmonization of the reading of the Weiss system criteria at the French level. Laboratory
2816 Investigation 2010 90 133A.

2817 213 Tissier F, Aubert S, Leteurtre E, Al Ghuzlan A, Patey M, Decaussin M, Doucet L,
2818 Gobet F, Hoang C, Mazerolles C et al. Adrenocortical tumors: improving the practice of the
2819 weiss system through virtual microscopy a national program of the French Network INCa-
2820 COMETE. American Journal of Surgical Pathology 2012 36 1194–1201.
2821 (<https://doi.org/10.1097/PAS.0b013e31825a6308>)

2822 214 Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing
2823 adrenocortical tumors. American Journal of Surgical Pathology 1984 8 163–169.
2824 (<https://doi.org/10.1097/00000478-198403000-00001>)

2825 215 Weiss LM, Medeiros LJ & Vickery AL Jr. Pathologic features of prognostic
2826 significance in adrenocortical carcinoma. American Journal of Surgical Pathology 1989 13
2827 202–206. (<https://doi.org/10.1097/00000478-198903000-00004>)

2828 216 van Slooten H, Schaberg A, Smeenk D & Moolenaar AJ. Morphologic characteristics
2829 of benign and malignant adrenocortical tumors. Cancer 1985 55 766–773.
2830 ([https://doi.org/10.1002/1097-0142\(19850215\)55:4<766::AID-CNCR2820550414>3.0.CO;2-
2831 7](https://doi.org/10.1002/1097-0142(19850215)55:4<766::AID-CNCR2820550414>3.0.CO;2-7))

2832 217 Duregon E, Fassina A, Volante M, Nesi G, Santi R, Gatti G, Cappellesso R, Dalino
2833 Ciaramella P, Ventura L, Gambacorta M et al. The reticulin algorithm for adrenocortical tumor
2834 diagnosis: a multicentric validation study on 245 unpublished cases. American Journal of
2835 Surgical Pathology 2013 37 1433–1440. (<https://doi.org/10.1097/PAS.0b013e31828d387b>)

2836 218 Bisceglia M, Ludovico O, Di Mattia A, Ben-Dor D, Sandbank J, Pasquinelli G, Lau SK
2837 & Weiss LM. Adrenocortical oncocytic tumors: report of 10 cases and review of the literature.
2838 International Journal of Surgical Pathology 2004 12 231–243. ([https://doi.
2839 org/10.1177/106689690401200304](https://doi.org/10.1177/106689690401200304))

2840 219 Duregon E, Volante M, Cappia S, Cuccurullo A, Bisceglia M, Wong DD, Spagnolo
2841 DV, Szpak-Ulczyk S, Bollito E, Daffara F et al. Oncocytic adrenocortical tumors: diagnostic
2842 algorithm and mitochondrial DNA profile in 27 cases. American Journal of Surgical Pathology
2843 2011 35 1882–1893. (<https://doi.org/10.1097/PAS.0b013e31822da401>)

2844 220 Wong DD, Spagnolo DV, Bisceglia M, Havlat M, McCallum D & Platten MA.
2845 Oncocytic adrenocortical neoplasms – a clinicopathologic study of 13 new cases
2846 emphasizing the importance of their recognition. Human Pathology 2011 42 489–499.
2847 (<https://doi.org/10.1016/j.humpath.2010.08.010>)

2848 221 Fuhrman SA, Lasky LC & Limas C. Prognostic significance of morphologic
2849 parameters in renal cell carcinoma. *American Journal of Surgical Pathology* 1982 6 655–663.
2850 (<https://doi.org/10.1097/0000478-198210000-00007>)

2851 222 Lu H, Papathomas TG, van Zessen D, Palli I, de Krijger RR, van der Spek PJ,
2852 Dinjens WN & Stubbs AP. Automated Selection of Hotspots (ASH): enhanced automated
2853 segmentation and adaptive step finding for Ki67 hotspot detection in adrenal cortical cancer.
2854 *Diagnostic Pathology* 2014 9 216. (<https://doi.org/10.1186/s13000-014-0216-6>)

2855 223 Papathomas TG, Pucci E, Giordano TJ, Lu H, Duregon E, Volante M, Papotti M,
2856 Lloyd RV, Tischler AS, van Nederveen FH et al. An international Ki67 reproducibility study in
2857 adrenal cortical carcinoma. *American Journal of Surgical Pathology* 2016 40 569–576.
2858 (<https://doi.org/10.1097/PAS.0000000000000574>)

2859 224 Morimoto R, Satoh F, Murakami O, Suzuki T, Abe T, Tanemoto M, Abe M, Uruno A,
2860 Ishidoya S, Arai Y et al. Immunohistochemistry of a proliferation marker Ki67/MIB1 in
2861 adrenocortical carcinomas: Ki67/ MIB1 labeling index is a predictor for recurrence of
2862 adrenocortical carcinomas. *Endocrine Journal* 2008 55 49–55. (<https://doi.org/10.1507/endocrj.K07-079>)

2864 225 Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P, Dousset B, Bertagna
2865 X & Bertherat J. Clinical and biological features in the prognosis of adrenocortical cancer:
2866 poor outcome of cortisol- secreting tumors in a series of 202 consecutive patients. *Journal of*
2867 *Clinical Endocrinology and Metabolism* 2006 91 2650–2655.

2868 226 Burotto M, Tajeja N, Rosenberg A, Mahalingam S, Quezado M, Velarde M, Edgerly
2869 M & Fojo T. Brain metastasis in patients with adrenocortical carcinoma: a clinical series.
2870 *Journal of Clinical Endocrinology and Metabolism* 2015 100 331–336. (<https://doi.org/10.1210/jc.2014-2650>)

2872 227 Leboulleux S, Dromain C, Bonniaud G, Auperin A, Caillou B, Lumbroso J, Sigal R,
2873 Baudin E & Schlumberger M. Diagnostic and prognostic value of 18-fluorodeoxyglucose
2874 positron emission tomography in adrenocortical carcinoma: a prospective comparison with
2875 computed tomography. *Journal of Clinical Endocrinology and Metabolism* 2006 91 920–925.

2876 228 Ardito A, Massaglia C, Pelosi E, Zaggia B, Basile V, Brambilla R, Vigna-Taglianti F,
2877 Duregon E, Arena V, Perotti P et al. 18F-FDG PET/ CT in the post-operative monitoring of
2878 patients with adrenocortical carcinoma. *European Journal of Endocrinology* 2015 173 749–
2879 756. (<https://doi.org/10.1530/EJE-15-0707>)

2880 229 Berruti A, Fassnacht M, Baudin E, Hammer G, Haak H, Leboulleux S, Skogseid B,
2881 Allolio B & Terzolo M. Adjuvant therapy in patients with adrenocortical carcinoma: a position
2882 of an international panel. *Journal of Clinical Oncology* 2010 28 e401–e402; author reply
2883 e403. (<https://doi.org/10.1200/JCO.2009.27.5958>)

2884 230 Megerle F, Herrmann W, Schloetelburg W, Ronchi CL, Pulzer A, Quinkler M,
2885 Beuschlein F, Hahner S, Kroiss M & Fassnacht M. Mitotane monotherapy in patients with
2886 advanced adrenocortical carcinoma. *Journal of Clinical Endocrinology and Metabolism* 2018
2887 103 1686–1695. (<https://doi.org/10.1210/jc.2017-02591>)

2888 231 Volante M, Terzolo M, Fassnacht M, Rapa I, Germano A, Sbiera S, Daffara F,
2889 Sperone P, Scagliotti G, Allolio B et al. Ribonucleotide reductase large subunit (RRM1) gene
2890 expression may predict efficacy of adjuvant mitotane in adrenocortical cancer. *Clinical*
2891 *Cancer Research* 2012 18 3452–3461. (<https://doi.org/10.1158/1078-0432.CCR-11-2692>)

2892 232 Ronchi CL, Sbiera S, Volante M, Steinhauer S, Scott-Wild V, Altieri B, Kroiss M, Bala
2893 M, Papotti M, Deutschbein T et al. CYP2W1 is highly expressed in adrenal glands and is
2894 positively associated with the response to mitotane in adrenocortical carcinoma. PLoS ONE
2895 2014 9 e105855. (<https://doi.org/10.1371/journal.pone.0105855>)

2896 233 Terzolo M, Baudin AE, Ardito A, Kroiss M, Leboulleux S, Daffara F, Perotti P,
2897 Feelders RA, deVries JH, Zaggia B et al. Mitotane levels predict the outcome of patients with
2898 adrenocortical carcinoma treated adjuvantly following radical resection. European Journal of
2899 Endocrinology 2013 169 263–270. (<https://doi.org/10.1530/EJE-13-0242>)

2900 234 Terzolo M, Daffara F, Ardito A, Zaggia B, Basile V, Ferrari L & Berruti A. Management
2901 of adrenal cancer: a 2013 update. Journal of Endocrinological Investigation 2014 37 207–
2902 217. (<https://doi.org/10.1007/s40618-013-0049-2>)

2903 235 Huang H & Fojo T. Adjuvant mitotane for adrenocortical cancer – a recurring
2904 controversy. Journal of Clinical Endocrinology and Metabolism 2008 93 3730–3732.
2905 (<https://doi.org/10.1210/jc.2008-0579>)

2906 236 Terzolo M, Fassnacht M, Ciccone G, Allolio B & Berruti A. Adjuvant mitotane for
2907 adrenocortical cancer – working through uncertainty. Journal of Clinical Endocrinology and
2908 Metabolism 2009 94 1879–1880. (<https://doi.org/10.1210/jc.2009-0120>)

2909 237 Polat B, Fassnacht M, Pfreundner L, Guckenberger M, Bratengeier K, Johanssen S,
2910 Kenn W, Hahner S, Allolio B & Flentje M. Radiotherapy in adrenocortical carcinoma. Cancer
2911 2009 115 2816–2823. (<https://doi.org/10.1002/cncr.24331>)

2912 238 Sabolch A, Else T, Jackson W, Williams A, Miller BS, Worden F, Hammer GD & Jolly
2913 S. Improved local control with adjuvant radiation therapy in localized adrenocortical
2914 carcinoma: a case- matched retrospective study. International Journal of Radiation Oncology
2915 Biology Physics 2013 1 S84. (<https://doi.org/10.1016/j.ijrobp.2013.06.219>)

2916 239 Nelson DW, Chang SC, Bandera BC, Fischer TD, Wollman R & Goldfarb M. Adjuvant
2917 radiation is associated with improved survival for select patients with non-metastatic
2918 adrenocortical carcinoma. Annals of Surgical Oncology 2018 25 2060–2066. (<https://doi.org/10.1245/s10434-018-6510-x>)

2920 240 Cerquetti L, Bucci B, Marchese R, Misiti S, De Paula U, Miceli R, Muleti A, Amendola
2921 D, Piergrossi P, Brunetti E et al. Mitotane increases the radiotherapy inhibitory effect and
2922 induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.
2923 Endocrine-Related Cancer 2008 15 623–634. (<https://doi.org/10.1677/erc.1.1315>)

2924 241 Cerquetti L, Sampaoli C, Amendola D, Bucci B, Misiti S, Raza G, De Paula U,
2925 Marchese R, Brunetti E, Toscano V et al. Mitotane sensitizes adrenocortical cancer cells to
2926 ionizing radiations by involvement of the cyclin B1/CDK complex in G2 arrest and mismatch
2927 repair enzymes modulation. International Journal of Oncology 2010 37 493–501.

2928 242 Khan TS, Imam H, Juhlin C, Skogseid B, Grondal S, Tibblin S, Wilander E, Oberg K &
2929 Eriksson B. Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients:
2930 long-term survival in its adjuvant use. Annals of Oncology 2000 11 1281–1287. (<https://doi.org/10.1023/A:1008377915129>)

2932 243 Hermesen IGC, Gelderblom H, Kievit J, Romijn JA & Haak HR. Extremely long survival
2933 in six patients despite recurrent and metastatic adrenal carcinoma. European Journal of
2934 Endocrinology 2008 158 911–919. (<https://doi.org/10.1530/EJE-07-0723>)

2935 244 Bednarski BK, Habra MA, Phan A, Milton DR, Wood C, Vauthey N, Evans DB, Katz
2936 MH, Ng CS, Perrier ND et al. Borderline resectable adrenal cortical carcinoma: a potential

- 2937 role for preoperative chemotherapy. *World Journal of Surgery* 2014 38 1318–1327. (<https://doi.org/10.1007/s00268-014-2484-4>)
- 2938
- 2939 245 Wangberg B, Khorram-Manesh A, Jansson S, Nilsson B, Nilsson O, Jakobsson CE,
2940 Lindstedt S, Oden A & Ahlman H. The long-term survival in adrenocortical carcinoma with
2941 active surgical management and use of monitored mitotane. *Endocrine-Related Cancer* 2010
2942 17 265–272. (<https://doi.org/10.1677/ERC-09-0190>)
- 2943 246 Rangel C, Scattolin G, Pais-Costa SR, Vieira E & Gaio E. Neoadjuvant chemotherapy
2944 and salvage surgery for an aldosterone-producing adrenal carcinoma with inferior vena cava
2945 thrombus: case report and literature review. *Asian Journal of Surgery* 2013 36 134–136.
2946 (<https://doi.org/10.1016/j.asjsur.2012.08.008>)
- 2947 247 Ronchi CL, Sbiera S, Kraus L, Wortmann S, Johanssen S, Adam P, Willenberg HS,
2948 Hahner S, Allolio B & Fassnacht M. Expression of excision repair cross complementing
2949 group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based
2950 chemotherapy. *Endocrine-Related Cancer* 2009 16 907–918. (<https://doi.org/10.1677/ERC-08-0224>)
- 2951
- 2952 248 Malandrino P, Al Ghuzlan A, Castaing M, Young J, Caillou B, Travagli JP, Elias D, de
2953 Baere T, Dromain C, Paci A et al. Prognostic markers of survival after combined mitotane-
2954 and platinum-based chemotherapy in metastatic adrenocortical carcinoma. *Endocrine-Related Cancer* 2010 17 797–807. (<https://doi.org/10.1677/ERC-09-0341>)
- 2955
- 2956 249 Roca E, Berruti A, Sbiera S, Rapa I, Oneda E, Sperone P, Ronchi CL, Ferrari L,
2957 Grisanti S, Germano A et al. Topoisomerase2alpha and thymidylate synthase expression in
2958 adrenocortical cancer. *Endocrine-Related Cancer* 2017 24 299–307.
2959 (<https://doi.org/10.1530/ERC-17-0095>)
- 2960 250 Laufs V, Altieri B, Sbiera S, Kircher S, Steinhauer S, Beuschlein F, Quinkler M,
2961 Willenberg HS, Rosenwald A, Fassnacht M et al. ERCC1 as predictive biomarker to
2962 platinum-based chemotherapy in adrenocortical carcinomas. *European Journal of Endocrinology* 2018 178 183–190. (<https://doi.org/10.1530/EJE-17-0788>)
- 2963
- 2964 251 Bates SE, Shieh CY, Mickley LA, Dichek HL, Gazdar A, Loriaux DL & Fojo AT.
2965 Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug
2966 resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical
2967 carcinomas. *Journal of Clinical Endocrinology and Metabolism* 1991 73 18–29. (<https://doi.org/10.1210/jcem-73-1-18>)
- 2968
- 2969 252 Almeida MQ, Fragoso MC, Lotfi CF, Santos MG, Nishi MY, Costa MH, Lerario AM,
2970 Maciel CC, Mattos GE, Jorge AA et al. Expression of IGF-II and its receptor in pediatric and
2971 adult adrenocortical tumors. *Journal of Clinical Endocrinology and Metabolism* 2008 93
2972 3524–3531. (<https://doi.org/10.1210/jc.2008-0065>)
- 2973 253 Boulle N, Logie A, Gicquel C, Perin L & Le Bouc Y. Increased levels of insulin-like
2974 growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic
2975 adrenocortical tumors. *Journal of Clinical Endocrinology and Metabolism* 1998 83 1713–
2976 1720.
- 2977 254 Gicquel C, Bertagna X, Schneid H, Francillard-Leblond M, Luton JP, Girard F & Le
2978 Bouc Y. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-
2979 II gene in sporadic adrenocortical tumors. *Journal of Clinical Endocrinology and Metabolism*
2980 1994 78 1444–1453.

2981 255 Giordano TJ, Thomas DG, Kuick R, Lizyness M, Misek DE, Smith AL, Sanders D,
 2982 Aljundi RT, Gauger PG, Thompson NW et al. Distinct transcriptional profiles of adrenocortical
 2983 tumors uncovered by DNA microarray analysis. *American Journal of Pathology* 2003 162
 2984 521–531. ([https://doi.org/10.1016/S0002-9440\(10\)63846-1](https://doi.org/10.1016/S0002-9440(10)63846-1))

2985 256 Weber MM, Fottner C & Wolf E. The role of the insulin-like growth factor system in
 2986 adrenocortical tumourigenesis. *European Journal of Clinical Investigation* 2000 30
 2987 (Supplement 3) 69–75. (<https://doi.org/10.1046/j.1365-2362.2000.0300s3069.x>)

2988 257 Jones RL, Kim ES, Nava-Parada P, Alam S, Johnson FM, Stephens AW, Simantov
 2989 R, Poondru S, Gedrich R, Lippman SM et al. Phase I study of intermittent oral dosing of the
 2990 insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced
 2991 solid tumors. *Clinical Cancer Research* 2015 21 693–700. (<https://doi.org/10.1158/1078-0432.CCR-14-0265>)

2993 258 Naing A, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N, Hong D, Chen HX, Doyle
 2994 LA, Heilbrun LK et al. Phase I trial of cixutumumab combined with temsirolimus in patients
 2995 with advanced cancer. *Clinical Cancer Research* 2011 17 6052–6060. (<https://doi.org/10.1158/1078-0432.CCR-10-2979>)

2997 259 Vezzosi D, Do Cao C, Hescot S, Bertherat J, Haissaguerre M, Bongard V, Drui D, De
 2998 La Fouchardiere C, Illouz F, Borson-Chazot F et al. Time until partial response in metastatic
 2999 adrenocortical carcinoma long-term survivors. *Hormones and Cancer* 2018 9 62–69.
 3000 (<https://doi.org/10.1007/s12672-017-0313-6>)

3001 260 Kroiss M, Quinkler M, Lutz WK, Allolio B & Fassnacht M. Drug interactions with
 3002 mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical
 3003 carcinoma. *Clinical Endocrinology* 2011 75 585–591. (<https://doi.org/10.1111/j.1365-2265.2011.04214.x>)

3005 261 Faggiano A, Leboulleux S, Young J, Schlumberger M & Baudin E. Rapidly
 3006 progressing high o,p'DDD doses shorten the time required to reach the therapeutic threshold
 3007 with an acceptable tolerance: preliminary results. *Clinical Endocrinology* 2006 64 110–113.
 3008 (<https://doi.org/10.1111/j.1365-2265.2005.02403.x>)

3009 262 Mauclore-Denost S, Leboulleux S, Borget I, Paci A, Young J, Al Ghuzlan A,
 3010 Deandreis D, Drouard L, Tabarin A, Chanson P et al. High-dose mitotane strategy in
 3011 adrenocortical carcinoma (ACC): prospective analysis of plasma mitotane measurement
 3012 during the first three months of follow-up. *European Journal of Endocrinology* 2011 166 261–
 3013 268. (<https://doi.org/10.1530/EJE-11-0557>)

3014 263 Terzolo M, Pia A, Berruti A, Osella G, Ali A, Carbone V, Testa E, Dogliotti L & Angeli
 3015 A. Low-dose monitored mitotane treatment achieves the therapeutic range with manageable
 3016 side effects in patients with adrenocortical cancer. *Journal of Clinical Endocrinology and
 3017 Metabolism* 2000 85 2234–2238.

3018 264 Terzolo M & Berruti A. Adjunctive treatment of adrenocortical carcinoma. *Current
 3019 Opinion in Endocrinology, Diabetes and Obesity* 2008 15 221–226.
 3020 (<https://doi.org/10.1097/MED.0b013e3282fdf4c0>)

3021 265 Kerkhofs TM, Baudin E, Terzolo M, Allolio B, Chadarevian R, Mueller HH, Skogseid
 3022 B, Leboulleux S, Mantero F, Haak HR et al. Comparison of two mitotane starting dose
 3023 regimens in patients with advanced adrenocortical carcinoma. *Journal of Clinical
 3024 Endocrinology and Metabolism* 2013 98 4759–4767. (<https://doi.org/10.1210/jc.2013-2281>)

3025 266 Moolenaar AJ, van Slooten H, van Seters AP & Smeenk D. Blood levels of o,p'-DDD
3026 following administration in various vehicles after a single dose and during long-term
3027 treatment. *Cancer Chemotherapy and Pharmacology* 1981 7 51–54. ([https://doi.org/10.1007/](https://doi.org/10.1007/BF00258213)
3028 [BF00258213](https://doi.org/10.1007/BF00258213))

3029 267 Kerkhofs TM, Derijks LJ, Ettaieb MH, Eekhoff EM, Neef C, Gelderblom H, den Hartigh
3030 J, Guchelaar HJ & Haak HR. Short-term variation in plasma mitotane levels confirms the
3031 importance of trough level monitoring. *European Journal of Endocrinology* 2014 171 677–
3032 683. (<https://doi.org/10.1530/EJE-14-0388>)

3033 268 Daffara F, De Francia S, Reimondo G, Zaggia B, Aroasio E, Porpiglia F, Volante M,
3034 Termine A, Di Carlo F, Dogliotti L et al. Prospective evaluation of mitotane toxicity in
3035 adrenocortical cancer patients treated adjuvantly. *Endocrine-Related Cancer* 2008 15 1043–
3036 1053. (<https://doi.org/10.1677/ERC-08-0103>)

3037 269 van Slooten H, Moolenaar AJ, van Seters AP & Smeenk D. The treatment of
3038 adrenocortical carcinoma with o,p'-DDD: prognostic implications of serum level monitoring.
3039 *European Journal of Cancer and Clinical Oncology* 1984 20 47–53.
3040 ([https://doi.org/10.1016/0277-5379\(84\)90033-6](https://doi.org/10.1016/0277-5379(84)90033-6))

3041 270 Chortis V, Taylor AE, Schneider P, Tomlinson JW, Hughes BA, O'Neil DM, Libé R,
3042 Allolio B, Bertagna X, Bertherat J et al. Mitotane therapy in adrenocortical cancer induces
3043 CYP3A4 and inhibits 5 α -reductase, explaining the need for personalized glucocorticoid and
3044 androgen replacement. *Journal of Clinical Endocrinology and Metabolism* 2013 98 161–171.
3045 (<https://doi.org/10.1210/jc.2012-2851>)

3046 271 Reimondo G, Puglisi S, Zaggia B, Basile V, Saba L, Perotti P, De Francia S, Volante
3047 M, Zatelli MC, Cannavo S et al. Effects of mitotane on the hypothalamic-pituitary-adrenal axis
3048 in patients with adrenocortical carcinoma. *European Journal of Endocrinology* 2017 177 361–
3049 367. (<https://doi.org/10.1530/EJE-17-0452>)

3050 272 Kerkhofs TM, Derijks LJ, Ettaieb H, den Hartigh J, Neef K, Gelderblom H, Guchelaar
3051 HJ & Haak HR. Development of a pharmacokinetic model of mitotane: toward personalized
3052 dosing in adrenocortical carcinoma. *Therapeutic Drug Monitoring* 2015 37 58–65.
3053 (<https://doi.org/10.1097/FTD.0000000000000102>)

3054 273 Alexandraki KI, Kaltsas GA, le Roux CW, Fassnacht M, Ajodha S, Christ-Crain M,
3055 Akker SA, Drake WM, WM, Edwards R, Allolio B et al. Assessment of serum-free cortisol
3056 levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study. *Clinical*
3057 *Endocrinology* 2010 72 305–311. (<https://doi.org/10.1111/j.1365-2265.2009.03631.x>)

3058 274 Russo M, Scollo C, Pellegriti G, Cotta OR, Squatrito S, Frasca F, Cannavo S & Gullo
3059 D. Mitotane treatment in patients with adrenocortical cancer causes central hypothyroidism.
3060 *Clinical Endocrinology* 2016 84 614–619. (<https://doi.org/10.1111/cen.12868>)

3061 275 Tada H, Nohara A, Kawashiri MA, Inazu A, Mabuchi H & Yamagishi M. Marked
3062 transient hypercholesterolemia caused by low-dose mitotane as adjuvant chemotherapy for
3063 adrenocortical carcinoma. *Journal of Atherosclerosis and Thrombosis* 2014 21 1326–1329.
3064 (<https://doi.org/10.5551/jat.27557>)

3065 276 Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO & Tabarin
3066 A. Treatment of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
3067 *Journal of Clinical Endocrinology and Metabolism* 2015 100 2807–2831. ([https://doi.](https://doi.org/10.1210/jc.2015-1818)
3068 [org/10.1210/jc.2015-1818](https://doi.org/10.1210/jc.2015-1818))

3069 277 Claps M, Cerri S, Grisanti S, Lazzari B, Ferrari V, Roca E, Perotti P, Terzolo M,
3070 Sigala S & Berruti A. Adding metyrapone to chemotherapy plus mitotane for Cushing's
3071 syndrome due to advanced adrenocortical carcinoma. *Endocrine* 2017 61 169–172.
3072 (<https://doi.org/10.1007/s12020-017-1428-9>)

3073 278 Castinetti F, Fassnacht M, Johanssen S, Terzolo M, Bouchard P, Chanson P, Do Cao
3074 C, Morange I, Pico A, Ouzounian S et al. Merits and pitfalls of mifepristone in Cushing's
3075 syndrome. *European Journal of Endocrinology* 2009 160 1003–1010.
3076 (<https://doi.org/10.1530/EJE-09-0098>)

3077 279 Chow E, Hoskin P, Mitera G, Zeng L, Lutz S, Roos D, Hahn C, van der Linden Y,
3078 Hartsell W & Kumar E. Update of the international consensus on palliative radiotherapy
3079 endpoints for future clinical trials in bone metastases. *International Journal of Radiation*
3080 *Oncology, Biology, Physics* 2012 82 1730–1737. (<https://doi.org/10.1016/j.ijrobp.2011.02.008>)

3082 280 Pin Y, Paix A, Le Fevre C, Antoni D, Blondet C & Noel G. A systematic review of
3083 palliative bone radiotherapy based on pain relief and retreatment rates. *Critical Reviews in*
3084 *Oncology/ Hematology* 2018 123 132–137. (<https://doi.org/10.1016/j.critrevonc.2018.01.006>)

3085 281 Ferrell BR, Temel JS, Temin S, Alesi ER, Balboni TA, Basch EM, Firn JI, Paice JA,
3086 Peppercorn JM, Phillips T et al. Integration of palliative care into standard oncology care:
3087 American Society of Clinical Oncology Clinical Practice Guideline update. *Journal of Clinical*
3088 *Oncology* 2017 35 96–112. (<https://doi.org/10.1200/JCO.2016.70.1474>)

3089 282 Herrmann LJ, Heinze B, Fassnacht M, Willenberg HS, Quinkler M, Reisch N, Zink M,
3090 Allolio B & Hahner S. TP53 germline mutations in adult patients with adrenocortical
3091 carcinoma. *Journal of Clinical Endocrinology and Metabolism* 2012 97 E476–E485.
3092 (<https://doi.org/10.1210/jc.2011-1982>)

3093 283 Raymond VM, Else T, Everett JN, Long JM, Gruber SB & Hammer GD. Prevalence of
3094 germline TP53 mutations in a prospective series of unselected patients with adrenocortical
3095 carcinoma. *Journal of Clinical Endocrinology and Metabolism* 2013 98 E119–E125.
3096 (<https://doi.org/10.1210/jc.2012-2198>)

3097 284 Waldmann J, Patsalis N, Fendrich V, Langer P, Saeger W, Chaloupka B,
3098 Ramaswamy A, Fassnacht M, Bartsch DK & Slater EP. Clinical impact of TP53 alterations in
3099 adrenocortical carcinomas. *Langenbecks Archives of Surgery* 2012 397 209–216.
3100 (<https://doi.org/10.1007/s00423-011-0868-6>)

3101 285 Raymond VM, Everett JN, Furtado LV, Gustafson SL, Jungbluth CR, Gruber SB,
3102 Hammer GD, Stoffel EM, Greenson JK, Giordano TJ et al. Adrenocortical carcinoma is a
3103 lynch syndrome-associated cancer. *Journal of Clinical Oncology* 2013 31 3012–3018.
3104 (<https://doi.org/10.1200/JCO.2012.48.0988>)

3105 286 Stoffel EM, Mangu PB, Gruber SB, Hamilton SR, Kalady MF, Lau MW, Lu KH, Roach
3106 N & Limburg PJ. Hereditary colorectal cancer syndromes: American Society of Clinical
3107 Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer:
3108 European Society for Medical Oncology Clinical Practice Guidelines. *Journal of Clinical*
3109 *Oncology* 2015 33 209–217. (<https://doi.org/10.1200/JCO.2014.58.1322>)

3110 287 Daly MB, Pilarski R, Berry M, Buys SS, Farmer M, Friedman S, Garber JE, Kauff ND,
3111 Khan S, Klein C et al. NCCN Guidelines Insights: genetic/familial high-risk assessment:
3112 breast and ovarian, version 2.2017. *Journal of the National Comprehensive Cancer Network*
3113 2017 15 9–20. (<https://doi.org/10.6004/jnccn.2017.0003>)

3114 288 Kratz CP, Achatz MI, Brugieres L, Frebourg T, Garber JE, Greer MC, Hansford JR,
3115 Janeway KA, Kohlmann WK, McGee R et al. Cancer screening recommendations for
3116 individuals with Li-Fraumeni syndrome. *Clinical Cancer Research* 2017 23 e38–e45.
3117 (<https://doi.org/10.1158/1078-0432.CCR-17-0408>)

3118 289 Ballinger ML, Best A, Mai PL, Khincha PP, Loud JT, Peters JA, Achatz MI, Chojniak
3119 R, Balieiro da Costa A, Santiago KM et al. Baseline surveillance in Li-Fraumeni syndrome
3120 using whole-body magnetic resonance imaging: a meta-analysis. *JAMA Oncology* 2017 3
3121 1634–1639. (<https://doi.org/10.1001/jamaoncol.2017.1968>)

3122 290 Gupta S, Provenzale D, Regenbogen SE, Hampel H, Slavin TP Jr, Hall MJ, Llor X,
3123 Chung DC, Ahnen DJ, Bray T et al. NCCN guidelines insights: genetic/familial high-risk
3124 assessment: colorectal, version 3.2017. *Journal of the National Comprehensive Cancer*
3125 *Network* 2017 15 1465–1475. (<https://doi.org/10.6004/jnccn.2017.0176>)

3126 291 Stoffel EM, Mangu PB & Limburg PJ. Hereditary colorectal cancer syndromes:
3127 American Society of Clinical Oncology clinical practice guideline endorsement of the familial
3128 risk-colorectal cancer: European Society for Medical Oncology clinical practice guidelines.
3129 *Journal of Oncology Practice* 2015 11 e437–e441. (<https://doi.org/10.1200/JOP.2015.003665>)

3130 292 Else T. Association of adrenocortical carcinoma with familial cancer susceptibility
3131 syndromes. *Molecular and Cellular Endocrinology* 2012 351 66–70.
3132 (<https://doi.org/10.1016/j.mce.2011.12.008>)

3133 293 McDonnell CM & Zacharin MR. Adrenal cortical tumours: 25 years' experience at the
3134 Royal Children's Hospital, Melbourne. *Journal of Paediatrics and Child Health* 2003 39 682–
3135 685. (<https://doi.org/10.1046/j.1440-1754.2003.00268.x>)

3136 294 Custodio G, Parise GA, Kiesel Filho N, Komechen H, Sabbaga CC, Rosati R, Grisa L,
3137 Parise IZ, Pianovski MA, Fiori CM et al. Impact of neonatal screening and surveillance for the
3138 TP53 R337H mutation on early detection of childhood adrenocortical tumors. *Journal of*
3139 *Clinical Oncology* 2013 31 2619–2626. (<https://doi.org/10.1200/JCO.2012.46.3711>)

3140 295 Wasserman JD, Novokmet A, Eichler-Jonsson C, Ribeiro RC, Rodriguez-Galindo C,
3141 Zambetti GP & Malkin D. Prevalence and functional consequence of TP53 mutations in
3142 pediatric adrenocortical carcinoma: a children's oncology group study. *Journal of Clinical*
3143 *Oncology* 2015 33 602–609. (<https://doi.org/10.1200/JCO.2013.52.6863>)

3144 296 Eschler DC, Kogekar N & Pessah-Pollack R. Management of adrenal tumors in
3145 pregnancy. *Endocrinology Metabolism Clinics of North America* 2015 44 381–397.
3146 (<https://doi.org/10.1016/j.ecl.2015.02.006>)

3147 297 Abiven-Lepage G, Coste J, Tissier F, Groussin L, Billaud L, Dousset B, Goffinet F,
3148 Bertagna X, Bertherat J & Raffin-Sanson ML. Adrenocortical carcinoma and pregnancy:
3149 clinical and biological features and prognosis. *European Journal of Endocrinology* 2010 163
3150 793–800. (<https://doi.org/10.1530/EJE-10-0412>)

3151 298 Sirianni R, Zolea F, Chimento A, Ruggiero C, Cerquetti L, Fallo F, Pilon C, Arnaldi G,
3152 Carpinelli G, Stigliano A et al. Targeting estrogen receptor-alpha reduces adrenocortical
3153 cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen
3154 receptor modulators (SERMs) for ACC treatment. *Journal of Clinical Endocrinology and*
3155 *Metabolism* 2012 97 E2238–E2250. (<https://doi.org/10.1210/jc.2012-2374>)

3157 299 Tripto-Shkolnik L, Blumenfeld Z, Bronshtein M, Salmon A & Jaffe A. Pregnancy in a
3158 patient with adrenal carcinoma treated with mitotane: a case report and review of literature.
3159 *Journal of Clinical Endocrinology and Metabolism* 2013 98 443–447.

3160 300 de Corbiere P, Ritzel K, Cazabat L, Ropers J, Schott M, Libe R, Koschker AC,
3161 Leboulleux S, Deutschbein T, Do Cao C et al. Pregnancy in women previously treated for an
3162 adrenocortical carcinoma. *Journal of Clinical Endocrinology and Metabolism* 2015 100 4604–
3163 4611. (<https://doi.org/10.1210/jc.2015-2341>)

3164 301 Hescot S, Seck A, Guerin M, Cockenpot F, Huby T, Broutin S, Young J, Paci A,
3165 Baudin E & Lombes M. Lipoprotein-free mitotane exerts high cytotoxic activity in
3166 adrenocortical carcinoma. *Journal of Clinical Endocrinology and Metabolism* 2015 100 2890–
3167 2898. (<https://doi.org/10.1210/JC.2015-2080>)

3168 302 Hescot S, Slama A, Lombes A, Paci A, Remy H, Leboulleux S, Chadarevian R,
3169 Trabado S, Amazit L, Young J et al. Mitotane alters mitochondrial respiratory chain activity by
3170 inducing cytochrome c oxidase defect in human adrenocortical cells. *Endocrine-Related*
3171 *Cancer* 2013 20 371–381. (<https://doi.org/10.1530/ERC-12-0368>)

3172 303 Sbiera S, Leich E, Liebisch G, Sbiera I, Schirbel A, Wiemer L, Matysik S, Eckhardt C,
3173 Gardill F, Gehl A et al. Mitotane inhibits sterol-O-acyl transferase 1 triggering lipid-mediated
3174 endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells. *Endocrinology*
3175 2015 156 3895–3908. (<https://doi.org/10.1210/en.2015-1367>)

3176 304 Hescot S, Amazit L, Lhomme M, Travers S, DuBow A, Battini S, Boulate G, Namer IJ,
3177 Lombes A, Kontush A et al. Identifying mitotane-induced mitochondria-associated
3178 membranes dysfunctions: metabolomic and lipidomic approaches. *Oncotarget* 2017 8
3179 109924–109940.

3180 305 Arlt W, Biehl M, Taylor AE, Hahner S, Libe R, Hughes BA, Schneider P, Smith DJ,
3181 Stiekema H, Krone N et al. Urine steroid metabolomics as a biomarker tool for detecting
3182 malignancy in adrenal tumors. *Journal of Clinical Endocrinology and Metabolism* 2011 96
3183 3775–3784. (<https://doi.org/10.1210/jc.2011-1565>)

3184 306 Kerkhofs TM, Kerstens MN, Kema IP, Willems TP & Haak HR. Diagnostic value of
3185 urinary steroid profiling in the evaluation of adrenal tumors. *Hormones and Cancer* 2015 6
3186 168–175. (<https://doi.org/10.1007/s12672-015-0224-3>)

3187 307 Taylor DR, Ghataore L, Couchman L, Vincent RP, Whitelaw B, Lewis D, Diaz-Cano
3188 S, Galata G, Schulte KM, Aylwin S et al. A 13-steroid serum panel based on LC-MS/MS: use
3189 in detection of adrenocortical carcinoma. *Clinical Chemistry* 2017 63 1836–1846.
3190 (<https://doi.org/10.1373/clinchem.2017.277624>)

3191 308 Hines JM, Bancos I, Bancos C, Singh RD, Avula AV, Young WF, Grebe SK & Singh
3192 RJ. High-resolution, accurate-mass (HRAM) mass spectrometry urine steroid profiling in the
3193 diagnosis of adrenal disorders. *Clinical Chemistry* 2017 63 1824–1835. (<https://doi.org/10.1373/clinchem.2017.271106>)

3195 309 Pinzani P, Scatena C, Salvianti F, Corsini E, Canu L, Poli G, Paglierani M, Piccini V,
3196 Pazzagli M, Nesi G et al. Detection of circulating tumor cells in patients with adrenocortical
3197 carcinoma: a monocentric preliminary study. *Journal of Clinical Endocrinology and*
3198 *Metabolism* 2013 98 3731–3738. (<https://doi.org/10.1210/jc.2013-1396>)

3199 310 Chabre O, Libe R, Assie G, Barreau O, Bertherat J, Bertagna X, Feige JJ & Cherradi
3200 N. Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer
3201 patients. *Endocrine-Related Cancer* 2013 20 579–594.

3202 311 Szabo DR, Luconi M, Szabo PM, Toth M, Szucs N, Horanyi J, Nagy Z, Mannelli M,
3203 Patocs A, Racz K et al. Analysis of circulating microRNAs in adrenocortical tumors.
3204 Laboratory Investigation 2014 94 331–339. (<https://doi.org/10.1038/labinvest.2013.148>)

3205 312 Perge P, Butz H, Pezzani R, Bancos I, Nagy Z, Paloczi K, Nyiro G, Decmann A, Pap
3206 E, Luconi M et al. Evaluation and diagnostic potential of circulating extracellular vesicle-
3207 associated microRNAs in adrenocortical tumors. Scientific Reports 2017 7 5474. (<https://doi.org/10.1038/s41598-017-05777-0>)

3209 313 Creemers SG, Korpershoek E, Atmodimedjo PN, Dinjens WNM, van Koetsveld PM,
3210 Feelders RA & Hofland LJ. Identification of mutations in cell-free circulating tumor DNA in
3211 adrenocortical carcinoma: a case series. Journal of Clinical Endocrinology and Metabolism
3212 2017 102 3611–3615. (<https://doi.org/10.1210/jc.2017-00174>)

3213 314 Garinet S, Nectoux J, Neou M, Pasmant E, Jouinot A, Sibony M, Orhant L, Pipoli da
3214 Fonseca J, Perlemoine K, Bricaire L et al. Detection and monitoring of circulating tumor DNA in
3215 adrenocortical carcinoma. Endocrine-Related Cancer 2018 25 L13–L17.
3216 (<https://doi.org/10.1530/ERC-17-0467>)

3217